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Abstract
Ovarian cancer represents the most lethal gynaecological malignancy in the UK.
Numerous tumour suppressor genes (TSG) are postulated to be involved in the
aetiology of epithelial ovarian cancer (EOC). Cytogenetic analyses of cancer cells by
methods such as LOH and CGH, have identified regions of genomic aberration.
Allele loss on chromosome 1 lp has frequently been implicated in ovarian cancers,
suggesting the presence of TSGs in these regions.
Ovarian cancer cell line OVCAR3 has lost a whole copy of chromosome 11. The
remaining copy is fragmented, rearranged and duplicated. Transfer of normal
chromosome 11 into OVCAR3 by Microcell Mediated Chromosome Transfer
(MMCT) produced microcell hybrids that display suppression of growth and
cellular migration in vitro and inhibition of tumour growth in vivo. Analysis of
revertant clones was unable to further minimise regions harbouring candidate
TSGs.
Subsequently, mRNA populations from OHN, a clonal derivative of the OVCAR3
parent line, and from 110H2.1, a growth suppressed microcell hybrid, were used
for expression difference analysis by Differential Display RT-PCR (DDRT-PCR),
cDNA-Representational Difference Analysis (cDNA-RDA) and cDNA high density
filter array (HDFA). In all, these techniques identified 159 up and 162 down
regulated genes with respect to growth suppression.
Quantitative real time RT-PCR was used to validate expression differences in 178
transcripts. We identified, in total, 12 validated upregulated products and 4
validated downregulated products.
Of the 12 upregulated products associated with growth suppression, 4 were
localised on chromosome 11, three at llpl5. These were cathepsin D (CTSD),
proteasome subunit PSMD13, ribosomal subunit RPL27A on 11 p 15 and aB
crystallin (CRYAB) on llq23. All were shown to have decreased expression in
several ovarian cancer cell lines and primary tumours. Furthermore, a tight
correlation was observed between the expression of PSMD13 and RPL27A in cell
lines and primary ovarian tumours. Low expression of CTSD and CRYAB were
associated with adverse survival in patients with ovarian cancers.
v
The genes downregulated in association with growth suppression, and therefore of
potentially oncogenic function, were RALDH2, IGFBP2 and 2 novel cDNAs.
When examined on cell line and primary tumour panels, these genes did not
however appear to demonstrate a global increase in expression over that of normal
OSE.
An extensive LOH analysis of 87 ovarian tumours and their matched normal
samples was then performed. Thirty-nine microsatellite markers spanning 19.8Mb
on 1 lp 15 were used in the most comprehensive analysis in ovarian cancer to date.
Loss of the complete region was common (24%) and peaks of high LOH (>35%)
were seen for 12 markers. Six microsatellite markers showed an association with
one or more clinicopathological variables (p<0.01). Nine minimal regions of LOH
were found.
PSMD13 and CTSD were both found within these regions of LOH as characterised
by the markers D11S2071 and D11S922. RPL27a resides on llpl5.4 near the
marker D11S932 which was not located within a minimal region of loss but LOH
of that marker was significantly associated with advanced FIGO stage (p=0.0001).
This approach has demonstrated that the integration of functional and positional
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In the UK, cancer, heart disease and stroke are the three biggest killers. The five
most common female malignancies in western countries are, in order of prevalence,
breast, lung, colon, stomach and ovarian. The total number of new cases of cancers
in women appears to have stabilised but the common types of cancer have altered,
with lung cancer cases on the increase and breast and cervical tumour incidence
declining. An improvement in diet is believed to have helped reduce the incidence of
many other common cancers such as bowel and colon. Another factor involved in
declining cancer incidence and mortality has been the improvement of screening
methods, particularly for cervical and breast cancers.
World-wide, there are over ten million new cases of cancer diagnosed annually and
even though Europe and North America accommodate only 11.5% of the global
population, they account for 41.2% of these cases (Parkin et al., 2001). The
incidence per person is therefore much higher in these areas.
1.2 Epithelial Ovarian Cancer: Global distribution and causation
1.2.1 Epidemiology
Ovarian cancer is the 6th most common malignancy and the 6th leading cause of
cancer related deaths, globally, in women (Parkin et al., 2001). It is the third most
common but the leading cause of mortality from a gynaecological malignancy in the
western world.
In 1990, worldwide, there were 165,000 new cases of ovarian cancer representing
4.4% of all female cancers (Parkin, 1998). Latest studies estimate 191,000 new cases
annually (Parkin et al., 2001). The frequency of ovarian cancer is greatest in the
developed world with highest incidence and mortality rates in Europe, particularly
northern (UK and Scandinavia) and North America (Parkin, 1998). Japan conversely
has a greater than 2 fold lower rate of incidence (Parkin, 1998).
Cancer Research UK statistics for the year 2000 show ovarian cancer affected 6884
women and was responsible for 4,430 deaths. This represents 1.5% of all women
affected by cancer and is the fourth (6%) most common cause of all female cancer
related deaths. Five-year survival rates are the fourth worst for cancers at 29.2% in
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1991-1993 compared to the average five-year survival rate of 43% for all cancers in
females.
Information and statistics division (ISD), Scotland, have reported that, as for the
whole of the UK, ovarian cancer was the fourth most frequently diagnosed cancer
and in 1998 represented 4.7% of all new cancer incidences in females. Over the past
~25 years incidence and mortality rates have increased 1.5- and 1.25-fold
respectively but there is, however, an associated increase in the five year survival of
3.9% to 35.9% as adjusted for age.
1.2.2 Cause and aetiology
The cause of ovarian cancer is widely debated with many environmental, endocrine
and genetic factors having been researched. Numerous protective and risk associated
factors have been identified or suggested. These include;
• Menstrual factors; age of menarche/menopause (Chiaffarino et al., 2001),
irregularity of cycles.
• Reproductive factors; pregnancy, breast feeding, tubal ligation/hysterectomy, oral
contraceptive use (Schildkraut et al., 2002), Hormone replacement therapy
(HRT), (Lacey et al., 2002a) and fertility treatment.
• Dietary factors; Fat/protein consumption, vegetable consumption (McCann et al.,
2001), caffeine/coffee and alcohol intake (Tavani et al., 2001), body mass index
(BMI) (Lukanova et al., 2002), lactose and cholesterol intake.
• Other factors; Family history, physical exercise (Bertone et al., 2002), talc use,
smoking (Modugno et al., 2002), aspirin use (Fairfield et al., 2002), radiation,
psychotropic drug intake, hair dye, asbestos exposure (Heller et al., 1996) and
race (Barnholtz-Sloan et al., 2002).
Multiple studies have shown that oral contraceptive use, parity, tubal ligation and
hysterectomy, and breast-feeding can protect from ovarian cancer (Holschneider and
Berek, 2000; Runnebaum and Stickeler, 2001; Titus-Ernstoff et al., 2001). Increased
risk has been associated with infertility, nulliparity and family history.
A case control study in Italy showed that population attributable risks (PAR)
accounted for 51% of cases. That is, 51% of cases could have been avoided if the
exposure had not been present in the population. PAR were 5% for nulliparity, 12%
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for no OC use, 4% for family history, 16% for late age at menopause, 24% for low
intake of vegetables and 7% for high fat intake (Parazzini et al., 2000). Three of
these factors are modifiable so it was thought that these could therefore be suitable
methods of prevention, which could be implemented within this and other
populations. The remaining 49% must be due to other non-inherited factors and
exposures that have not been analysed in this paper. The latter three risks examined
however have yet to be fully recognised as ovarian cancer risk factors.
There are multiple theories to the causation of ovarian cancer. The earliest was
suggested by Fathalla in 1971 and called the incessant ovulation theory (Fathalla,
1971). Fie proposed that chronic repetitive ovulation without interruption from
pregnancy or OC use could induce neoplasia of the ovarian surface epithelium
(OSE). The OSE undergoes rapid proliferation for 24 hours post ovulation and
invaginations of the epithelium are more prevalent at this time so clefts and cysts are
common. There is some support that these cysts may be associated with neoplasia
and tubal metaplasia and so sites of potential carcinomas (Resta et al., 1993).
Epithelial cancers of the ovary arise most frequently within these inclusion cysts.
Repeated proliferation of the OSE may also lead to mutations in epithelial cells,
making them susceptible to transformation.
Casagrande added to this hypothesis by suggesting that periods of anovulation could
decrease cancer risk by providing 'protected time' (Casagrande et al., 1979).
Ovulation also exposes some OSE to stromal estrogens, through the production of
inclusion cysts, which may further contribute to transformation. Support for the
theory comes from numerous studies into the protective effects of OC, parity and
breast-feeding as all of these methods lead to anovulation. There are however,
discrepancies to the hypothesis. La Vecchia suggested that, assuming ovulation
occurs for 20 years of a woman's life and if 1 pregnancy halts ovulation for one year
then that accounts for 5% of all ovulation (La Vecchia et al., 1983). The risk
reduction per pregnancy however is approx. 14%. This discrepancy between
numbers suggests there may be a parallel mechanism that induces ovarian
transformation. Also, as ovarian cancers appear to arise more frequently from
inclusions cysts, which themselves are not constantly affected by repetitive
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proliferation from ovulation and repair of the OSE, it is thought there are other
environmental factors involved in progression (Godwin et al., 1992).
A number of alternative or perhaps corresponding theories study the involvement of
hormones with neoplastic progression. The main idea is called the 'gonadotropin
hypothesis'. Excessive gonadotrophin secretion is not associated directly with
ovulation and surface epithelium damage but causes consequent estrogen stimulation
which is believed to result in proliferation and malignant transformation of the OSE.
This theory is supported by the protective effects associated with parity and OC use
as both of these mechanisms decrease levels of basal and peak gonadotrophins (FSH
and LH) (Risch, 1998). Levels of FSH and LH are known to rise peri/post
menopausally, due to loss of feedback inhibition on the pituitary. This suggests an
association between these increased hormone levels and onset of ovarian cancers, as
they are associated with age (Risch, 1998). However, LH and FSH do not stimulate
estrogen post-menopausally and levels decrease. Gonadotrophins may therefore act
through a non-estrogen related mechanism. Increased LH is also known to prevent
apoptosis and increase angiogenesis, which may promote cancer formation in these
post-menopausal women.
Another hormone to be potentially associated with ovarian cancer risk is estrogen.
Estrogen levels in a normal ovary peak at rupture of the OSE at ovulation. During
menstrual cycles, the OSE proliferates most when estradiol levels are high. Estrogen
may therefore have a proliferative role that could increase mutation risk in the
exposed OSE cells. Support for the role of estrogens in ovarian carcinoma initiation
is seen from the effects of breast-feeding, OC use and HRT. The former two suppress
LH and subsequently decrease levels of estrogen so inhibit proliferation. Estrogen-
only HRT causes a serum increase in estradiol and recent studies have associated this
therapy with increased cancer risk (Lacey et al., 2002b). As for many hypotheses
however, there is evidence against this idea. For example, pregnancy causes a 100-
fold increase in estrogen levels but confers protection (Risch, 1998). This suggests
that there may be yet another/other hormone(s) involved in neoplasia.
Androgens cause increased proliferation and cell death in OSE cells (Edmondson et
al., 2002). Inclusion cysts, themselves formed from OSE, are exposed to high levels
of androgens in the ovarian cortex. A study looking at levels of androgens in ovarian
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cancers discovered 50% higher levels of androstenedione and dehydropiandrosterone
in both pre and postmenopausal cases as compared to normal controls (Helzlsouer et
al., 1995). The postmenopausal ovary sees a 15-fold increase in levels of the
androgen testosterone correlating with the incidence of EOC in postmenopausal
women. Testosterone has also been detected at 30-65% of normal levels in OC users
who have a decreased lifetime risk of developing ovarian cancer (Judd et al., 1974).
The in vitro effects of estrogen and testosterone were studied in human epithelial
cells and both showed a positive effect upon cell growth after three weeks,
supporting their role in increasing OSE proliferation (Karlan et al., 1995).
Progesterone may have a protective role in ovarian cancer as a 10-fold increase in
levels is found in pregnant women and risk of EOC decreases with parity. It is
suggested that high progesterone levels and 'protective time' from anovulation
during pregnancy may be additive to close the gap in risk reduction between
postulated and actual risk (La Vecchia et al., 1983). High levels of physical activity
may decrease progesterone levels and increase androgen levels that may cause the
inflated risk of EOC found in a few very active women (Bertone et al., 2001).
Parmley and Woodruff suggested that EOC might arise from the transformation of
OSE cells exposed to pelvic contaminants and carcinogens (Parmley and Woodruff,
1974). This theory is linked to the idea that inflammation may be involved in EOC.
Inflammation produces toxic oxidants that may cause direct damage to DNA and
proteins, leading to disruption of normal gene expression. Chronic inflammation is
also known to increase cellular division. Evidence that contaminants may travel up
the fallopian tubes was found when traces of asbestos fibre were noticed in the
ovaries of cancer patients who had been exposed (Heller et al., 1996). It is believed
that blocking the upper genital tract disallows exposure to proinflammatory
substances and support for this hypothesis is seen from strong data that tubal ligation
and hysterectomy are protective for EOC (Runnebaum and Stickeler, 2001).
Aspirin, an anti-inflammatory, has in some cases been found to decrease cancer risk
if used three or more times a week (Akhmedkhanov et al., 2001). The protection
appears to reduce over time with more recent users being at less risk. Aspirin may
also however act by inhibiting both angiogenesis and, importantly, the activity of the
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cox-2 enzyme that indirectly induces cell proliferation. Cox-2 inhibition induces
apoptosis, so may protect against cancerous induction from damaged progenitor cells
by undergoing programmed cell death (Rodriguez-Burford et al., 2002). Aspirin is
known to inhibit proliferation of ovarian cancer cells by blocking the effects of the
HER-2/neu/ErbB-2 receptor, which may also confer protective effects in normal
OSE cells (Drake and Becker, 2002). The most recent case study in America
however, suggests that aspirin does not decrease risk but there was a 40% reduction
of risk of ovarian cancer occurrence with other non-steroidal anti-inflammatory
usage (Fairfield et al., 2002).
1.3 Ovarian Histopathology
1.3.1 Normal Ovarian development
The ovaries are ovoid, paired organs. They consist of a thick peripheral cortex that
surrounds the medulla, and are covered in a continuous sheet of cuboidal epithelial
cells that lie on a basement membrane. This in turn lies on a dense layer of
connective tissue called the tunica albuginea. Ovarian epithelial cells are attached
lightly to the basement membrane by desmosomes and tight junctions. The surface of
the ovary is contoured with invaginations of the epithelia which, with age, internalise
into the inner stroma to form inclusion cysts.
The OSE is derived from embryonic coelomic epithelium that arises from enlarged
mesoderm upon gastrulation. Foetal development of the ovaries involves
invagination of the coelomic epithelium to form the Mullerian duct. The duct then
differentiates to form the uterus, cervix, fallopian tubes and upper vagina. Coelomic
epithelium persists to line the ovaries as the OSE. These cells, importantly, retain the
potential for Mullerian differentiation to display metaplasia and neoplastic
progression.
The normal involvement of the OSE is in cyclical ovulatory rupture and repair.
Ovarian epithelial cells are believed to produce proteolytic enzymes important for
release of the ovum and they also have the potential to proliferate for repair of the
wound.
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The work of Auersperg documents the development and roles of the OSE in great
detail. The biology, endocrinology and pathology of the OSE are documented in a
great review from 2001 (Auersperg et ai, 2001).
1.3.2 Ovarian Cancer histopathology
Ovarian cancers arise from all cell types within the ovary. The oocytes give rise to
various germ cell tumours and cancers may also arise from sex cord/stromal origin.
These tumours generally have a good prognosis and can be treated successfully.
Most importantly, tumours can arise from the ovarian surface epithelium (OSE).
Ninety percent of all malignant neoplasia are believed to originate from the surface
epithelium. OSE cells, when neoplastic, retain the potential for Miillerian
differentiation giving rise to tumours with different pathological characteristics. The
most common are serous, endometrioid, mucinous, and clear cell tumours. Rare
Brenner tumours are formed when the tumour develops along wolffian lines to
resemble uroepithelium.
Ovarian surface epithelium tumours may be benign, borderline (low malignant
potential LMP), or malignant. It is the latter which are the frank epithelial ovarian
carcinomas (EOC). The spread of an EOC is seen in Figure 1.1.
Benign tumours generally have a very good prognosis. They are characterised by a
single layer of columnar cells with lack of atypia and a normal nucleocytoplasmic
ratio. They undergo few mitoses and display no invasion into the underlying stroma.
They tend to be of serous or mucinous origin and large and cystic. The most common
are mucinous cystadenomas which are characterised by large, smooth multilocular
cysts, and are usually unilateral and filled with gelatinous fluid. Serous
cystadenomas are less common, being thin-walled unilocular cysts which are filled
with watery fluid and are well differentiated. The cells resemble epithelia of the






Figure 1.1 The spread of EOC through the intraperitoneal cavity.
Borderline tumours (LMP) are multilayered with irregular budding and cellular
atypia. They resemble malignant neoplasms but are distinguished by the lack of
stromal invasion. Median age of diagnosis is 40 years and prognosis is good with
95% five-year survival. Most LMP tumours behave in a benign fashion and few
become malignant. Serous borderline tumours are the most common histological
type.
Malignant tumours tend to be aggressive with a very poor prognosis if disseminated
from the site of origin. Primary tumours often have regions of solid tissue which is
haemorrhagic and necrotic as well as being destructively invasive. They infiltrate
locally into pelvic tissue and seed tumour implants into the peritoneum, including the
fatty tissue structure, called the omentum. They, however, rarely metastasise to
distant sites. Malignant cells are characterised by cellular atypia, high
nucleocytoplasmic ratio with frequent mitoses. These tumours are rare before 20
years of age and incidence increases linearly after 55 years old. Tumours are
classified, as already mentioned, according to histological similarities to epithelial
components distinctive of different Miillerian structures. They are also classified by
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grade of differentiation. Well-differentiated tumours give the best prognosis with
little cellular atypia and few mitoses. Moderate and poorly differentiated cells show
increasing cellular atypia, more frequent mitoses and enhanced aggressiveness.
Undifferentiated tumours are rapid growing and aggressive with very poor outcome.
Serous ovarian carcinomas, the commonest type of ovarian cancer, are usually cystic
with numerous papillary ingrowths and are often solid in areas. These represent
about half of all EOC. Approximately 65% are bilateral with poor prognosis
(dependent upon stage) of 20-30% five-year survival. They are most likely to arise
de novo as carcinomas as opposed to development from benign lesion.
Twelve percent of EOC are mucinous cystadenocarcinomas. They are cystic,
multilocular and often well differentiated. They often progress from mucinous
cystadenomas. At the cellular level they are irregular structures lined by abnormal,
endocervical-like epithelium.
Endometrioid cancers are rarely benign or borderline and represent 15% of all EOC.
They are solid with areas of haemorrhage and tend to be less cystic than other
histological sub-types. Endometrioid tumours are characterised by glands lined with
columnar cells containing a large nucleus and little cytoplasm. Twenty-five percent
of cases are associated with endometrial carcinoma and a minority arise from foci of
pre-existing endometriosis. Five-year survival is better than for serous tumours at
about 51%.
Clear cell or mesonephroid tumours are thought to be a morphological variant of
endometrioid neoplasms. They are invariably malignant and are characterised by
large polyhedral cells containing abundant clear cytoplasm. They predominantly
affect post-menopausal women and, as for endometrioid carcinoma, may co-exist
with endometriosis. Clear cell carcinoma has a worse prognosis, stage for stage, than
serous carcinomas.
Brenner tumours are the most rare EOC as this histology is most commonly
associated with benign tumour type. They are characterised by rounded islands of
transitional type epithelia of wolffian origin embedded in a dense fibrous stroma.
Five-year survival is approximately 50%. Other malignant sub-types are mixed
Miillerian and undifferentiated tumours. The latter have a very poor five-year
survival of 16% due to the aggressive nature of the neoplasm.
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1.3.3 Origins and Progression of EOC
The origins and pathway of progression of ovarian carcinoma, although well studied,
are still undefined. There are two possible hypotheses for occurrence. The first
follows the progression theory, similar to that suggested for colon cancer by Fearon
and Vogelstein, in which, through the acquisition of defined genetic changes, a
benign tumour will progress to an aggressive carcinoma (Fearon et al., 1987). The
second, and most widely held view, is that the tumours arise de novo from direct
transformation of the OSE within inclusion cysts. There is also the potential that both
pathways of progression occur.
Colorectal cancer progresses from the collection of defined genetic lesions in
oncogenes and tumour suppressors. This multistep process ultimately produces the
neoplastic phenotype from the original normal colon epithelial cells. This
progression theory is rarely applied to ovarian cancers due to the lack of evidence for
early genetic lesions. A study by Zanetta looking at the progression of borderline
tumours to EOC showed only 2% progress, of both mucinous and serous histologies
(Zanetta et al., 2001). This suggests that the vast majority (98%) of EOCs do not
progress from borderline tumours. Molecular studies analysing expression of the
oncogene K-RAS in mucinous and serous tumours suggest that progression from
borderline and benign lesions may occur in only a subset of mucinous tumours (Haas
et al., 1999; Mandai et al., 1998). From these analyses, they determined that serous
tumours are unlikely to have progressed from borderline tumours or even from well-
differentiated carcinomas (Haas et al., 1999). A more recent study of K-RAS
mutations in serous tumours found 50% of borderline tumours and low-grade
invasive micropapillary serous carcinomas had K-RAS mutations (Singer et al.,
2002). None of the 23 high-grade serous carcinomas carried the mutation. They also
noted that 95% of bilateral ovaries from non-invasive serous carcinomas had
discordant patterns of genetic lesions. They found that the majority of the high-grade
serous carcinomas showed clonal allelic imbalances, which supports the notion that
they arise de novo. This study suggests two pathways of tumorigenesis. Firstly, a
low-grade invasive serous carcinoma may arise in a step-wise fashion from a
borderline tumour. In the second pathway, high-grade carcinomas develop de novo
by transformation of the ovarian surface epithelium. Singer does note however that
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other pathways of progression may exist. More support for the de novo theory is that
benign tumours appear phenotypically stable over long periods of time showing no
biological changes towards a more aggressive tumour-type.
In a study looking for a genetic lesion, loss of Chr 1 lpl5, common to the high-grade
tumour phenotype, Zheng showed that in those high-grade tumours which lie
adjacent to seemingly low-grade or benign sections of tumour, that the whole clonal
tumour has the lesion (Zheng et al., 1993). This suggests that the carcinomas are
heterogeneous in appearance with differing degrees of maturation and also lends
support to the idea that low-grade tumours may progress to higher grade lesions or
that the high-grade lesions may differentiate into benign-looking structures.
A review of the multistep pathway of EOC progression is seen in Figure 1.2.
There has also been debate about the origins of ovarian carcinomas of differing
histological sub-types and the suggestion that these may represent distinct disease
entities. Genetic lesions within a tumour sub-type differ. For example K-RAS
mutations are more frequent in mucinous tumours and p53 mutations are more
common in serous tumours. A recent study of gene expression analysis using
oligonucleotide microarrays showed mucinous and clear-cell EOCs can be readily
distinguished from serous ovarian cancers, regardless of tumour stage and grade
(Schwartz et al., 2002). This wide genetic heterogeneity may further separate ovarian
carcinomas into biologically and, importantly, clinically meaningful subgroups.
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Figure 1.2 Multistep pathway of EOC progression. Proposed pathways of EOC generation
from precursor lesions. Red pathways are the progression to EOC, blue pathways are the
progression to a benign or borderline histology.
1.4 Clinical management
1.4.1 Clinical prognostic factors
Clinical prognostic factors for survival from ovarian carcinoma include age, stage,
histological subtype, volume of disease pre and post operatively, differentiation
status, performance status and presence of ascites. It has been found that women of a
younger age at diagnosis generally have a better outcome. Five-year survival for
women aged 15-45 years is 65% compared to the over 75s survival of just 18%,
although younger women tend to have earlier stage, so less aggressive disease. The
histological subtypes of mucinous and clear cell carcinomas have a worse prognosis
than serous carcinomas. Grade of differentiation of the tumour is also important to
assess. Undifferentiated, high-grade, tumours are highly aggressive and have a
poorer prognosis. Lesser residual disease post-operatively is favourable and masses
under 1cm give a survival of 50% compared with those 2+cm of 13%. Stage is also a
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prognostic factor with the five-year survival rates of stages of disease seen in Table
1.1.
STAGE FIVE-YEAR FIVE-YEAR FIVE-YEAR
SURVIVAL SURVIVAL SURVIVAL
(STAGE A) (STAGE B) (STAGE C)
1 92% 85% 82%
II 67% 56% 51%
III 39% 26% 17%
i iv 12%
Table 1.1 Five-year survival rates of patients with differing stages of EOC. Subgroups A-C
represent increased spread of the cancer.
1.4.2 Clinical diagnosis
Early stage ovarian cancer is generally asymptomatic. The most common symptoms,
such as nausea and abdominal fullness and discomfort, are often related to the later
spread of the disease outside of the pelvis. Abnormality is often detected by pelvic
examination followed by transvaginal ultrasound and analysis of serum CA125
levels. CA125 is a large glycoprotein that is anchored to the surface epithelium. It is
secreted by way of cleavage in tumours. For the last 20 years CA125 has been used
as a tumour marker in ovarian cancers and which, although not only limited to
expression from ovarian carcinomas, is elevated in 80% of patients with advanced
stage ovarian cancer. Only 50% of early stage carcinomas, however, have elevated
levels of the antigen. Other less used diagnostic tests are CT scan or biopsy via a
laparoscopy. The latter method has however caused concern for spread of the cancer
due potential cyst rupture.
1.4.3 Staging and surgery
In the absence of extra-abdominal metastatic disease, staging of ovarian carcinomas
is done during exploratory laparotomy. Designated by FIGO, the stages represent the
extent of spread of the tumours (Table 1.2). Staging is important to determine
follow-up treatment although is often suboptimal. The laparotomy is often required
to diagnose the cancer. Once confirmed, surgery is performed; a total abdominal
hysterectomy (TAH), a bilateral salpingo-oophrectomy (BSO) and omentectomy.
Examination of all serosal surfaces is carried out and ascites or peritoneal washings
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are collected for cytogenetic analysis and histological diagnosis. A biopsy may also
be taken of peritoneal surfaces. Gross disease is then maximally debulked and
residual implants are noted for size. Debulking surgery is often stabilising for low
stage and grade disease and these patients have a five-year survival of 91-98%.
Optimal debulking is dependent upon the biology of the tumour and the ability of the
surgeon.
STAGE CHARACTERISTICS
la Growth limited to one ovary; no ascites. No tumour on the external
surfaces; capsule intact.
lb Growth limited to both ovaries; no ascites. No tumour on the external
surfaces; capsule intact.
Ic Tumour either stage la/lb but with tumour on surface of one or both
ovaries; or with capsule ruptured; or with ascites present.
lla Extension and/or metastasis to the uterus and/or tubes.
lib Extension to other pelvic tissues.
lie Tumour either stage 1 la/I lb but with tumour on surface of one/both
ovaries; or with capsule ruptured; or with ascites present.
Ilia Tumour grossly limited to the true pelvis with negative nodes but with
histologically confirmed microscopic seeding of the peritoneal
surfaces.
1Mb Tumour involving one or both ovaries with histologically confirmed
implants of abdominal peritoneal surfaces. Nodes- none exceeding
2cm diameter and negative.
lllc Abdominal implants >2cm diameter and/or positive nodes
IV Growth involving one or both ovaries with distant metastases. Positive
cytology.
Table 1.2 FIGO classification of EOC. Stages I-IV represent increased spread of the disease
with generally poorer prognosis.
1.4.4 Chemotherapy
Combination chemotherapy is the standard postoperative therapy for patients with
residual disease or those at high risk of recurrence. Patients with well-differentiated,
stage IA/B disease have a good five-year survival after surgery, which is not
improved by adjuvant therapy. Those however with stage IC or I- high grade, stages
II-IV or clear cell carcinoma (any stage) should receive chemotherapy. It is for this
reason that accurate staging and pathological review is essential.
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Carboplatin/paclitaxel combination therapy is currently classed as the gold standard
in treatment of the disease. External abdomino-pelvic radiotherapy is also an option,
but rarely used.
Chemotherapy after second-look surgery has no standard regimen. Options are to
stop treatment, continue same chemotherapy, use other chemotherapy or
intensification.
1.5 Genetic Epidemiology of ovarian cancer
1.5.1 Familial epithelial ovarian cancer.
Malignant transformation is believed to be a multistep process and data has
suggested that a series of 5 or 6 genetic alterations is rate limiting for cancer
development (Boyd and Rubin, 1997). Most ovarian cancers are sporadic, only 5-
10% are familial. Aside from age, family history is the strongest predictor of ovarian
cancer risk with one or two affected primary relatives with ovarian cancer conferring
a 5% and 7% risk respectively over the general population (Kristensen and Trope,
1997). There are distinct hereditary patterns for ovarian cancers that have high
penetrance of autosomal dominant genes.
Site-specific ovarian cancers account for 10-15% of all hereditary cases. Virtually all
are linked to mutations in the BRCA1 tumour suppressor gene on chromosome
17q21 (Boyd and Rubin, 1997). BRCA1 mutation carriers have a cumulative risk of
developing ovarian cancer, by age 70, of 63% (Boyd and Rubin, 1997; Elit, 2001;
Kristensen and Trope, 1997).
Breast/ovarian cancer syndrome accounts for 65-70% of all familial cases. Patients
with 5+ primary or secondary relatives with breast/ovarian cancer or, 3 cases early-
onset breast/ovarian cancer are categorised with the syndrome. It has been suggested
that site-specific ovarian cancer may be part of the same syndrome, but in which
early onset breast cancer has not occurred. BRCA1 mutations account for 75% of all
cases and most others are linked to BRCA2 on chromosome 13ql2-13 (Boyd and
Rubin, 1997).
The second distinct syndrome, HNPCC, accounts for 10-15% of all hereditary cases
(Bewtra et al., 1992). It is a cancer susceptibility syndrome that confers an increased
risk of colon, gastric, endometrial, small bowel and ovarian cancers. Patients are
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classified with HNPCC if they have 3+ primary relatives with either endometrial or
colon cancers and 2 were diagnosed with the latter earlier than age 50. HNPCC
confers a 3.5 fold increased risk of ovarian cancer over the general population and is
linked to four mismatch repair genes MSH2, MLH1, PMS1, and PMS2 (Boyd and
Rubin, 1997). Ovarian cancer is detected in 10% of HNPCC patients with mutations
of one of these four genes. Greater than 90% of HNPCC/ovarian cancer mutations
are in MLH1 (Chr 3p) and MSH2 (Chr 2p) (Boyd and Rubin, 1997). These mismatch
repair pathway genes are often silenced by loss of function mutations associated with
genetic instability.
1.5.2 Sporadic epithelial ovarian cancer
Sporadic ovarian carcinomas arise by clonal selection and accumulation of somatic
mutations in critical genes. Genetic changes such as amplification, altered expression
and mutations in oncogenes and tumour suppressor genes contribute to the
development of sporadic ovarian neoplasms. Those genetic lesions that confer a
selective advantage will predominate through a heterogeneous tumour.
Genes commonly over expressed or amplified in ovarian cancer include c-myc, c-
fos, CSF-1, ErbB2, PIK3CA and AKT. CSF-1 and its receptor, encoded by oncogene
c-fms, are over expressed in 78-89% of ovarian tumours and mostly co-expressed
(Baiocchi et al., 1991). They are involved in autocrine control of proliferation in
ovarian cancer cells.
Amplification or over expression of the oncogene c-myc is often associated with the
more common serous EOC histology. It is amplified in 50% of serous tumours and
over expression appears to be related to increased stage and aggressiveness (Bian et
al., 1995).
ErbB2/HER-2/neu gene, which encodes an EGF receptor, is amplified in 24-31% of
ovarian carcinomas and is commonly associated with poor survival and advanced
stage (Bian et al., 1995; Fan et al., 1994). More recently, a study in serous
carcinomas confirmed the association of amplification with late stage, showing 71%
amplification in stage III tumours as compared with only 22% amplification in stage
I tumours (Afify et al., 1999). EGFR/HER-1/ErbBl is another EGF receptor, which
is expressed in 70-100% of ovarian tumours (Baekelandt et al., 1999a). This over
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expression is believed to play a role in enhancing the invasive phenotype of the
tumour. Increasing expression correlates with increasing FIGO stage.
Hormone receptors ER and PR have been reported as prognostic factors in ovarian
cancer. The estrogen receptors ERa and ER8 are co-expressed in normal OSE. Over
expression of ERa relative to ER6 may be a marker of ovarian carcinogenesis (Pujol
et al., 1998). PR expression is commonly decreased in ovarian cancers and can be
used as a significant independent prognostic variable of progression-free survival in
advanced tumours (Hempling et al., 1998).
Recently, amplification of signalling molecules PIK3CA and AKT1/2 has been
reported. CGH detected that PIK3CA, a subunit of PI3K, is amplified in 40% of
tumours. AKT1/AKT2 are downstream molecules of the PI3K signalling pathway.
AKT1 has increased kinase activity in 39% of ovarian tumours with 73% of these
being of high grade and stage. AKT2 is amplified in 12% of ovarian tumours and
may be associated with high grade aggressive tumours (Bellacosa et al., 1995).
K-RAS, as mentioned previously, is commonly mutated in 71-75% of mucinous
tumours as compared to only 13-20% serous (Enomoto et al., 1991; Fujita et al.,
1994).
Finally, CDKN2A/MTS1 is a chromosome 9p21 cell cycle regulator that has been
reported as both a TSG and an oncogene. LOH at 9p21 is 45-65% but the gene is not
frequently mutated or methylated (Niederacher et al., 1999; Shih et al., 1997). A
paper by Dong suggests that increased expression of CDKN2A is related to
progression and unfavourable prognosis with 89% of tumours overexpressing the
gene (Dong et al., 1997).
Tumour suppressor genes are inactivated by mutation, LOH and epigenetic
mechanisms, such as methylation and acetylation. The most frequently reported
TSG, for all carcinomas, is p53. In ovarian tumours it is mutated in 50% of late stage
tumours (Berchuck et al., 1992). Mutations are also more prevalent in high-grade
serous tumours than other histological subtypes (Milner et al., 1993). Abnormal p53
expression is detected in 50% malignant tumours and over expression is correlated
highly with the presence of mutations in the p53 gene (Marks et al., 1991).
BRCA1 and BRCA2 have already been discussed as tumour suppressors in familial
cancer but they are also implicated in the progression of sporadic cancers. Reduced
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or absent BRCA1 protein and RNA expression has been detected in 90% of sporadic
epithelial ovarian tumours (Russell et al., 2000). LOH at the BRCA1 locus is
reported at 44% although somatic mutation rate is low at 3.5% (Russell et al., 2000).
BRCA1 is also methylated in 15% of sporadic ovarian tumours (Baldwin et al.,
2000). BRCA2 however is not methylated and rarely mutated but LOH of 43% at
13q is reported and is more frequent in serous tumours, with an LOH rate of 75% in
these (Gras et al., 2001).
Other candidate ovarian cancer TSGs include PTEN, Dab2/DOC2, and the more
recently described NOEY2/ARH1, LOT1/ZAC, OVCA1, SPARC and WWOX.
PTEN is a PI3K inhibitor, so antagonistically associated with the oncogene PIK3CA,
and is often allelically deleted and mutated in endometrioid EOC. LOH of 43% and
mutation in 21% of the endometrioid subtype has been reported (Obata et al., 1998).
These mutations appear to be implicated with early stage and low grade disease. Loss
of PTEN expression is also linked to increased phosphorylation of oncogene AKT,
probably via the resulting lack of PI3K inhibition (Kurose et al., 2001).
Dab2/DOC2, first described in ovarian cancer by a differential DNA fingerprinting
technique comparing OSE cells and ovarian carcinomas, is down regulated
particularly in serous ovarian tumours (Mok et al., 1998; Mok et al., 1994). It is an
essential suppressor of the RAS mediated signalling cascade and loss has been
implicated in the initiation of ovarian tumorigenicity (Yang et al., 2002).
NOEY2/ARH1 is an imprinted gene discovered by DD-RT-PCR with high
homology to RAS and RAP (Yu et al., 1999). Imprinting of the gene means that it is
expressed from either a maternal or paternal allele, as regulated by methylation.
There is 40% LOH at the ARH1 locus on lp31 in breast and ovarian cancers and the
gene is aberrantly methylated in breast cancer cells (Luo et al., 2001; Yu et al.,
1999).
LOT1/ZAC, first described in 1997 from loss of expression in transformed rat
ovarian surface epithelial cells, is also imprinted (Abdollahi et al., 1997). It lies in a
region of common LOH at 6q25 and is a nuclear protein that induces growth arrest
and apoptosis so is an ideal TSG candidate (Abdollahi et al., 1999; Piras et al.,
2000). LOT1 also exhibits maternal imprinting and demethylation experiments in
breast cancers have shown re-expression of the gene (Bilanges et al., 1999).
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0VCA1/DPH2L1 was identified by LOH and positional cloning on 17pl3.3 and is
expressed in normal OSE but transcription is undetectable/reduced in 92% of ovarian
tumours/cell lines (Schultz et al., 1996). Reexpression of OVCA1 in ovarian cell
line A2780 caused an increase of cells in G1 of the cell cycle due to increased
degradation of cyclin Dl. The reduction of this gene to hemizygosity by LOH is
thought to be enough to deregulate the cell cycle and promote tumorigenesis in
ovarian cancer cells (Bruening et al., 1999).
SPARC, a calcium-binding extracellular matrix glycoprotein also identified by DD-
RT-PCR, is expressed at lower levels in ovarian cancer cells/cell lines than in normal
OSE. Functional studies by transfection of SPARC into ovarian cancer cell line
SKOV3 showed it induced slower growth and suppressed tumorigenicity (Paley et
al., 2000). SPARC has also recently been reported to induce apoptosis in ovarian
cancer cells (Yiu et al., 2001).
Finally, WWOX has been reported as a tumour suppressor in multiple tissue types.
Initially identified by Bednarek through breast cancer mapping, the WWOX protein
has 2 WW domains and a short chain reductase region (Bednarek et al., 2000). The
gene itself spans about 750Kb and is situated at the fragile site FRA16D. It is
believed that WWOX may play a role in apoptosis. Paige et al showed that in some
ovarian cell-lines, WWOX has homozygous deletion of exons as well as finding
missense mutations (Paige et al., 2001).
1.6 Genomic analysis of ovarian tumours.
Genomic analysis of ovarian tumours has been important in the definition of regions
that potentially harbour genes associated with tumorigenesis and cancer progression.
It is thought that 30% of a solid tumour genome may be abnormal in copy number.
Methods used to identify these abnormalities include Fluorescent in Situ
Hybridisation (FISH), Competitive genomic hybridisation (CGH), and
Representational Difference Analysis (RDA).
The first involves hybridisation of probes targeted to specific chromosomes or
subregions to detect losses, gains or rearrangements but is complicated to interpret
for complex tumour karyotypes. CGH examines genome-wide DNA copy number
gains and losses rather than looking at focussed regions by FISH analysis. RDA is a
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subtractive method, again detecting copy number differences between two genomes,
comparing a normal reference sample and a tumour genome.
Loss of Heterozygosity (LOH) is a method which detects allelic loss at regions
within a cancer genome utilising polymorphic microsatellite markers. Significant
levels of allele imbalance may suggest the presence of a TSG(s) within the regions of
LOH identified as one of the two 'hits' required for knockout of the gene.
Fluorescence in situ hybridisation (FISH) of metaphase ovarian cancer cells has
shown frequent chromosomal abnormalities at one or more loci. Jenkins found 80%
of ovarian tumour cells had genomic abnormalities, with common gain of
chromosomes +1, +2, +3, +6, +7, +9, +12 and loss of -X, -4, -8, -11, -13, -15, -17
(Jenkins et al., 1993). Structural abnormalities involved regions lp36, lq32, lq42,
3pl3-p26, 3q26-q29, 7p22, 9q34, Ilpl3-pl5, 17q21-q23, 19pl3.3 and 19ql3.3.
Other, but more specific, chromosome hybridisations have shown loss of
chromosomes 17 and X and gains of chromosomes 12 and 8 (Persons et al., 1993).
Comparative genome hybridisation (CGH) compares the whole genome structure of
one cell type to another. Multiple CGH experiments have identified a number of
regions frequently associated with ovarian cancers. Chromosome regions 3q25-26
and 20ql3 were associated with low-grade tumours where as 8q24 gains are frequent
in high-grade tumours (Iwabuchi et al., 1995). An analysis of 24 non-aggressive low-
grade tumours showed common gains at chromosomes +lq, +2p, +7q, +8q, +17q and
losses at -8p, -9p, and -13q (Tapper et al., 1997). Two recent CGH studies
implicated gain at +8q, and +20q and loss at —13q, -18q and -4 with ovarian tumour
progression (Kiechle et al., 2001; Watanabe et al., 2001). Kiechle also reported gains
at +19p, +3q and +lq and correlated high-grade tumours with loss at -1 lp and -13q
and gains at +8p and +7p. Low-grade tumours were associated with loss at -12p and
gains at +18p (Kiechle et al., 2001). Watanabe also reported loss at 1 lpl4-15 and 9p
and gains at 5pl5, 7q32-36 and 20p (Watanabe et al., 2001). Cisplatin resistance has
been associated with, via CGH, gains of chromosome regions +2ql4.1-q33,
+4pl5.2-pl3, +4q22-q25, +4q31.1-q43, +6ql3-ql6 and +8ql2-q21.1 and loss of
regions -Xp22.2-q21, -7p21-pl4 and-1 lcen-pl4 (Wasenius et al., 1997).
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RDA is a little used method that identifies specific regions of loss on a chromosome
associated with a certain phenotype. Homozygous deletions in ovarian cancer have
been identified by the method at 9p21, 16q23.2 and at 22ql3 (Lin et al., 2000; Paige
et al., 2000; Watson et al., 1999). The last has been dismissed as a potential TSG
harbouring region whereas recently a candidate has successfully been identified at
16q23.2 (Paige et al., 2001).
LOH or 'allelic imbalance' analysis is used to hunt for regions of heterozygous loss.
According to Knudson's two hit hypothesis LOH would be classed as one 'hit' so
one further hit is needed at that locus for gene inactivation. Potential TSGs may
therefore lie in these regions. Regions of LOH in ovarian cancer have been
commonly identified at 5q21, llpl5, 13q, 17p, and 17q. Launonen associated loss at
llpl5.1, llq23.3 and 16q24.2 with late stage disease and loss at 17pl3.1 with early
disease (Launonen et al., 2000). Weitzel and Saretzki both showed LOH at llpl5
(50%), 5q21 (30.4-50%) and at 9p (53%) (Saretzki et al., 1997; Weitzel et al., 1994).
The CGH and LOH data is summarised in Table 1.3, with loses and gains
highlighted on each chromosome arm. Those studies chosen were mainly genome
wide assays of chromosome amplification and loss. There are many papers that
investigate LOH on individual chromosomes but these are excluded from this figure.
LOH analyses of specific chromosome arms are common and have been used to
identify many candidate ovarian cancer TSGs including BRCA1 and p53. An
overview of these analyses is seen in Table 1.4.
These above genomic techniques have successfully pinpointed regions of potential
tumour suppressor genes and oncogenes. For example, the common regions of loss
on chromosome 17p and q correlate with p53 and BRCA1 respectively.
Amplification at lq may correlate to the oncogene SK at lq22-24 and at 8q24.12-
q24.13, another common region of amplification, lies c-myc.
There are however regions which have been implicated in ovarian cancer but no
corresponding genes have been identified. For example, 3q is commonly over
represented in advanced tumours but as yet no confirmed oncogenes have been
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identified in this region. Loss at 1 lp 15 is also often seen in ovarian cancers by LOH
and CGH analyses but no confirmed tumour associated suppressor genes have been
found to date.
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Author 1P iq 2p 2q 3p 3q 4p 4q 5p 5q 6p 6q 7p
CGH Hauptmann et a/., 2002 gain loss gain loss gain
Tapper et at., 1997 q22-q32 p15-p22 qc«n-q23 p21-22
Arnold et at., 1996 p35-pter gain gain q26-qter loss p21-22
Sonoda et at., 1997 q32 q26-qter q26-q31 q21
Kiechle et at., 2001 gain gain loss gain
Watanabe et at., 2001 p11-p14 p15
LOH Gallion et at., 1992 *
Cliby etai, 1993 (all) loss loss loss loss
Dodson etal., 1993 (all) loss
Weitzel etal., 1994 * * * *q21 * *
Saretzki et at., 1997 *q21-22 * loss *q21 * *
Launonen et at., 2000 * p14.2
*
Author 7q 8p 8q 9p 9q 11p 11q 12p 12q 13p 13q 14q 15q
CGH Hauptmann etal., 2002 gain gain loss loss
Tapper et al„ 1997 gain loss gain loss loss
Arnold et at., 1996 q23-qter p12 q21
Sonoda et at., 1997 q36 q24 p21-pter loss gain
Kiechle et at., 2001 gain loss loss
Watanabe etal., 200) q32-q36 q23-24 loss p14-p15 p11-12 q22-24
LOH Gallion et at., 1992 * loss *loss
Cliby etal., 1993 (all) loss loss loss loss loss
Dodson et at., 1993 (all) loss loss




Saretzki etal., 1997 * p21 *





Author 16q 17p 17q Q.00 18q 19p 19q 20p 20q 21 q 22q Xp Xq
CGH Hauptmann etal., 2002 loss gain
Tapper et at., 1997 gain
Arnold et at., 1996 q23-qter q22-qter gain gain loss
Sonoda etal., 1997 loss loss q25 q13 gain q13-qter loss
Kiechle et at., 2001 loss gain gain
Watanabe et at., 2001 q21-23 q22-q23 gain q12-13
LOH Gallion etal., 1992 * * loss
Cliby etal., 1993 (all) lOGO looo loss loss loss
Dodson etal., 1993 (all) loss loss loss
Weitzel et at., 1994 * p11 *q22-24
Saretzki et at., 1997 * * qzi
* *
Launonen et at., 2000 * q24.3 *p13.1
Table 1.3. Summary of chromosome losses and gains in ovarian cancers as identified by
genome-wide studies using CGH and LOH. Amplifications are highlighted in red and losses
in blue. First authors of papers shown. LOH studies are genome-wide unless * shown which












RASSF1A Me in 40% tumours
Associated with Chr 17 LOH
Lounis et al., 1998, Fullwood et at., 1999,
Agathanggelou et at., 2001, Sekine et at.,
2001, Yoon et al., 2001, Zhang and Xu,
2002, Manderson et al., 2002.
5q 5q13-q21 APC 5q21-q22?, Associated with p53
mutation, Early stage.
Allan et al., 1994, Tavassoli et al., 1996,






Foulkes et al., 1993b, Cheng et al., 1996,
Colitti et al., 1998, Otis et al., 2000, Suzuki
et al., 2000, Wang et al., 2001b.
7P 7p Early stage Watson etal., 1998
7q 7q31.1
7q21-31
Advanced stage, fragile site FRA7G,
TES candidate
Associated with Chr 13 LOH
Zenklusen etal., 1995, Kerr etal., 1996,
Koike etal., 1997, Edelson etal., 1997,
Huang etal., 1999, Neville et al., 2001,
Tobias et al., 2001.
8p 8p12-p21, 8p21.1,
8p22-p23.1, 8p23.1
Advanced stage, associated with Chr
9p LOH, serous histology, poor grade,
FEZ1, GATA4 candidates.
Wright et al., 1998, Ishii et al., 1999, Brown
etal., 1999, Lassus etal., 2001a, Pribill et
al., 2001.
9p 9p21-p22 CDKN2A candidate, serous histology,
early stage
Rodabaugh et al., 1995, Campbell et al.,
1995, Watson etal., 1998,Niederacheref a/.,
1999.
11p 11 p15.5-15.3,
11 p15.1, 11 p13
Adverse survival, poor grade,
advanced stage, nonmucinous
histology.
Eccles et al., 1992a, Viel et al., 1992,
Kiechle-Schwarz et al., 1994, Lu etal., 1997.
11 q 11 q22-23, 11q23.2-
q24.3
Adverse survival, early stage, serous
histology, Loss of PR protein, ATM
candidate
Foulkes et al., 1993b, Watson et al., 1998,
Gabra et al., 1995, Koike et al., 1999.
13q 13q12, 13q14.1,
13q33-q34
Early event, Chr 17q LOH, BRCA2,
MCJ, RB candidates
Yang-Feng et al., 199), Yang-Feng et al.,
1993, Liu et al., 1994, Foster et al., 1996,




Poor grade, CDH13 candidate,
advanced stage
Iwabuchi et al., 1995, Kawakami et al., 1999.
17p 17p13.1, 17p13.3 Serous histology, advanced stage,
poor grade, aberrant p53 expression,
p53, OVCA1/OVCA2 candidates
Eccles et al., 1992b, Gallion et al., 1992,
Foulkes et al., 1993a, Yang-Feng et al.,
1993, Godwin etal., 1994, Wertheim etal.,




Poor grade, advanced stage, serous
histology, BRCA1, septin candidates
Eccles et al., 1992b, Foulkes etal., 1993a,
Tavassoli et al., 1993, Nagai et al., 1994,
Godwin ef al., 1994, Chen etal., 1995,
Wertheim et al., 1996, Otis et al., 2000, Dion
etal., 2000, Russell etal., 2000.
18q 18q21, 18q22-q23 Serous histology, advanced stage,
SMAD4/SMAD2, DCC candidates
Zborovskaya et al., 1999, Lassus et al.,
2001b.
19p 19p13.3 STK11 candidate Wang et al., 1999b.
19q 19q13.2-13.4 ERCC1/ERCC2 candidates Bicher et al., 1997.
22q 22q12 - Englefield et al., 1994, Bryan et al., 2000.
XP Xp21.1-p11.4 - Yang-Feng et al., 1992.
Xq Xq25-26.1, Xq11.2-
q12, Xp22.2-22.3
Advanced stage, poor grade, Chr 17p
LOH, Androgen receptor candidate,
BRCA1 associated.
Choi etal., 1997, Edelson et al., 1998,
Buekers et al., 2000.
Table 1.4 Individual analyses of LOH in ovarian cancers. These papers analyse only regions
or just a few chromosome arms. Regions of loss, histopathological correlations and
candidate TSGs within those regions are shown.
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1.7 Chromosome lip And Ovarian Cancer
Numerous LOH and cytogenetic studies have implicated Chr 11 in ovarian cancer.
The earliest cytogenetic study showing Chr 11 loss in ovarian neoplasia was
published in 1989 and found structural loss of 1 lpl3-1 lpter in 55% of high grade
serous carcinomas (Pejovic et al., 1989). Pejovic later reported frequent loss of
genetic material at 1 Ipl3-pl5 (Pejovic et al., 1992).
The H-RAS locus on 1 lpl5.5 has been analysed in multiple LOH studies. Viel
reported LOH at H-RAS in 4 of 7 cases of ovarian cancer but mutation analysis of
the gene suggested that H-RAS is not a TSG candidate (Viel et al., 1991). Lee also
detected LOH at this locus in 46% of ovarian cancers (Lee et al., 1990). Another
study of H-RAS showed LOH in 53% of invasive tumours and associated loss with
an advanced stage in progression (Gallion et al., 1992). It was thought, from these
studies, that a TSG might lie nearby this gene marker.
Further LOH mapping suggested the presence of two candidate TSG loci at 1 lpl5.5
and 1 lpl3 (Viel et al., 1992). LOH analyses of chromosome lip by Lu et al
narrowed down the regions of LOH to an 1 lcM region spanning from D11S2071 to
D11S988 at 1 lpl5.5 and a 4cM region surrounding the marker D1 IS 1310 at 1 lpl5.1
(Lu et al., 1997). These regions correlated with LOH rates of 43% and 32%
respectively. They also reported that 52% of tumours had allelic deletion in both
regions and that these losses are associated with high-grade non-mucinous epithelial
ovarian carcinoma (Lu et al., 1997).
Using 4 polymorphic microsatellite markers, Kiechle-Schwarz detected 48% LOH
along 1 lpl5.5-l lpl5.1 (Kiechle-Schwarz et al., 1994). A significant association was
seen between loss at 1 lpl5 and late stage and high grade tumours. A correlation was
seen between the rate of LOH and grade of differentiation, further indicating that
1 lp 15 loss plays an important role in ovarian cancer development.
An early study using RFLP analysis of markers on 1 lp showed 33% LOH at 1 lpl5.4
and LOH of only 18% at the H-RAS locus at 1 lpl5.5 (Eccles et al., 1992a). Loss at
one or both of these loci was associated with significantly poorer survival of patients.
A recent clinicopathological study associated LOH at 1 lpl5.5 (D1 IS 1318) with high
tumour stage, metastasis, residual tumour after surgery and reduced patient survival.
This again supported a role for loss in this region at a late point in disease
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progression (Launonen et al., 2000). LOH at 11 p 15.5 also correlated with loss at
6q27 (Launonen et al., 2000). Zborovskaya however reported loss at D11S922
(llpl5.5), adjacent to D11S1318, in benign and borderline malignancies
(Zborovskaya et al., 1999). The majority of studies however support the association
of 1 lp allelic deletion with high grade aggressive tumours.
Chromosome lip 15 is a very gene dense region containing >100 genes. Despite the
extensive LOH and CGH mapping that has been performed, no candidates within
this region have been identified in ovarian cancers. The region has however been
minimised substantially by the efforts. Prior to this work being performed, the
minimal candidate TSG-containing regions were an llcM region spanning
D11S2071-D11S988 and a 4cM region centred on the marker D11S1310, bordered
by D11S926 and D11S899, from the LOH analysis by Lu et al (Lu et al, 1997).
LOH mapping in other cancers has been more successful in minimising candidate
regions. For example in Lung cancer, two regions, labelled LOH11A and LOH1 IB,
through fine mapping of the region have been minimised to D11S1758-D1 IS 12 and
H-RAS-D1 IS 1363 respectively (O'Briant and Bepler, 1997). These regions span
approximately 2Kb and 1Kb. In breast cancers, LOH is again detected in two
regions, between D11S1318- D11S4088 and D11S1338-D11S1323 (Karnik et al.,
1998a). These regions overlap with others detected in Wilm's tumour, lung cancer
and rhabdomyosarcoma. Although this mapping is substantial only one candidate
TSG has been investigated. The gene is SRBC and lies in breast cancer region 2 (Xu
et al., 2001). SRBC transcription is affected by frameshift and truncating mutations
in a few lung and ovarian cancer cell-lines. Methylation of the promoter CpG island
was also detected in breast and lung cancers and SRBC was re-expressed upon
treatment with demethylating agents 5'azacytidine and Trichostatin A (Xu et al.,
2001).
Further mapping in ovarian cancers is required to minimise interesting regions of
high LOH along 1 lpl5 in the eventual aim of identifying EOC-associated TSGs.
1.8 Microcell Mediated Chromosome Transfer
As discussed previously, cytogenetic and LOH studies have implicated loss of
normal Chr 11 in tumour suppression. Evidence for regional loss has been reported
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in numerous tumour types including EOC. This data however does not prove that the
chromosome disruptions are functionally important in cancer. Functional evidence
can be obtained by introducing an intact copy of a TSG into a cancer cell that lacks a
fully functional copy. A method was developed by which single specific
chromosomes were transferred into cancer cells to generate clones with suppressed
tumour phenotypes, so suggesting that a functional TSG(s) lies on that chromosome
(Harris et al., 1969). This method is called microcell-mediated chromosome transfer
(MMCT). It is used to transfer selectable-tagged chromosomes into cancer cells that
have previously been shown to have deletions at a particular locus based upon
cytogenetic studies or by LOH. The first study to use this technique transferred an
HPRT- tagged Chr 11 from mouse A9 x t(X;l 1) hybrid cells into tumorigenic HeLa
cells (Saxon et al., 1986). They reported complete suppression of HeLa cell
tumorigenicity caused by the transfer.
The method originates from a technique used by Stanbridge in which he cell-fused
HeLa cells and normal diploid fibroblasts (Stanbridge et al., 1981). These fused
hybrids were found to be completely suppressed for the tumorigenic phenotype. Only
after prolonged passage did rare tumorigenic segregants arise. Karyotype analysis of
the segregants showed a correlation between loss of a single copy of chromosomes
11 and 14 and their reversion back to the tumorigenic phenotype. A later study by
Klinger confirmed this result and Kaelbling reported that it was the normal fibroblast
Chr 11 that was being lost in the tumorigenic segregants, rather than the HeLa
derived copy (Kaelbling and Klinger, 1986; Klinger, 1982).
Since these early studies, normal chromosome 11 has been reported to suppress
tumorigenicity when transferred into numerous carcinoma cell-lines including
Wilm's tumour, cervical cancer, rhabdomyosarcoma, uterine endometrial cancer,
breast cancer, lung adenocarcinoma and ovarian carcinoma (Cao et al., 2001; Negrini
et al., 1992; O'Briant et al., 1997; Oshimura et al., 1990; Weissman et al., 1987;
Yamada et al., 1990).
Microcell-mediated chromosome transfer itself is a powerful tool used to locate
senescence, metastasis and tumour suppressors, in the mapping of disease genes such
as Fanconi anaemia group D and Leigh syndrome and in the physical mapping of
chromosomes. It has been useful in both locating and identifying genes as well as
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narrowing interesting regions by the transfer of chromosome sub-fragments.
Examples of genes identified by MMCT are KAI1, a metastasis suppressor in
prostate cancer at 1 lpl 1.2-13, Ribosomal Protein L14, a candidate TSG at 3p21.3 in
lung carcinomas and PTEN at 10q23 in gliomas (Dong et al., 1995; Satoh et al.,
1993; Shriver et al., 1998) (Steck et al., 1999). Potential ovarian cancer related TSG
containing regions which have been narrowed by the method are a 2 cM locus at
D6S1637 to D6S1564, and a region at chromosome 22qll-ql2 lost in SKOV3 cells
(Wan et al., 1999; Kruzelock et al., 2000). In prostate cancer, MMCT has minimised
a 1.2 Mb region spanning D10S1172- D10S226 (Fukuhara et al., 2001).
The success ofMMCT makes it a good method to hunt for potential TSGs in ovarian
cancer. Chromosomes 3, 6, 10, 11,12, 14, 17 and 22 have successfully been
transferred into the ovarian cancer cell-lines SKOV3 and/or HEY (Cao et al., 2001;
Kruzelock et al., 2000; Rimessi et al., 1994; Sandhu et al., 1996; Wan et al., 1999).
Rimessi introduced, using MMCT, normal chromosomes 3, 6, 11 and 17 into HEY
ovarian cancer cells (Rimessi et al., 1994). Chr 3, when transferred, caused gradual
growth arrest and decreased tumorigenicity of cells in nude mice. Chr 11 produced
no morphological differences although in vitro growth rate and clonogenic activity in
agar was reduced. They noted that tumorigenicity of clones was varied and
concluded that chromosome 11 was not involved in the phenotype. HEY cells,
however, only have loss at llq21 so the addition of chromosome 11 into the cells
may only complement this region. Transfer of chromosomes 6 and 17 are not
discussed in the paper.
Sandhu reported that transfer of chromosome 6 or 6q into human and rat ovarian
tumour cells restored senescence but no similar effect was seen with transfer of
either chromosome 10 or 14 (Sandhu et al., 1996). Revertant rat microcell clones
revealed a deletion at 6q 14-21 suggesting this is the locus of a senescence gene,
confirmed by transfer of the 6q 13-21 region into human and rat cells. They named
the senescence-related gene, which lies within this region, SEN 6A. A second
transfer of chromosome 6 but into ovarian lines HEY and SKOV3 by Wan abolished
tumorigenicity (Wan et al., 1999). Revertants were subsequently isolated from the
suppressed clones and microsatellite mapped to determine extent of chromosome 6
in the cells. They identified a 2 cM region potentially harbouring a TSG at 6q26-27.
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As a control, a fragment of distal chromosome 11 q was also transferred but clones
were not suppressed in growth or tumorigenicity.
Kruzelock reported the transfer of chromosome 22 by MMCT again into SKOV3
(Kruzelock et al., 2000). Complete suppression of tumorigenicity and cell growth
was seen in 89% of clones. Again, the region was successfully minimised to 22ql 1-
ql2, characterised by the marker D22S429.
Chromosomes 11 and 17 are the most recently reported to be transferred into the
ovarian cancer SKOV3 cell-line (Cao et al., 2001). Chr 17 hybrids showed an
increased latency period when injected into nude mice. Tumour volume was also
significantly decreased but there was little change in in vitro doubling times, so,
tumorigenicity was not completely suppressed in these hybrids. Introduction of Chr
11 into SKOV3 produced 5 independent clones, all of which contained informative
microsatellite markers, so transfer of the chromosome. FISH analysis revealed that
all hybrids had gained one copy of chromosome 11. Four of the five had prolonged
in vivo tumour latency of >100 days as compared to normal SKOV3 latency of just 7
days. Tumour volume on average was about half of that of SKOV3 parental cell-line
and in vitro doubling times were longer than normal meaning the cells were growing
more slowly. The contradiction of these results of chromosome 11 transfer compared
to transfer into HEY cells has been explained by the difference in subtype of ovarian
cancers. Cao noticed that one of the five hybrids, even though it contained all 4
microsatellite markers, grew like the parental SKOV3 line. This may be due to
incomplete transfer of chromosome 11 and the clone having lost the TSG at a region
out with the microsatellite markers. Markers D11S1984, D11S1999, WT1 and
D11S2000 were used located at llpl5.5, llpl5.3, 1 lp 13 and llq22 respectively.
Further mapping would be required to narrow the region of a potential TSG.
None of the studies that transferred chromosome 11 in an ovarian cancer cell-line
have successfully minimised the area of interest by microsatellite mapping. Further
revertant studies or repeat of the chromosome 11 transfer is needed in order to refine
the TSG containing region. It should be noted however, that with the advent of the
Human Genome sequencing project, MMCT is becoming redundant in its use due to
the huge gene positioning effort that has occurred.
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1.9 Differential gene expression analysis
1.9.1 Gene expression analysis - techniques
Cancer genetics over the past 60 years has focussed on the identification and analysis
of genes that are differentially expressed between normal and cancerous phenotypes.
It is thought that there are 20,000 genes expressed at once in a typical cell and 1% of
those may be involved in cancer. These cancer genes are associated with apoptosis,
angiogenesis, cell cycle control, signalling, adhesion, migration, and DNA repair
among other processes (Hanahan and Weinberg, 2000). It is the study of such genes
that will give us an insight into the progression of cancers. Identified candidate genes
may translate to a clinical setting for use in prevention, detection, diagnosis or
therapy. Currently, however, only a small subset of genes has been identified as
playing a role in ovarian cancer.
Techniques applied to ovarian cancer-related gene discovery in recent years have
included differential display RT-PCR (DD-RT-PCR), cDNA representational
difference analysis (cDNA-RDA), and serial analysis of gene expression (SAGE).
All have been successful in identifying cancer-implicated genes. Even more recently,
microarray analyses have been applied to the problem; hunting for genes that are
differentially expressed between either differing histological subtypes of ovarian
cancer or between normal ovarian surface epithelial cells and pooled tumour sources.
Differential display RT-PCR dates back to 1992 when first described by Welsh and
then further developed by Liang and Pardee (Liang et al., 1993; Welsh et al., 1992).
The method is based upon arbitrarily primed PCR fingerprinting and detects
differences in gene expression between two RNA populations. The general strategy
is to compare patterns of radiolabelled cDNA sequences that are amplified by PCR
and separated on a sequencing gel. The use of several different primer sets allows
analysis of a large number of genes. Each mRNA is represented as a single band,
which may or may not be altered in expression between the sample populations, and
differentially expressed bands are excised, cloned and sequenced for identification.
Differential display is a simple technique that can be performed in a standard
molecular biology lab, requiring minimal bioinformatics ability. DD-RT-PCR can
identify known and novel genes. The disadvantages are that the method is limited in
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sensitivity so that not all differences are detected by using a single primer. The main
drawback of DD-RT-PCR however is the high level of false positives. 50% false
positives have previously been reported (Martin et al., 2000).
Hubank and Schatz adapted cDNA-RDA from genomic RDA, a method used to
identify regions of deletion between two genomes (Hubank and Schatz, 1994;
Lisitsyn and Wigler, 1993). Unlike DD-RT-PCR, cDNA-RDA couples PCR
amplification with subtractive hybridisation so in theory the method should identify
only actual differences between the two populations. The cDNA populations are
restriction enzyme digested to generate representations, containing fragments
ranging from 50bp to 1Kb, called the tester and driver. cDNA-RDA requires less
than 5% of the mRNA amount required for DD-RT-PCR, so is suitable for analyses
with limited samples. The representations are ligated to adapter sequences and PCR
amplified with primers complementary to these. The driver has linkers removed and
then is mixed in excess with the tester population. Kinetic enrichment amplifies only
those tester fragments that do not have a counterpart in the driver pool. The RDA
procedure is usually reiterated twice or more to produce sequential, increasingly
stringent 'difference products' and the cDNA fragments within these are identified
by sub-cloning and sequencing. The method requires validation of products to
establish the actual expression difference. The identification of differential genes
relies on the relative difference in expression levels between sample populations.
Those genes with a greater expression difference appear to be amplified
preferentially so are more abundant within the difference products. Although
sensitive, cDNA-RDA is technically demanding and, as for DD-RT-PCR, is prone to
a high rate of false positives (Hubank and Schatz, 1999)
SAGE is a more recent difference analysis method (Velculescu et al., 1995) and
based upon sequence analysis of short regions, close to the 3' end, of every cDNA in
a sample. Sequence tags of 10-14 bp from the 3' mostNlalll restriction sites of genes
are ligated together, separated by a distinctive linker sequence. These concatamers
are sequenced and results compiled to form a distribution showing the frequency of
various gene- associated tags. The frequency of tags is related directly to the
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expression of the gene associated with the tag. This method requires specialised
computer software to count the abundance of thousands of tags simultaneously.
SAGE data is then compared between different cDNA samples, with a gene with
differential expression represented by more tags in one population as compared to
the other. The downside to the method is the need for detailed computer analysis and
also the extensive sequencing strategies required for a high level of sensitivity.
In comparison to the above open systems, that is methods that are capable of
identifying all- including novel- differentially expressed genes, cDNA array
technology assays a set of fixed known genes for expression. cDNA arrays are
formed by amplification of 0.6-2.4 Kb DNA segments by PCR then mechanical
spotting of these at a high density onto a glass or membrane 'chip'. The DNA is
chemically fixed to the surface and heat denatured prior to hybridisation. Chips are
then simultaneously probed with fluorescent-tagged cDNA representations of total
RNA from tester and reference samples. Cy3 and Cy5 dUTP tags are commonly
used. A confocal laser scanner measures fluorescence to determine intensity of
hybridised sequences.
cDNA arrays are sensitive detecting a single transcript in 100,000 or less of total
RNA (Lockhart and Winzeler, 2000). They are also practical for application on a
large scale. The major drawbacks to the method are cost and the technical expertise
required to carry out the experiment and the subsequent data analysis. cDNA arrays
also need a large amount of RNA (50-200//g) although this may be decreased if
RNA amplification is used. They do not have such a high level of false positives as
the previous methods but a single hybridisation may still have a misclassification rate
of up to 9% (Lee et al., 2000). The reliability and accuracy of results increase with
repeats of analysis with 3 replicates giving a final error rate of just 0.7%. It has also
been recommended that validation of products are done in using RT-PCR or
Northern blotting to confirm the findings of a microarray. This is important when
single genes are being analysed as candidates.
cDNA arrays, even though they have limitations, are one of the most widely used
methods for profiling gene expression, often with the an aim of identifying gene
signatures of certain cancer types.
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1.9.2 DD-RT-PCR and epithelial ovarian cancer.
DD-RT-PCR was the first published method to be used in the gene expression
analysis of ovarian tumours in comparison the their normal counterpart.
Mok et al successfully used DD-RT-PCR to isolate genes differentially expressed
between normal OSE cells and ovarian tumours (Mok et al., 1994). Two cDNA
fragments were found to be absent in all of the ovarian cancer cell lines used in DD-
RT-PCR. These were named DOC-1 and DOC-2. They also identified a fragment,
LF4.0, which is over expressed in most tumour cell lines in comparison to normal
OSE. Results were confirmed by Northern blotting (Mok et al., 1994). DOC-2 has
been further characterised as a candidate TSG in multiple tumour types through
functional studies (Fulop et al., 1998; Tseng et al., 1999; Wang et al., 2001a).
A later DD-RT-PCR study, in 1999, identified NOEY2/ARH1 as a RAS and rap
homologue expressed only in normal breast and ovary epithelial cells (Yu et al.,
1999). The gene was confirmed as differentially expressed by Northern blotting and
identified as being maternally imprinted. This gene has subsequently been
characterised as aberrantly methylated in breast cancer cells (Luo et al., 2001).
Candidate oncogene Opl8/stalthmin was identified by DD-RT-PCR and shown to be
over expressed in 12 malignant ovarian cancers (Price et al., 2000). Protein over
expression was also determined using IHC. This cell cycle protein had been
previously identified by 2D-gel electrophoresis as over expressed in ovarian tumours
(Alaiya et al., 1997).
DD-RT-PCR has been used in a number of studies to identify chemotherapy
resistance related genes in ovarian cancers (Duan et al., 1999; Shridhar et al., 2001a;
Yamamoto et al., 2001a; Yamamoto et al., 2001b).
The comparison of cisplatin (CDDP) sensitive and CDDP resistant cell lines 2008
and 2008/C 13*5.25 discovered heat shock proteins HSP75, HSP27 and HSP70 were
associated with the resistant phenotype (Yamamoto et al., 2001a). A novel gene
CRR9 (CDDP resistance related gene 9) was also identified by DD-RT-PCR
highlighting its ability to discover uncharacterised transcripts (Yamamoto et al.,
2001b). Another novel gene TRAG-3 was seen to be associated with taxol resistance
(Duan et al., 1999).
38
Shridhar reported the association of a DNAJ protein family member, MCJ, with
chemotherapy resistance (Shridhar et al., 2001a). Expression of MCJ (Methylation
containing J Protein) was absent or reduced in a majority of primary and ovarian
cancer cell lines. MCJ nonexpressing cell lines showed resistance to paclitaxel,
topotecan and CDDP.
1.9.3 cDNA-RDA and ovarian cancer.
cDNA-RDA has in the literature been described only once for ovarian cancer. Its use
with other tumour types has proven it as a successful method of gene identification
(Chang et al., 1998; Gress et al., 1997; Lang and Schuller, 2001; Wallrapp et al.,
1999).
Ismail described the comparison of gene expression profiles of a HOSE sample and
two pooled tumours to identify candidate cancer genes using cDNA-RDA (Ismail et
al., 2000). Instead of using the method of cDNA-RDA alone, they coupled it with
array analysis for identification of genes that are aberrantly expressed in a large
number of ovarian tumours.
After 2 rounds of cDNA-RDA subtractive hybridisation, 255 differentially expressed
genes were identified, 160 upregulated and 95 down regulated with respect to HOSE
cell expression. These candidates were then spotted onto filters to create the cDNA
array. Pooled cDNA representations from 5 HOSE and 10 serous ovarian tumours
respectively were hybridised onto the filters. Sixty genes were subsequently
identified as having >2.5-fold difference in expression. The majority of genes
identified by cDNA-RDA were be differentially expressed by <2.5- fold on the array
suggesting a high false positive rate for the cDNA-RDA. They found that variability
in gene expression within tumour and HOSE samples was leading to elimination of
previously published cancer associated genes such as DOC-1. The array analysis was
thought to have been effective in identifying genes that display a constant pattern of
expression differences in a large number of tumour samples. The ability of arrays to
comparatively analyse multiple samples is one advantage of not using simply cDNA-
RDA alone. The coupling of these two techniques has been further supported in
Ewing's sarcoma (Welford et al., 1998).
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A method called Suppression Subtraction Hybridisation (SSH), which is similar to
cDNA-RDA has also been used on ovarian cancer samples (Shridhar et al., 2002).
SSH selectively amplifies target cDNA fragments whilst simultaneously suppressing
non-target DNA amplification in a population, generating a library of differentially
expressed sequences. Unlike cDNA-RDA however, it does not need several rounds
of subtraction. Shridhar generated down regulated cDNA libraries from two early
and two late stage ovarian cancer cDNA libraries subtracted against pool of 20
normal OSE cell brushings. Forty-five genes were identified as decreased in
expression in all four tumours. These included ovarian cancer associated genes such
as NOEY2, IGFBP5, Caveolin 1 and SPARC. These genes were then chromosomally
organised and many were found to map to regions of known deletions and LOH in
ovarian cancers, suggesting that the method has successfully identified ovarian
cancer related genes which may act as TSGs.
1.9.4 SAGE and ovarian cancer
As for cDNA-RDA, SAGE has been used in the analysis of multiple tumour types
and has successfully identified cancer-associated genes.
Recently SAGE databases such as that funded by Cancer Genome Anatomy Project
(CGAP) have been established for public use (www.ncbi.nlm.nih.gov/SAGE/).
These databases contain more than 3 million tags from 88 different cancer associated
libraries.
SAGE studies have been performed on patient material from colon, lung, ovarian and
breast cancers to name but a few (Polyak and Riggins, 2001).
Hough carried out the most substantial work, using SAGE, in ovarian cancer (Hough
et al., 2000). They compared normal tissues in the form of OSE cultures,
immortalised OSE and cystadenoma cells with malignant tissues composed of pooled
cell lines and individual primary serous ovarian cancers using SAGE. A huge
sequencing effort identified >56,000 individual genes in 10 different libraries from
ovarian tissues, 3 normal and 7 cancer derived. They found 45 genes over expressed
>10-fold in all three primary ovarian tumours analysed compared to OSE cells, and 9
downregulated >10-fold. Up regulated genes included secreted proteins, tight
junction proteins and other cell surface proteins. Those genes down regulated in
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normal OSE generally play roles in proliferation and cellular architecture and
adhesion. Over expressed genes Ep-CAM, Apo J, claudin-3 and -4 were all validated
at the protein level by IHC (Hough et al., 2000).
A subsequent study of 13 ovarian cancer associated genes, many identified by the
original SAGE analysis, was done using real-time quantitative PCR (Hough et al.,
2001). Expression of each was analysed in 39 microdissected ovarian tumours of
varying histology, stage and grade. All genes analysed showed various levels of
upregulation in the majority of the tumours. Induction levels were higher when
validated than previously determined by SAGE, possibly due to removal of
contaminating normal stroma by microdissection. They identified overexpression of
three genes not previously implicated in ovarian cancer progression being S100A2,
STAT1 and MGP. Confirmed ovarian cancer associated genes include Ep-CAM,
Folate receptor, SLPI, Apo E, Apo J, Kop, ceruloplasmin, IGFBP2, TIMP3 and
GPX3. The paper shows the importance of validation of genes identified from
difference analysis methods.
1.9.5 cDNA arrays and ovarian cancer
Microarrays, due to their ability to analyse a large number of genes simultaneously,
are the most published method of gene expression analysis in ovarian cancers. There
have been more than 10 papers published in this field ranging from the comparison
of cell lines with normal tissues to the comparison of ovarian cancers with other
tumour types.
Ono et al identified 55 up and 48 down regulated genes when 9 ovarian tumours
were sampled (Ono et al., 2000). Using a glass 9121 cDNA array, they compared 9
serous/mucinous ovarian tumours with their corresponding normal ovary samples.
Using cut-off values they identified 55 genes up in 6 or more tumours and 48 genes
down in 8 or more tumours. Examples of up regulated genes include Protein
disulphide isomerase related protein, RBP1, HE4, RpnAO, EIF46, 14-3-3a,
calreticulin and keratin-17, and -18. Genes down regulated in more than 8 tumours
include Golgi SNARE, TGFBIIRot, KIAA0851, calcineurin A2, calmodulin, CLIM1,
MOV34 and DAP5. They also compared microarray profiles of 5 serous to 4
mucinous tumours and identified 115 genes as differentially expressed. Protein
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kinase PKX1, RPL8, complement B and a regulator of G protein signalling, RGS12,
were all down regulated in mucinous compared to serous tumours. They found that
creatine kinase B and myosin heavy polypeptide 11 were down regulated in serous
tumours. These differences in gene expression between histologies suggest different
pathways of progression.
RT-PCR was used to validate the differential expression of 8 genes standardised
against G3PDH. KSA, claudin-10, complement factor B, RhoA, TSG101 and DOC1
were all confirmed as down regulated in tumours of both histologies. Two genes,
haptoglobin and secretory protein Pl.B, were both confirmed as up regulated by RT-
PCR. In this study they also identified genes, such as HE4, 14-3-3a, and DOC-1,
which have been previously implicated in tumour progression. Both HE4 and DOC-1
were identified by other difference analysis methods as being over expressed in
ovarian tumours (Hough et al., 2000; Mok et al., 1994).
Wang used a 5766 clone cDNA array to compare gene expression between RNA
extracted from frozen ovarian tumour tissue blocks and normal whole ovary RNA
(Wang et al., 1999a). Arrays were hybridised independently with 7 different tumour
specimens representing all histologies. They found that 30% of cDNAs had a >2-fold
difference in expression and 9% altered >3-fold. In total 726 clones were identified
to have 3-fold difference in expression between tumour and normal samples. These
cDNAs consisted of 94 ribosomal protein-encoding genes, 149 mitochondrial gene
transcripts and 248 other genes including 12 uncharacterised genes. All
mitochondrial transcripts were over expressed and all but 1 (RPS6) ribosomal protein
genes were down regulated in tumours. Other down regulated genes included FOS,
vimentin, glutathione S transferase, JUN, protease nexin and TR3 orphan receptor.
Upregulated candidate oncogenes included cofilin, a enolase, HepG2, CD9,
mesothelin, HE4, MMP7 and cytokeratin 8. Again, many of these genes have been
previously implicated in cancers. RT-PCR was used to validate the expression levels
of 15 putative cancer markers on a panel of normal tissues and ovarian cancers.
Overexpression of mesothelin, HE4 and MMP7 are all confirmed in this paper.
Interestingly, HE4 is once again identified as over expressed in multiple tumours.
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The comparison of ovarian carcinomas with benign adenomas on a 588-gene
microarray again identified numerous up and down regulated genes (Tapper et al.,
2001). Using an Atlas Human Cancer cDNA array, Tapper et al compared
expression between firstly carcinomas and benign tumours, then local highly
differentiated tumours to benign tumours and, finally, advanced and moderate/poorly
differentiated tumours with local, highly differentiated tumours.
Six serous adenocarcinomas, of varying grade and stage, were compared in
expression to a benign serous cystadenoma. This identified 38 up and 19 down
regulated genes in the tumour samples. Those up regulated include Rho family
genes, MMP9, ERBB3, Cad6 and MDM2s. Down regulated genes included cell
cycle regulators, such as cyclins D3 and G1 and CDK1, invasion regulators, MMP11
and TIMP2, and receptors PDGFA/B and EGFR.
When three local and highly differentiated adenocarcinomas were compared to a
benign tumour, 49 genes were found to be differentially expressed. Up regulated
genes include, of the 23, apoptosis regulators AKT2, caspases and TNFA, cell
interaction genes, Cad6 and integrin 88, and others including MMP7 and ERBB3.
Downregulated genes included thrombospondin 1, collagens, TIMP2, MMP2,
IGFBP4 and SKY.
Fifty-eight genes were found to be differentially expressed between generally poor
prognosis advanced tumours and local highly differentiated tumours. Twenty-one
genes were up and 12 down regulated in all advanced carcinomas. Those genes
highly expressed in tumours included motility related genes; collagens, fibronectin
and semaphorin, and oncogenes/tumour suppressor genes; Met, cFOS, RBQ1 and
STATE Down regulated genes again included apoptosis related genes, DNA damage
repair genes and various others. These genes may be involved in the progression of
low grade tumours to a more aggressive poorly differentiated phenotype. Using
semi-quantitative RT-PCR, upregulation of two genes, RHOGD12 and COL3A1 was
confirmed in at least 4 tumours. Tapper et al have successfully identified genes
which may play a role in the progression of cancers to the more advanced phenotype.
Welsh reported the comparison of gene expression in individual serous tumours and
cell lines with 4 un-matched normal whole ovary samples (Welsh et al., 2001). Their
technique used an 'array of arrays' suitable for analysing multiple RNA samples in a
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single experiment so removing experiment to experiment variability (Zarrinkar et al.,
2001). Affymetrix HuGeneFL arrays, carrying >6,000 human genes were hybridised
individually with RNA samples. Results were analysed by hierarchical cluster
analysis. A cluster of approx. 100 genes were highly expressed in normal tissue and
under expressed in the majority of tumours. These included many immediately early
genes such as cFOS, Jun B and EGR1 and others including IGFBP5, ZFP-36,
Transcription factor ETR101, CL138 protein tyrosine phosphatase and 3 nuclear
receptor family members. A second cluster showed genes that are underexpressed in
normal tissue as compared to ovarian tumours and cell lines. This cluster included
HE4, PRAME, COX8, SMARC A4 and glutathione s-transferase PI (GSTP1).
Candidate oncogenes HE4 and PRAME were highly expressed respectively in 51%
and 55% of the tumours. Three other gene clusters are represented as proliferative,
ribosomal and stromal. It is noted that generally ribosomal genes are over expressed
except for in a group of poorly differentiated and rapidly growing tumours in which
there was a relative under expression of these genes.
Thirty transcripts were designated as having high expression in 24 ovarian tumours
and cell lines. These genes had low expression in normal tissue and high expression
in neoplastic tissues so may be candidate molecular markers for ovarian cancer.
These genes include CD24 and -9, Keratins -7, -8, -18 and -19, mucinl, HE4,
ENOl, MEIS1, and GA733-2 (TACSTD1). Increased expression of the genes CD24,
HE4 and LU was confirmed on a panel of four normal and 11 tumour samples by
RT-PCR. Again many of these genes, such as CD24, CD9 and HE4, have been
previously reported as over expressed in ovarian cancers using microarray profiling,
supporting Welsh's' data.
Tonin reported the comparison of gene expression between ovarian cancer cell lines
and a primary culture of normal ovarian surface epithelium (Tonin et al., 2001).
They used cell lines to avoid problems with tumour heterogeneity, stromal
contamination and simply because they can generate sufficient RNA for the studies.
Cell lines have, however, a drawback in that their gene expression compared to
tumour gene expression may have altered through repeated passaging in culture so
that the cell lines do not wholly represent true ovarian cancers. Four long-term cell
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lines, derived from malignant tumours, and one solid tumour were compared in gene
expression to normal OSE cells using a Hs6000 gene chip from Affymetrix. The chip
contains probes for 6416 genes. A threefold difference was deemed significant and
two way comparisons between samples were carried out to determine the number of
3- 5- and 10-fold differences between them. A six-way comparison of all cell-
lines/tumour to normal OSE was also performed. They found that the majority of
genes only varied in expression in 1 carcinoma sample (280), and only 1 gene varied
in all 5 cell-lines/tumour. Furthermore, the expression profiles of >80% of genes did
not differ greater than 3-fold in comparison to normal OSE. Differentially expressed
genes were then assigned to respective chromosomes using Genemap'99.
Chromosomes 1 and 19 appeared to harbour a lot of the genes that were over
expressed.
Although the paper discusses genome-wide profile similarities between samples,
only specific differentially expressed genes (other than those on Chr 6) are
highlighted. This was due to their previous identification as over expressed in
ovarian cancers. Genes discussed for example were Jun D, PAI 1, ILB1 which have
all been confirmed as differentially expressed at the protein level by IHC. Genes
previously identified as over expressed include CD24, HE4, CD9 and Mucin 1,
Keratins -8, -9, -10, -18, and -19, MACMARKS and adenylosuccinate synthase.
Tonin was able to conclude that all cell lines are more similar to one another than to
normal OSE.
Arnold, like Tonin, reported the comparison of ovarian cancer cell lines and human
OSE cells (Arnold et al., 2001). Using a Clontech Atlas array carrying 588 cDNA
fragments they individually hybridised RNA from three ovarian cancer cell lines and
1 OSE sample. A visual comparison of arrays identified 17 genes expressed at a
higher level and 10 and a lower level in OSE cells as compared to cell-line
expression. Visual rather than computational analysis of data however, may have
missed out vital low expressed candidate genes. OSE associated genes include Id3,
TAF131, ICAM1, CD44, and neural cadherin. EAR-1 and -2, RAF, CLK, ETR103,
ETR101, Integrin-al and -76 were all highly expressed in the three ovarian cancer
cell lines. Six potential tumour suppressor genes were validated using RT-PCR on a
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panel of HOSE and ovarian cancer cell lines. Only three of these genes were
however validated as having lost or decreased expression in multiple ovarian cancer
cell lines, showing the importance of using further gene difference validation
techniques. The gene Id3 was taken forward for further studies.
Interestingly, Tapper and Arnold used the same Clontech Atlas array but the genes
identified were completely different in both directions of expression (Arnold et al.,
2001; Tapper et al., 2001). Tapper compared tumour samples with benign
cystadenoma where as Arnold compared cell lines with human OSE cells. The
differences between these two papers show the variation between primary samples
and those that have been cultured. The choice of 'normal' RNA may also be
important. Most groups have chosen to use OSE cells because all frank ovarian
carcinomas are believed have progressed from these cells. However, a few groups
have used benign ovarian tumours but there is little evidence that these actually
progress to epithelial ovarian cancer so they may not be suitable for use as 'normal'
controls.
The MICROMAX™ cDNA microarray system was used by Wong in the comparison
of three pooled human OSE samples with three pooled ovarian cancer cell lines with
the aim of identifying tumour markers (Wong et al., 2001). The array system
contains 2400 known human cDNAs. The system was chosen as it uses 20-100 times
less RNA than a conventional microarray technique due to the use of an efficient
amplification system. This lower RNA usage makes the method valuable in
analysing precious RNA samples. Thirty different genes were identified as over
expressed in the ovarian cancer cell lines. Those over expressed by >10-fold include
antigen GA733-2, prostasin, CD24, ATF3, proteasome subunit HC8, Creatine kinase
B, thymosin 8 10 and kinase myt 1. To validate this data they used real time
quantitative RT-PCR on 5 genes that are known cell surface antigens or secreted
proteins which would be easily detectable if used as tumour markers. Six ovarian
cancer cell lines were examined and overexpression of only one gene, GA733-2, was
detected in all of these compared to OSE cells. Overexpression of prostasin and
Creatine kinase B was detected in five samples and only three of six samples showed
elevated osteopontin and KOC transcripts.
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Wong discusses that pooling RNA samples allows identification of genes that may
be over expressed in only a proportion of cancer cell lines so would be useful in
molecular classification. Their validation again highlights the need to use a
complementary follow up technique with microarray analysis so false positives that
are not representative of ovarian tumours are ruled out. A later paper further studies
the overexpression of prostasin and identified protein overexpression in a majority of
tumour samples supporting its potential role as a tumour marker (Mok et al., 2001).
Schummer used a large 21,500 clone cDNA array in the individual comparison of 10
tumour samples to OSE and other normal tissue samples (Schummer et al., 1999).
The high density array allowed analysis of a large number of genes in one
hybridisation so saving time and experimental variation. It was noted that tumour
samples are often contaminated with normal cells and that cultured OSE will
probably have some differences in expression patterns to in vivo OSE cells. This was
overcome by setting suitable limits of detection. As for Wong, Schummer et al only
studied up regulated genes, which may be of use as molecular markers. They found
that, in the comparison of tumour tissues to OSE, 7%, 0.9%, and 0.5% of genes
exhibited tumour-to-OSE ratios of 2.5- 5.0- and 10-fold respectively.
Sixteen cDNA clones with overexpression in 6 or more of the 10 ovarian cancers
were identified but 14 of these were also expressed in non-ovarian tissues. To
eliminate those non-specific genes that are expressed in non-ovarian tissues,
selection criteria were introduced. Ratios of >2.5-fold in at least five tumours and
below 2.5 in other tissues as compared to OSE were used. Using these values they
identified 134 clones which consisted of 26 mitochondrial and ribosomal genes, 37
other known genes, 47 EST's and 24 Novel sequences. Focussing on the 37
characterised genes, 10 had previously been identified as expressed in epithelial
tissues including 14-3-3a, CD44, HE4, mucin 1, COL1A2 and Rho A. Thirty-five
percent of genes had been reported as over expressed in various cancers including
those genes previously mentioned as well as BA46, El6, IGFBP3, G-ACTIN and
MDC15 metalloprotease. The fact that a lot of the genes identified have been
previously reported as up regulated shows that analysis of a large number of genes is
capable of narrowing down to a few cancer related transcripts.
47
Eight genes were validated using RT-PCR. Semi-quantitative RT-PCR analysis of
14-3-3a varied widely from the array tumour-to-OSE ratio, supporting the need for
sensitive validation. Other genes did show a general concordance between
microarray and RT-PCR ratios. The largest difference between the two methods was
however seen for HE4, which for the array showed 11-fold overexpression but only
4-fold by RT-PCR. They attribute this difference to a better signal-to-noise ratio in
RT-PCR or simply due to the use of different tumour samples. HE4 gene expression
was further analysed by Northern blotting, as this gene was the only one with clear
tumour restricted expression. It was found that of four patient tumour samples, two
over expressed HE4 as compared to normal paired ovarian tissues. HE4 is suggested
to be a suitable candidate marker protein and this is supported by multiple
microarray studies, as previously mentioned.
Wong and Schummer both analysed a set of similar transcripts (Schummer et al.,
1999; Wong et al., 2001). Schummer identified 32 genes upregulated in ovarian
tumour samples compared to human OSE RNA. The MICROMAX™ array used by
Wong, carries 14 of these although only 5 were up more than three-fold in their
study. Differences between cell lines and primary tumour samples may be
responsible for these discrepancies. Tonin suggested that due to this tumour
heterogeneity, analysis of cell lines, primary cultures and tumours needs to be
extended before signature expression profiles and biologically important candidates
in ovarian cancer can be fully established (Tonin et al., 2001).
Gene expression in seven early and seven late ovarian tumours and normal OSE
brushings pooled from 20 patients was examined using a ~25,000 clone cDNA
microarray (Shridhar et al., 2001b). All tumours were poorly differentiated but of
varying histology. It was found that gene expression in all tumour types tended to be
more often down rather than up regulated as compared to normal OSE expression.
Genes up regulated >5-fold in both early and late stage tumours include HE4,
properdin, lipocalin 2, keratin-13, mucin 1, MMP7, ceruloplasmin and claudin 4.
Those genes down regulated by >5-fold include c-type lectin, E25 protein, CD36,
amphiregulin, PEG3 and Glutathione-S-transferase A3. Genes which showed
expression changes were clustered into four categories: cell-cell interactions;
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intermediate filament markers; cell cycle and growth regulators and genes involved
in invasion and metastasis. These categories include keratins, cadherins, matrix
metalloproteases and cyclins.
Semi-quantitative RT-PCR was used to validate these results standardised against
GAPDH. A set of genes was tested for expression on a panel of seven ovarian cancer
cell lines, and 20 early and 16 late stage ovarian tumours. The number of genes that
were validated by RT-PCR is not mentioned but loss of expression of PAI1, FGF7
and Decorin in the majority of tumours is reported. Upregulation of genes PUMP1
(MMP7) and HE4 was also confirmed. A set of five genes was also analysed by real¬
time RT-PCR and results were said to be similar as for semi-quantitative RT-PCR
data.
Although the paper is titled 'Genetic analysis of Early- versus Late-stage Ovarian
Tumours', this comparison is not clearly seen. Early and late stage tumours are
pooled in their analysis and there is no direct comparison of the two stages. Unlike
the paper by Tapper, Shridhar et al do not report any specific gene differences
between the early and late tumour stages. The only genes discussed are those which
are altered in expression in all tumours regardless of stage. Of those identified, again
many had previously been reported as differentially expressed between normal and
cancerous tissues.
In an interesting paper by Giordano the molecular profiles of 57 lung, 51 colon and
46 ovarian adenocarcinomas are compared (Giordano et al., 2001). RNA from each
of these tumours was individually hybridised onto 7129-clone oligonucleotide
HuGeneFL arrays. Using principle component analysis (PCA), a method that
identifies those two-way comparisons with the greatest amount of discrimination,
four 'views' were generated. These views each contained 25% of all transcripts, with
increasing abundance. For example the first view contains the 25% of transcripts
with the least average abundance and so on. All views showed substantial differences
in gene expression between the three tumour types that clustered individually within
the region. They revealed that ovarian tumours showed the greatest heterogeneity. A
set of markers for each tumour type was next identified. These genes had much
higher expression in one cancer type as compared to either of the other two. Thirty-
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one unique genes were identified as ovarian cancer specific. These include PEG3,
WT1, somatostatin, cyclinAl, SLPI, MEIS1, StAR, PRAME, CLU and IGFBP2. Of
these genes, many have been associated with ovarian cancers such as MEIS1 and
PRAME, both reported previously as over expressed in tumours by microarray
analyses (Welsh et al., 2001).
This study did not aim to identify genes that were differentially expressed between
tumours and their normal counterparts, it was instead attempting to group the
individual tumour types using gene expression patterns. The genes identified cannot
therefore be compared directly to other published data. For example the genes StAR
and PAI have previously been identified as down regulated in tumours but in this
system their expression is seemingly increased.
Most recently, in a follow on from their successful SAGE work, Sawiris et al have
generated a 516 cDNA chip which is a specialised ovarian cancer array (Hough et
al., 2000; Sawiris et al., 2002). The Ovachip contains genes chosen from their
previous SAGE and cDNA array data, some of which have been validated by real¬
time RT-PCR (Hough et al., 2001). The aim of such a specialised chip is to reduce
noise from irrelevant genes during data analysis. The Ovachip was used to analyse
11 late stage ovarian tumours, four colon tumours and various cell-lines. They found
that the array data could distinguish clearly the ovarian from the colon tumours.
In a comparison of ovarian tumours with non-malignant OSE cells using the
Ovachip, 25 genes were up and 11 genes down regulated. Those up regulated genes
included IGF2, HSP90, RAB1, BRF1, SLPI, IGFBP2 and SPRR1B. Candidate
TSGs, which are down in tumours, included the previously characterised BRCA1 as
well as other novel cancer genes such as B-tubulin, LDHA, BTF3, RPL7A and
MYLK.
Four genes were validated for gene expression by real time RT-PCR and it was
found that although results from the array and the RT-PCR were not exact, they
followed the same trends. Quantitative RT-PCR, which is both sensitive and
accurate, is an essential complement to arrays, as was shown in these studies. The
chip has identified two clusters of co-altered genes that have been named the IGF
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and CAK clusters, which contain up and down regulated genes respectively. These
clusters are being studied further for their roles in cancer progression.
As discussed, many gene expression analysis techniques have been used in ovarian
cancer for the identification of candidate TSGs and oncogene ovarian cancer
markers. These studies have linked numerous genes with ovarian cancer progression
although some genes, such as HE4, are reported by numerous groups as differentially
expressed between normal and tumour samples. Those genes identified by two or
more papers as differentially expressed are listed in Figure 1.3.
Although gene expression analysis techniques have only been available for ten years,
many groups have applied the technologies to many aspects of ovarian cancer
studies. The multitude of papers published in the area and the number of individual
genes shown to be associated with ovarian cancer progression has proven the power
of such investigations, and the complexity of apparently differentially expressed
ovarian cancer genes.
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Figure 1.3 Genes identified as differentially expressed in EOC versus normal OSE. Red
boxes= up in tumours (oncogenic) blue= down in tumours (TSGs). First Authors shown
along top with year and analysis method.
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10 Background
Dr Hani Gabra carried out MMCT of a neo-tagged human chromosome 11 from
donor mouse cell-line 556.1.5 into a clonal derivative of the ovarian cancer cell-line
OVCAR3. These transfers generated independent clones that have been fully
phenotypically characterised in relation to the parent OVCAR3.
OVCAR3 is an ovarian cancer cell-line established from malignant ascites of a
patient with progressive adenocarcinoma of a poor differentiation grade (Hamilton et
al., 1983). Chromosome 11 in OVCAR3 is markedly rearranged and hypotetraploid
suggesting a mechanism of whole homologue loss and then reduplication. It is
postulated that some genes on chromosome 11 in OVCAR3 are non-functional and
therefore potential TSGs.
Parental lines with neo tags were generated for use as controls by either transfecting
the hyg resistant clonal line OH3 with a neo containing plasmid (OHN) or by use of
ON3 as a microcell donor to transfer neo tagged Chr 11 into OH3 (ONOH).
Functional studies showed no differences between these two controls. As
chromosome 11 is rearranged in OVCAR3, these clonal lines should not carry any
functional TSGs along this chromosome.
MMCT of donor 556.1.5 chromosome 11 into OH3 generated two series of
independent clones (110H1 and 110H2). The cell-line OHX was generated from an
OH3 xenograft that was then subjected to MMCT to generate hybrids 11OHX 1-3.
OHX was created in order to more readily form tumours in mice, requiring a far
fewer cell number than OH3.
Microsatellite mapping of these clones determined the extent of chromosome 11
transferred in each case (Figure 1.4). Cell-lines llOHl.l and llOHl.3, generated
from the same MMCT, have complete transfer of chromosome 11. Fragmentation of
chromosome 11 occurred in cell-lines 110H2.1-2.4, which lack the region telomeric
to marker D11S936 at llq23. They also appear to be missing a small region at
1 lpl3, defined by the marker D11S935.
Xenograft clones llOHXl.l and 110HX3.1 contain a complete chromosome 11
whereas 110HX2.1 has only partial transfer, missing llq23-ter, two regions at
1 lq 13 and D11S935 at llpl3.
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The 1 lOH hybrid cell-lines all exhibited in vitro and in vivo growth suppression
(Figure 1.5). This supported the hypothesis of a tumour suppressor on chromosome
11. Also, as all of the clones showed slowed growth, it is suggested that the
suppressor must lie within the regions transferred in the 110H2 series so
outwithllq23-ter and llpl3.
Matrigel invasion studies showed a clear decrease in invasion by the 110H1 clones.
The 110H2 hybrids did not have this altered phenotype. This suggests that an
invasiveness suppressor maps to llq23-ter, which is supported by morphological
studies. Cellular attachment assays showed 110H1 hybrids were inhibited in
attachment to a laminin matrix. This effect was not seen in thel 10H2 hybrids.
Apoptosis and cell cycle studies showed no differences in phenotypes between












Parental line OHN Normal Normal Normal Normal Normal Normal
Hybrids 110H1 Suppressed Suppressed Suppressed Normal Normal Normal
Hybrids 11OH2 Suppressed Suppressed Normal Normal Normal Normal
Hybrids 11OH3 Suppressed Suppressed Normal Normal Normal Normal
Hybrids 110HX Suppressed Suppressed Normal Normal Normal Normal
Table 1.5 Overview of hybrid characteristics as compared to parental line OHN. Suppressed
characteristics are highlighted in red.
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Figure 1.5 In vitro growth and in vivo tumorigenicity curves of hybrid cell-lines as compared
to parental line OHN/ONOH. Error bars represent the standard error for each cell-line.
A traditional approach of revertant mapping to identify those regions harbouring
TSGs was conducted. Growth suppression occurred in those clones with deletion of
56
markers D11S533 and D11S1358 on 11 q and at 1 lpl3 suggesting that a growth
suppressor may be positioned outwith here. As frequent LOH is detected at 1 lp 15 in
ovarian cancers (see introduction- section 1.7), clones were mapped along this region
in order to identify areas of loss associated with a change in the growth and
tumorigenic phenotypes. 110H and 110HX hybrid cell-lines were further passaged
with the aim of generating revertant clones to identify regions of chromosome loss
by microsatellite mapping.
A more novel approach was to use this hybrid resource in multiple difference
analysis techniques to identify genes along chromosome 11 which showed increased
expression in the growth suppressed clones to investigate these as candidate tumour
suppressor genes.
Using three difference analysis methods, Differential Display RT-PCR, cDNA-
Representational Difference Analysis and Clontech High Density Filter Arrays
(HDFA), we compared gene expression between Parental OVCAR3 derivative OHN
and hybrid line 110H2.1. This hybrid was chosen with identification of candidate
genes responsible for the growth suppression phenotype in mind.
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2. MATERIALS AND METHODS
58
Unless stated, consumables and reagents were purchased from Sigma-Aldrich or
Fisher Scientfic Chemicals. Other suppliers are listed in Table 2.1.
Supplier Methods in which reagents were
used
Abeam, Cambridge, UK Western blotting and IHC
Amersham Biosciences, Chalfont St Giles, UK Northern blotting, Western blotting
Applied Biosystems (Perkin Elmer), Foster City,
USA
ABI310 work and sequencing
BioGenex, San Ramon, USA Western blotting
Bio-Rad, Hercules, USA Electrophoresis
BD Biosciences Clontech, Palo Alto, USA High density filter array
GeneSys Ltd, Farnborough, UK Light Cycler analysis
Fisher Scientific Chemicals, Loughborough, UK General
Idaho Technology Inc., BioGene Ltd, Kimbolton,
UK
Light Cycler analysis
Invitrogen-Life Technologies, Paisley, UK RNA work
Millipore, Bedford, USA Western blotting
New England Biolabs Inc., Beverly, USA Western Blotting
Novagen, Madison, USA Sequencing
Pfizer Inc., New York, USA Northern Blotting
Promega, Madison, USA Plasmids and transformation
Qiagen, Crawley, UK RNA/DNA extraction and purification
Roche Applied Science, Basel, Switzerland cDNA synthesis, Northern blotting,
Western blotting
Sigma-Aldrich, St Louis, USA General
Stratagene, La Jolla, USA RNA extraction
Table 2.1 Suppliers of reagents and equipment used in my studies.
2.1 DIFFERENCE ANALYSIS METHODS.
2.1.1 Differential display RT-PCR
DD-RT-PCR was carried out by Genevieve Rabiasz and Dr Grant Sellar. DD-RT-
PCR was performed according to described protocols using a combination of 3 single
base anchored antisense primers and 7 arbitrary sense primers. Antisense primers
used were: 5'-AAGCTTTTTTTTTTTA-3'; 5'-AAGCTTTTTTTTTTTC-3'; 5'-
AAGCTTTTTTTTTTTG-3'. Sense primers used were: 5'-AAGCTTTCTACCC-3';
5AAGCTTTGGCTCC-3'; 5' -AAGCTTATACAGG-3'; 5'-AAGCTTGTCATAG-
3'; 5 '-AAGCTTCAAGTCC-3'; 5'-AAGCTTCTGACAC-3'; 5'-
AAGCTTCTAACCG-3'. Products identified as being differentially expressed were
excised from 6% (w/v) polyacrylamide sequencing gels, re-amplified, subcloned and
sequenced (See section 2.1.2). Analysis was performed by me.
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2.1.2 cDNA Representational Difference Analysis.
Dr Grant Sellar carried out cDNA-RDA comparing reciprocal OHN and 110H2.1
gene expression and I performed sequencing and analysis of products. The method
used was modified from Hubank and Schatz (Hubank and Schatz, 1994). Briefly,
double stranded cDNA from tester and driver samples is generated and DpnII
digested. R linkers (R12- 5'-GATCTGCGGTGA-3\ R24 -
5'AGCACTCTCCAGCCTCTCACCGCA-3') are ligated onto the DpnII fragments
and amplified by PCR to generate representations. These representations are further
DpnII digested. The tester population has J linkers (J12 5'-GATCTGTTCATG-3',
J24 5'ACCGACGTCGACTATCCATGAACA-3') ligated to it and subtractive
hybridisation between the tester and driver (in 80-fold excess) is carried out in a
PCR-based step. Those fragments present more abundantly or solely in the tester are
enriched and amplified. Single stranded, unpaired fragments are digested using mung
bean nuclease. This generates the first difference product (DPI). To generate DP2,
adapters are changed from J to N (N12 5'-GATCTTCCCTCG-3', N24 5'-
AGGCAACTGTGCTATCCGAGGGAA-3') in DPI and driver added in further
excess in a second subtractive hybridisation step. This process is repeated until
sufficient enrichment of products has been achieved, usually progressing to DP3 or
DP4 with increasing excess of driver.
Products in high abundance (MMLV and RALDH2) were amplified by PCR and
added into the driver sample at a following stage of subtractive hybridisation by a
method called 'spiking'. The addition of these PCR products prevents saturation of
DPs with the aim of cloning out other, less abundant genes.
Difference products were run on a low melting point gel, bands excised, then
purified using QIAquick gel extraction kit (Qiagen). Briefly, the gel is melted at
50°C with three volumes buffer QG. Once dissolved, one volume of isopropanol is
added and the DNA is bound to a spin column. The DNA is washed with 0.75ml
buffer PE and eluted in 50//1 EB (lOmM Tris-Cl).
These fragments were ligated into pGEM-T Easy TA vectors (Promega) and inserts
sequenced using SP6/T7 primers. Sequence files were analysed using EditView
software.
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2.1.3 Clontech Atlas™ array hybridisation.
Clontech provide an Atlas™ nylon array hybridisation and analysis service.
Frozen cells (>107) for OHN and 110H2.1 clonal lines were sent to Clontech who
carried out hybridisation of three Atlas™ arrays. The nylon arrays carry 1,176 cDNA
fragments (200-600bp) each. Three arrays were hybridised; Human 1.2k I, Human
1.2k II and Human Cancer array. The method for hybridisation is available on the
Clontech web site (www.clontech.com).
Briefly, RNA is extracted from the cell samples and bound to fluorochromes to
generate labelled probes. This is then hybridised to the array of choice and
phosphoimages of the membranes are produced. These images are scanned and
analysed using Atlas Image™ software that quantitatively analyses and compares
signal intensities on the arrays. The spots are normalised to nine housekeeping genes
carried on the array and signal intensities a corrected for background by subtracting
the average of several non-hybridised regions of on the membrane. Clontech carried
out the analysis of these arrays. A report of up and down regulated genes is provided
for further analysis containing gene identifiers, signal intensities and fold differences
in expression for each gene between our samples. Clontech recommend results be
corroborated with another method of gene expression analysis such as Northern
blotting or RT-PCR.
2.1.4 Identification of transcripts
cDNA-RDA and DD-RT-PCR generate transcripts which are sequenced for
identification. These sequences are BLAST searched against the non-redundant
(NR) and high throughput genome sequencing (HTGS) databases using the online
facility at NCBI (www.ncbi.nlm.nih.gov). Characterised sequences were then
researched for cellular function using the OMIM and GeneCards databases (at NCBI
and http://bioinformatics.weizmann.ac.il/cards/). Other sequences were analysed in
LocusLink and UniGene for homologues in other species (NCBI).
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2.2 Gene expression analysis-verification
2.2.1 RNA extraction for use in Northern blotting and RT-PCR
RNA was extracted from monolayers of cells using TRI REAGENT (Sigma-
Aldrich). 1ml of TRI REAGENT was used per 10cm2 of tissue culture plate. Cells
were pipetted into RNase free tubes. After standing at room temperature for 5
minutes, 0.2ml chloroform per ml of TRI REAGENT was added. The solution was
vigorously shaken for 15s and allowed to stand for 10 minutes at room temperature.
This mixture was centrifuged at 12,000g for 15 minutes at 4°C. Centrifugation
separates the mix into three phases with the upper colourless aqueous phase
containing the RNA. This layer is transferred to a clean RNase-free tube and 0.5ml
isopropanol per ml of TRI REAGENT was added and mixed by inverting. The
sample stood at room temperature again for 10 minutes. When centrifuged at
12,000g for lOminutes at 4°C a pellet of RNA formed on the side of the tube. This
pellet was washed with 1ml 75% ethanol per ml TRI REAGENT and mixed. The
RNA was re-pelleted by centrifugation at 12,000g for 5 minutes at 4°C. The pellet
was transferred to an eppendorf tube with 1ml 75% ethanol and re-compacted by
centrifuging at 13,000 rpm in a microfuge for 5 minutes at 4°C. It was then air dried
and resuspended in 50]A DEPC-treated H20. Once quantitated the RNA was
aliquotted in 20//g amounts and stored at -70°C.
2.2.1.1 Quantitation of DNA/RNA by spectrophotometry
5ji\ DNA or RNA solution is added to 995//1 DEPC-treated H20 (1 in 200 dilution).
A reading of absorbance was taken at 260nm and also at 280nm for RNA samples. A
ratio of absorbance at 260nm divided by 280nm indicates purity of the sample. A
value of 1.6 to 1.8 indicates pure RNA. A higher value of about 2.0 indicates DNA
contamination whereas a low value <1.5 suggests protein contamination. The
calculation below determines the concentration of DNA/RNA in the solution and
relies on the fact that an OD260 of 1.0 indicates a DNA concentration of 50/<g/ml.
Concentration A^ x dilution factor (200) x X = /<g///l
1000
Where X is 40 for RNA, 50 for DNA, 33 for single stranded DNA.
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2.2.2 Quick RNA extraction from cell lines for RT-PCR
An Absolutely RNA™ RT-PCR mini prep kit (Stratagene) was used for ease and
time as per manufacturer's instructions to extract RNA from transfected clonal lines.
Briefly, 25cm3 tissue culture flasks of cells at 70% confluence were washed twice in
PBS. 350/d of lysis buffer containing 2.5//1 6-mercaptoethanol was added onto the
monolayer of cells which were then transferred to a microfuge tube. This mix was
transferred to a prefilter spin cup and centrifuged at 4°C for 5 minutes at maximum
speed. The filtrate was then added to an equal volume of 70% EtOH and vortexed to
mix. This was transferred to a RNA binding spin cup and centrifuged at 13,000 rpm
for 30-60 sec. Bound RNA was then DNase I treated after washing with 600/d lx
low salt wash buffer. A mix of 50/d DNase I digestion buffer and 5/d DNase I was
added to the spin cup and incubated at 37°C for 15 minutes. The cup was then
washed in turn with 600/d high salt buffer, 600/d low salt buffer, then 300/d low salt
buffer, and each time centrifuging at 4°C. The DNase I treated RNA was then eluted
in 50/d EB and quantitated by spectrophotometry. RNA was stored at -70°C long-
term. This RNA is suitable for use directly with the Roche 1st strand cDNA synthesis
kit.
2.2.3 DNase I treatment of RNA
20-40/<g of total RNA, made up to a total volume of 50/d in DEPC-treated water,
was DNase I treated with 5.7/d lOx buffer and 10 Units DNase I for 30 minutes at
37°C on a MJ thermocycler. Treated RNA was then extracted with 40/d phenol/
chloroform in a 3:1 ratio for 10 minutes on ice. After centrifugation at 10,000g for 5
minutes at 4°C, the upper phase was collected into a clean tube. The RNA was then
ethanol precipitated with 5/d NaOAc and 100/d 100% ethanol at -70°C for 2 hours.
A 10 minutes centrifugation pelleted the RNA and this was then washed with 70%
Ethanol in DEPC-treated H20. The RNA was air-dried, dissolved in 15/d DEPC-
treated H20 and 1/d quantitated by spectrophotometry. DNase I treated RNA was
stored in 3/d aliquots (3/<g) at -70°C.
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2.2.4 cDNA generation
A Roche 1st Strand cDNA Synthesis Kit for RT-PCR (AMV) was used to generate
cDNA as per manufacturers instructions. 1 //g of DNase I treated RNA was mixed
with final concentrations of lx reaction buffer, 5mM MgCl2, ImM deoxynucleotide
mix, 1.6pg oligo-p(dT)15 primer, 50 Units RNase inhibitor, 20 Units AMV reverse
transcriptase, and made up to the volume of 20pl with sterile water. This mix was
then incubated at 25°C for 10 minutes followed by 42°C for 60 minutes and the
AMV-RT denatured at 95°C for 5 minutes. Control reactions minus reverse
transcriptase were also performed. cDNA was then aliquotted into 2pi or 3.2 pi
volumes for use directly in RT-PCR and real-time RT-PCR respectively.
2.2.4.1 RT-PCR
RT-PCR was carried out using multiple primer pairs at the standard conditions of
2mM MgCl2 normally using a touchdown 67-55°C program on a MJ thermocycler.
The RT-PCR reaction volume was 25pi and contained 2pi cDNA, 2mM MgCl2, 12.5
pMol each primer, 1.25 Units PicTaq polymerase (Cancer Research UK), 200pM
dNTPs and lx buffer. Products were run on a 2% agarose gel and visualised under
UV light with ethidium bromide.
Products were quantitated for use as Light Cycler standards by spectrophotometry.
PCR products were diluted to standards of lxl09copies/pl, lxl07copies/pl and
lxl05copies/pl, as calculated from product size and OD260 reading.
2.2.5 Primer Design
Primers for use in RT-PCR and Light Cycler analysis were designed using the
Primer3 program at www.genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi/. All
primers were synthesised at the Cancer Research UK oligonucleotide synthesis
service, London. Sequences for the primers used in validation can be acquired from
Dr Hani Gabra.
2.2.6 Light Cycler analysis.
Quantitative RT-PCR analysis used Roche and Idaho Technologies Light Cyclers.
Initially PCR standards were run to check the melt temperature (Tm) of the primers.
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RT-PCR reaction volume was lOpl containing IX PCR master mix (GeneSys Ltd.)
5pMol forward and reverse primers, 4mM MgCl2, 1:20,000 volume SYBR Green I
fluorescent dye (BioGene Ltd.) in a lOmM Tris (pH8) - ImM EDTA buffer and lpl
cDNA. Quantitative RT-PCR was performed in thin-walled glass capillaries by
initial denaturation at 95°C for 10 sec followed by 45 cycles of 95°C for 0 sec, 55°C
for 2 sec, and 72°C for 15 sec. Reading of fluorescent emission from SYBR Green I
bound to double stranded DNA was taken over 2 sec after each PCR cycle at a
temperature ~4°C lower than the Tm. A final extension at 72°C for 10 sec was
included before a temperature ramp from 72°C to 95°C at 0.1°C/sec continuously
reading fluorescence. Inspection of melt curves generated by this process
demonstrated amplification of a single product. Standards were run in duplicate and
RT-PCRs in triplicate. Expression levels were normalised with respect to (3-Actin.
2.2.7 Northern Blotting
2.2.7.1 DEPC treatment of water and glassware
All glassware, gel tanks and consumables used in Northern blotting were sterile /
DEPC-treated to avoid RNA degradation. Glassware was treated by filling with a
solution of 0.1 % DEPC in distilled water and left in a fume hood over night. The
water was then poured into a pre-treated tub and autoclaved along with the empty
glassware. RNase AWAY (Invitrogen-Life Technologies) was used on surfaces such
as Pyrex dishes and gel tanks to ensure removal of residue RNases and rinsed with
DEPC-treated water.
2.2.7.2 Sample electrophoresis and transfer
20^g RNA samples were run on an agarose / formaldehyde gel with lx
MOPS/EDTA running buffer. Sample buffer was made from 0.75ml Deionised
formamide, 0.15ml 10% MOPS/EDTA, 0.24ml 37% formaldehyde, 0.10ml glycerol,
0.10ml DEPC-treated water, and 0.08ml 10%w/v bromophenol blue and stored in
aliquots at -20°C. RNA samples and marker, with 25/d sample buffer, were
denatured at 65°C for 15minutes then \ftg ethidium bromide added to each sample
then loaded onto the gel. It was run overnight at 30-40V until the dye front was 4/5
down the gel.
65
The RNA was then transferred onto hybond-N membrane after washing in 0.05M
NaOH and 20x SSC. Transfer apparatus was assembled as in Maniatis (Maniatis,
1989) and transferred overnight in lOx SSC. Once disassembled, the gel lanes were
marked on to the membrane and the RNA was UV cross-linked using a stratalinker at
150MJ.
2.2.7.3 Hybridisation of Membrane
120//1 sonicated salmon sperm DNA (sssDNA) was boiled for 5 minutes and
quenched on ice. The membrane was then rolled in 6x SSC separated by a 0.1% SDS
boiled gauze and placed into a hybridisation bottle, RNA facing inwards. Hybond
mix was made from 6x SSC, 5x Denhardts (0.4g BSA, 0.4g Ficoll, 0.4g PVP, 0.1%
SDS), 0.1% NaPPi, and 10% dextran sulphate made up to 500ml with water and
filtered to store at room temperature. 20ml Hybond hybridisation mixture, containing
100fi\ of the boiled sssDNA, was then incubated with the blot overnight at 68°C.
DNA probes for labelling were generated by RT-PCR and products purified using
the QIAquick PCR product kit. The probes were quantified on 2% agarose gel as
compared to known dilution ofDNA marker.
25ng of probe in 13pt\ distilled H20 was boiled for 5 minutes then incubated with 4/d
High prime (Roche) and 3/d 32P dCTP redivue ambient l.llMBq (Amersham
Biosciences) for 15 minutes at 37°C.
Incorporation of 32P dCTP was determined by 5% TCA extraction of 0.5/H probe
through a filter using a vacuum manifold. All probes used were well labelled.
A NICK sephadex 50 column (Pfizer) was used to remove unincorporated
nucleotides from the labelled probe. 400/d of label in lxTE was dripped through the
column into 100/d sssDNA and boiled for 10 minutes then quenched and added to
the hybridisation bottle to incubate overnight at 68°C.
Non-specific background labelling was removed from the membrane by washing in
2x SSC/ 0.1%SDS for 20 minutes followed by four washes with 0.2x SSC/ 0.1%
SDS. Each wash was done at 68°C. The membrane was then sealed in plastic to
remain moist and exposed to Hyperfilm™-MP (Amersham Pharmacia Biotech Ltd)
in a sealed cassette at -70°C.
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Exposed films were developed using an AGFA curix 60 developer. The blot was re-
exposed until a suitable autoradiograph was produced. Densitometry on the scans of
the autoradiographs was carried out using LabWorks software (UVP)
Blots were stripped up to four times in a solution of boiling 0.1% SDS, and residue
radioactivity was detected again by exposure to film.
2.3 Protein expression analysis
2.3.1 Making protein lysates.
Lysis buffer made up of 50mM TRIS pH 7.5, 5mM EDTA pH8.5, 150nM sodium
chloride, 100/tg apotonin, 2mM sodium orthovandate, 50mM sodium fluoride, ImM
PMSF, 100//g leupeptin, lOmM sodium molybdate, 20//M phenylarsine oxide, 100/d
1 % triton X-100 and made up to 10ml with distilled water.
A 70-80% confluent flask of cells is washed with cold PBS and lysis buffer added to
the bottom of the flask for 10 minutes at 4°C. Cells were scraped off the plastic and
collected into tubes. They were then centrifuged at maximum speed for 6 minutes at
4°C. Pellets are then quantitated by a Bradford assay.
2.3.2 Bradford assay
TUBE PROTEIN (pL) WATER (pL)
A 20 o S
B 60 20
C 60 from B 20
D 60 from C 20
E 60 from D 20
F 60 from E 20
G 60 from F 20
H 60 from G 20
1 0 20
Table 2.2 Serial dilution of protein standard for Bradford assay.
Control protein standards were made as in Table 2.2. Dilution of lysates in a final
volume of 20/d was made. To each of these and the controls was added 1ml Bio-Rad
protein assay dye. 200/<l of each sample then transferred to a 96-well plate and run
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on a spectrophotometer at 600nm (Kruger, 2001). The Assayzap programme was
used to determine to concentration of the samples as compared to protein standards.
2.3.3 Western Blotting
Cell lysates were prepared and quantified as described. 20 pg of protein was run on
a mini-gel apparatus (Bio-Rad). Protein samples were aliquotted, and their volumes
equalised using lysis buffer. Samples were denatured at 95°C for 5 minutes in
loading buffer containing SDS, 6-mercaptoethanol and bromophenol blue. Protein
was loaded onto a 10% polyacrylamide gel, along with 10/<1 protein marker (New
England BioLabs Inc.)
Mini tanks were run at 80mA for 25 minutes, then up to 200mA for 1 to 1.5 h. After
electrophoresis, proteins were transferred to a permeablised Immobilon-P membrane
(Millipore) via a wet transfer method at 30 V, 4°C for 1 -4 h. Proteins were detected
using a chemiluminescence Western Blotting Kit (Roche). Membranes were blocked
using 1% blocking agent (diluted in Tris Buffered Saline (TBS): 6.05g Trisma base,
8.76g NaCl, made up to 1L with dH20, pH adjusted to 7.5) for 1 h at room
temperature. They were then incubated overnight with CTSD primary antibody
(Abeam) at a dilution of 1/1000 in 0.5% blocking solution, at 4°C. Membranes were
washed 3 times for 5 minutes in TBS-Tween (TBS-T, TBS containing 0.1% Tween
20), then twice for 5 minutes with 0.5% blocking solution, and treated with
secondary anti-mouse and anti-rabbit IgG antibody (Roche) at a dilution of 1/1000 in
0.5% blocking solution for 1 h at room temperature. Membranes were then washed
three times for 5 minutes with TBS-T and 3 times for 5 minutes with TBS. After a 1
minute incubation with the luminescence substrate solution, light emission was
detected on Hyperfilm™ECL™ (Amersham Pharmacia Biotech Ltd).
2.3.4 Avidin-Biotin Conjugate Immunohistochemistry
Sections were cut to a width of 10/<M using a microtome and mounted on glass
slides.
Sections were dewaxed in xylene and then hydrated in ascending grades of ethanol.
They were then incubated in 3% hydrogen peroxide for 30minutes. Antigen
presentation was enhanced by boiling samples in citric acid (pH6.0) for 3x 5minutes
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in a full power microwave and standing for 20 minutes in a fume hood. 0.05M TBS
was used to rinse sections which were then blocked with 20% FCS in TBS. This was
replaced with CTSD primary antibody at 1/200 dilution in 20% FCS in TBS and
incubated for lhour at room temperature. Sections were rinsed briefly with TBS and
washed twice for 5 minutes. A StrAviGen MultiLink kit (BioGenex) was used for the
labelling. Linking antibody (100/d in 20%FCS/TBS) was added onto the sections for
20 minutes and again rinsed and then washed twice with TBS. IgG anti-mouse
labelling antibody (100//1 made up in TBS) was incubated for another 20 minutes
and again the sections were rinsed and washed with TBS. A lmg/ml of DAB,
containing 0.003% hydrogen peroxide, was dropped onto the slide, incubated for 5
minutes and then removed with water. Haematoxylin was used to counter stain the
slides, which are then rinsed, in order, in water, 0.1%HC1 in ethanol, water, lithium
carbonate and then water again. Sections were dehydrated in ascending grades of
alcohol and cleared twice, for 2 minutes each, in xylene. Slides were then mounted
with a coverslip using a drop of DPX mounting medium (Fisher Scientific
Chemicals) and analysed under a microscope for protein staining.
CTSD staining was scored for intensity and location by Dr Owatif Al-Nafusi, Senior
Lecturer in Pathology, Edinburgh University Dept. of Pathology.
2.4 Loss of heterozygosity and revertant analysis studies
2.4.1 Rapid mini-prep extraction of DNA for microsateilite analysis
DNA was extracted using a QIAamp DNA mini kit (Qiagen). 105-106 cells were
harvested, pelleted and resuspended in 200^1 PBS. 20]A proteinase K was added
along with 200/d buffer AL, vortexed, then incubated for 10 minutes at 56°C. 200/d
100% ethanol was added and again vortexed. This mix was applied to a QIAamp
spin column and centrifuged for 1 minute.
The column bound DNA was washed with 500/d buffer AW1 and spun for 1 minute.
The DNA was washed with 500/<l buffer AW2 and spun for 3 minutes. Carryover
buffer AW2 was removed by a further 1 minute spin. DNA was eluted in a total of
100/d of warmed buffer AE (lOmM Tris-Cl; 0.5mM EDTA) over two spins and
stored at 4°C.
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DNA levels were too low to quantify by spectrophotometry so concentrations were
determined by PCR (normally 2/d per reaction) using G-actin primers.
2.4.2 Clinical data
I examined LOH in 38 fresh and 49 paraffin embedded epithelial ovarian tumours
and their corresponding normal tissues (blood, normal ovary, and normal omentum).
The specimens were collected between 1989 and 2001 at ICRF medical oncology
unit.
A gynaecological pathologist confirmed all histopathological diagnoses and grades
of the ovarian cancers. The average age at presentation was 59.8 years (range, 30 to
87 years). Patient characteristics are collated in Table 8.1.
Sample DNA was extracted by Diane Scott.
2.4.3 Identification of LOH primers
Forty-four polymorphic markers were identified on chromosome 11 pi5 using
GeneMap '99 (www.ncbi.nlm.nih.gov/genemap/) and Genethon and Marshfield
maps at NCBI (www.ncbi.nlm.nih.gov/cgi-bin/Entrez/map_search). Markers were
confirmed as polymorphic using links to the UniSTS database. The position of these
markers along 1 lpl5 was determined by electronic PCR of marker sequences again
non-redundant and HTGS databases using BLAST. The order of the markers was
further refined using UCSC June 2002 web browser fhttp://genome.ucsc.edu/).
2.4.4 PCR of microsatellite markers.
Oligonucleotides were obtained from the Cancer Research UK oligonucleotide
synthesis lab, London. Primers were selected on basis of location and spread over
chromosome 1 lpl5. Table 2.3 shows the 39 markers that were optimised for PCR
and used in LOH and revertant analysis. Primers consist of fluorescinated primer
pairs, 5' end labelled with fluorochromes TET/FAM that amplify dinucleotide repeat
fragments of 90-348 bp.
Essentially two PCR programs were used for LOH and revertant analysis.
Touchdown 67-55°C is composed of 2 cycles of 94°C for 30 sec, 67°C for 30 sec and
72°C for 45 sec followed by repeats of the above but at decreasing temperatures of
70
64°C to 61°C to 58°C, for two cycles each, then 30 cycles of 94°C for 30 sec, 55°C
for 30 sec and 72°C for 45 sec finishing off with 72°C for 5 minutes. All other
touchdown programmes are similar but with altered annealing temperatures.
Standard 55°C program runs for 30 cycles of 94°C for 30 sec, 55°C for 30 sec and
72°C for 45 sec followed by 5 minutes at 72°C.
PCR reaction volume was 25/d and mixes consisting of 1.25-2.5mM MgCl2, 12.5pM
each primer, 1.25U taq polymerase, 200//M dNTPs, lxBuffer and l-2/<l of DNA
were run on an MJ thermocycler.
2.4.5 Agarose gel electrophoresis
PCR products were run on 2% agarose gels at 40-100V in lxTAE with 0.1/<g/ml of
ethidium bromide (Sigma) and visualised and photographed under UV light.
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2.4.6 Use of ABI310.
PCR products were pooled at suitable dilutions, from 1 in 5 to 1 in 50, with distilled
water to a total volume of 50/d.
3/d of diluted PCR products were mixed with 10.5/d deionised formamide and 0.5/d
internal size standard (TAMRA 350). Before electrophoresis, samples were
denatured for 5 minutes at 95°C and then snap cooled on ice. Electrophoretic
separation was conducted in an ABI Prism 310 Genetic analyser (Applied
Biosystems). Samples were electrokinetically injected for 5 sec at 15kV and run on a
47cm (36cm length to detector) 50ji\ ID capillary filled with the denaturing polymer
POP4. The separation was conducted for 24 minutes at 15kV, 9piA, lOmW and 60°C.
Raw data was analysed with GeneScan software Version 2.1 (Perkin Elmer). LOH
was determined by calculating the ratio of peaks between normal and tumour
samples.
Normal B x Tumour A Exp. E
= Expected Tumour B = ^ va'Ul
Normal A ^ Actual Tumour B
LOH was present when the ration of alleles in tumour was 60% or less than the ratio
of alleles in normal tissue DNA (rs0.6).
2.4.7 Statistical methods
Computer packages InStat 2.01 (GraphPad software) and SPSS for Windows (SPSS
Inc) were used for all clinicopathological correlations. A two-tailed Fisher's exact
test was used to determine significant associations between marker/region LOH and
clinicopathological variables. Kaplan-Meier and Log-rank analyses were done using
SPSS to determine any associations of LOH with survival. Protein and gene
expression associations were also determined using a Fisher's exact test. P values
were determined on the basis of sample numbers used in each analysis. The null
hypothesis is that there will be no correlation of samples with the variables
representing the normal situation in the population. The p value is a measure of
discrepancy between our data and the null hypothesis. A p=0.05 shows that there is a
1 in 20 chance of this event happening in the normal population. The p value does
not however take into account the size of the sample set. An arbitrary cut-off should
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therefore be decided upon. For LOH analyses, the number of samples used in each
correlation ranged from n=21 to n=80. A p value of 0.05 is therefore not suitable so
p=0.01 (1 in 100) was chosen. Survival analyses for LOH used a lower sample
number so p=0.05 was used to indicate significance. The correlations of gene
expression in 18 HOV tumours also used this cut-off.
All of the analyses performed are univariate, that is each variable does not take into
account any dependencies on other variables. For example, the serous histology
maybe associated with a more advanced stage and therefore these variables are not
independent. A multivariate analysis of data would be more precise showing
independent correlations of LOH or gene expression changes with
clinicopathological variables.
Correlation between expression of individual genes was done using the data analysis
tools on Microsoft Excel.
2.5 Bacterial culture and Plasmid preparation
2.5.1 Media and additives
L-Broth was made with 2.46g magnesium sulphate, lOg Bacto-tryptone, 5g yeast
extract, and 5g sodium chloride made up to 1L with distilled water at pH 7.0. L-agar
has 15g agar added per 1L of L-Broth.
SOC media was prepared with 2.0g Bacto-tryptone, 0.5g yeast extract, lOmM
sodium chloride, 2.5mM potassium chloride, 20mM Mg2+, and 20mM glucose in
100ml distilled water. This was filter sterilised and adjusted to pH 7.0.
Ampicillin was added to the above L-broth and L-agar at a concentration of
100^g/ml to select for transformants carrying the amp resistance gene. Ampicillin
(Sigma-Aldrich) stock was prepared sterile at a concentration of 50mg/ml and stored
at -20°C.
X-gal and IPTG were used for blue/white colour selection with the pGEM-T Easy
plasmid (Promega) to select for bacteria successfully transformed by insert
containing plasmids. IPTG stock was made to a concentration of 100//M and used at
a concentration of 0.5//M. A 2% (20mg/ml) X-Gal stock was made up in DMF to use
at a concentration of 80//g/ml. Solutions were stored at -20°C.
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2.5.2 Bacterial strains
JM109 competent cells (Promega) were used for all transformations. They are a
highly efficient cell line and compatible with blue/white colour screening. Stock cells
were stored at -20°C and thawed prior to use.
2.5.3 Plasmids
The pGEM-T Easy (Promega) plasmid was chosen for convenience of use. The 3Kb
plasmid has 3' T overhangs for ease of cloning PCR products and lac operon
sequences for use with blue/white detection. Insertional inactivation of the alpha-
peptide of the enzyme G-galactosidase disallows X-gal to be cleaved and white
colonies are formed. It also carries an ampR gene for selection.
CMV promoter driven vector pcDNA3.1/Zeo (+) (Invitrogen-Life Technologies)
carries a zeoR gene to allow selection with the antibiotic Zeocin. This 5kb plasmid
was chosen for use in transfection of both Hyg and/or Neo resistant cell lines and has
a BGH polyadenylation signal for efficient termination and increased stability of the
transcript. The plasmid is not suitable for blue/white colour selection, but carries an
amp resistance gene.
2.5.4 Bacterial transformation.
Full length PCR products with 3' A overhangs were generated and ligated overnight
into pGEM-T Easy vector. A Promega ligation kit was used to ligate 3p\ PCR
product into 50ng vector with 3 units of T4 DNA ligase and Rapid ligation buffer.
After incubation overnight at 4°C, 2p\ was added to 50/d JM109 cells and left on ice
for 20 minutes. This mix was then heat shocked at 42°C for 45 sec and added to SOC
media to be incubated at 37°C for uptake of the plasmid into bacterial cells. Culture
was plated onto LB/ampicillin/IPTG/X-Gal plates and left overnight at 37°C.
For the pcDNA3.1/Zeo (+) vector, no blue/white screening was used so the culture
was plated onto LB/ampicillin plates.
2.5.5 Plasmid DNA preparation
Plasmids were isolated from lysed bacterial cells using the QIAprep miniprep kit
(Qiagen). Briefly, cells from an overnight culture in L-broth at 37°C were pelleted
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and resuspended in 250/d buffer PI (RNase A). 250/d of buffer P2 then added and
inverted to mix. Protein was precipitated out using 350/d buffer P3 and pelleted by
centrifuging for 10 minutes at maximum speed in a microfuge.
The DNA in solution was bound to a spin column and washed with 0.5ml buffer PB,
then with 0.75ml buffer PE.
Plasmid DNA was eluted off the column with 50/d buffer EB (lOmM Tris-Cl,
pH8.5).
Presence of inserts in the purified plasmid was checked by EcoRI digestion for 2hrs
at 37°C and 1/d visualised on 2% agarose gel with ethidium bromide under UV light.
Directionality of inserts was determined by DNA sequencing.
2.5.6 Sequencing of inserts.
Sequencing was carried out using an ABI prism dRhodamine terminator cycle
sequence ready reaction kit (Applied Biosystems). A mix was made up of 8/d ready
reaction mix (containing labelled oligonucleotides, deoxynucleoside triphosphates,
AmpliTaq DNA polymerase, MgCl2, and TRIS HC1 buffer), 4/d (~50ng) plasmid
preparation, 1 /d (3.2pM) primer (either SP6 or T7), and made up to a total of 20/d
with water. This mix was then incubated on an MJ thermocycler for 25 cycles of
94°C for 10 sec, 50°C for 5 sec and 60°C for 4 minutes and kept at 4°C until ready to
precipitate. To each reaction was added 2/d 3M NaOAc at pH4.6, 50/d 100% EtOH
and 1/d pellet paint (Novagen). This precipitated out the amplified DNA by standing
at room temperature for 1 hour. The DNA was then pelleted by a 20 minutes spin at
4°C. The pellet was then rinsed with 250/d 70% EtOH and air dried. The samples
were sequenced on an ABI 3700 at the sequencing core of the MRC Human Genetics
unit, Edinburgh.
2.5.7 Digestion of plasmids
Once directionality was established, plasmids were digested with Sspl restriction
enzyme for 2 hours at 37°C. This mix contained 6/d plasmid, 1/d Sspl, 1/d lOx
buffer and 2/d water. Sspl cuts pcDNA3.1/ Zeo once.
Complete plasmid linearisation was checked by running 1/d digested product on a
1.5% agarose gel compared to undigested plasmid.
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2.5.8 Plasmid purification
Linearised plasmids were purified using QIAquick PCR purification kit. Five
volumes of buffer PB are added to the digested plasmid. This is then placed into a
spin column and centrifuged for 1 minute. The DNA is washed with 0.75ml buffer
PE and then the plasmid is eluted in 50y\ lOmM Tris/ HC1.
Plasmid DNA was quantified by spectrophotometry.
2.6 Human cell culture techniques
Sterile conditions were used throughout. Cell lines maintained on DMEM/10% FCS/
penicillin and streptomycin. Predetermined levels of antibiotics hygromycin and
G418 were also added to the media as required. They were cultured at 37°C, 5% C02
in humidified incubators. Sterile flasks, plates, glassware, solutions and other
consumables were used. Tissue culture was carried out in a laminar flow hood.
Cells were harvested by washing twice in PBS and incubating with a minimal
volume of trypsin. Then resuspended in 10% FCS media and pelleted at l,000g for 5
minutes for further manipulation.
Cells were frozen in liquid nitrogen in a freezing mix composed of 10% DMSO in
FCS. They were stored initially for 24 hours at -70°C prior to this.
Recovery was by rapid thawing of vials in a water bath at 37°C followed by pelleting
in media and plating with fresh DMEM in a suitable sized flask.
2.7 Transfection of plasmid DNA into cell lines.
2.7.1 Transfection reagents
Two different transfection solutions were used in the transfection of sense and
antisense plasmids into OH1 cells. Lipofectin was initially used with the pCDNA3-
Neo RALDH2 plasmids. Lipofectin (Invitrogen-Life Technologies) is a 1:1 (w/w)
liposome formulation of the cationic lipid DOTMA and DOPE in membrane filtered
water. It interacts spontaneously to form a lipid-DNA complex. Fusion of complex
with cells results in efficient uptake and expression of DNA.
FuGene6 was the other method used in transfection of the candidate TSG plasmids
into OH1 cells. This switch to using FuGene6 was because of problems with
transfection efficiency and toxicity of Lipofectin. FuGene6 (Roche) is a non-
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liposomal lipid based transfection reagent with low toxicity and high transfection
efficiency.
2.7.2 Method of transfection
Both reagents are added to cells in a similar manner. Initially, 2xl05 cells are plated
into each well of a six-well plate and left overnight or until ~70% confluent. Each
sense or antisense plasmid transfection is done in triplicate.
Serum-free DMEM is warmed to 37°C and the transfection reagent and plasmid
DNA are warmed to room temperature. 100//1 DMEM is then mixed with either 3//1
or 6/d of FuGene6 and 1 //g DNA. Using Lipofectin, 200ji\ DMEM is mixed with 2/d
DNA and 10/d Lipofectin. These mixes are left to stand at room temperature for 15-
30 minutes. Meanwhile, cells are washed with serum-free DMEM. The FuGene6
mixture is added directly to the cells. The Lipofectin mixture is added to 1.8ml
DMEM, which is then poured over the cells. These are then placed in an incubator at
37°C for 6hrs, after which the media is replaced with fresh DMEM containing 10%
FCS.
After 48 hours each well is split 1/5 in maintenance media. Zeocin/Neomycin
selection is added 24 hours later.
2.7.3 Selection conditions
Bacterial gene zeo confers resistance to the antibiotic zeocin in mammalian cells.
Zeocin is the commercial name of a formulation containing Phleomycin Dl, a
copper-chelated glycopeptide antibiotic of the bleomycin family. Zeocin allows the
selection of cells expressing the Sh ble gene, which encodes a small protein (MW
13.665 kDa). The Sh ble protein binds zeocin with a strong affinity and inhibits its
DNA strand cleavage activity allowing further cell growth.
Geneticin/G418/neomycin is an aminoglycoside related to gentamycin that inhibits
translation by binding to the small subunit of ribosomes. The neo resistance gene
encodes aminoglycoside 3'-phosphtransferase whose expression allows resistance to
geneticin through its phosphorylation so allows translation and cell growth.
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Hygromycin is an aminoglycoside antibiotic, which inhibits protein synthesis. The
bacterial gene hphR, encodes a kinase which inactivates hygromycin by
phosphorylation so protein synthesis may occur.
Kill curves for antibiotics were previously determined by Dr Hani Gabra for neo/hyg
and for zeo by Dr Karen Watt. Cells with resistance are maintained on 150/d Hyg
(7.5mg), 175/d Zeo (17.5mg) and 2ml G418 (400mg) per 100ml DMEM.
2.7.4 Picking of resistant clones
Cells were maintained under selection conditions which killed controls, resistant
colonies arising from single cells were picked at 2-6 weeks post antibiotic selection. .
When colonies reached >lmm, the flask was washed twice with PBS and colonies
picked by dislodging cells into the tip of a fine tip pastette containing trypsin. They
were transferred to 24 well plates containing 1ml of selection media, refed every 3-4
days and passaged up to larger flasks as required.
2.7.5 Determination of Insert expression and endogenous expression change
2.7.5.1 Determination of insert presence and correct orientation.
DNA was extracted from each of the individual clones and used in PCR to determine
insert presence. Using SP6 and T7 primers, which bind to sequence within the
plasmid, and the forward/reverse primer used in cloning the full-length cDNA, both
the presence and direction of the insert could be seen.
2.7.5.2 Determination of insert expression.
RNA was extracted from each of the clones using the Absolutely RNA™ RT-PCR
mini prep kit as previously mentioned. From this, cDNA was made and used in RT-
PCR to determine insert expression. The SP6 and T7 primers lie within the region of
plasmid which is transcribed. These primers were therefore used in conjunction with
the forward/reverse primer used above. A control cDNA was generated for each
clone which were all found to be negative.
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2.7.5.3 Determination of endogenous expression.
Those clones that have insert expression were used in RT-PCR to determine if there
is an alteration in the levels of endogenous cDNA as compared to normal. For
example, if an antisense transcript knocks out endogenous expression, this alteration
can be detected using primers designed outwith the full-length coding sequence
within the plasmid.
Clones with alterations in endogenous expression can then be used in functional
studies to determine whether the gene has an effect on phenotype.
2.7.6 Growth analysis of transfected clones
In order to determine cell concentration for experimental set up, trypsinised cells
were resuspended in a minimum of 1:1 trypsin to media and counted on a
haemocytometer, cells were then diluted down appropriately for seeding.
Cells were seeded from 70% confluent flasks into 24 well trays at 2 x 103 cells per
well, in 1 ml normal growth media (day 0) in triplicate wells. Cells were counted
every 5 days, here after for a total of 15 days.
To count cells, they were washed with 1ml PBS then 250/d trypsin added and plates
incubated at 37°C. Once cells were detached, 250//1 of normal growth media was
added and the plates kept on ice. Cell suspension was syringed to break up any
aggregations and 200/d added to 9.8ml sodium chloride (0.9%), which was then
counted by a coulter counter. Each well was counted twice, generating six counts for
each cell-lines that were then averaged.
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3. MMCT CLONAL HYBRID ANALYSIS
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3.1 Microsatellite mapping of MMCT hybrids
Prior to my arrival, MMCT of chromosome 11 was carried out. OVCAR3 is an
ovarian cancer cell-line from which clonal lines OH1 and OHN were generated by
hygromycin and hyg/neomycin tagging. 556.1.5 is a mouse line containing a
complete copy of neo-tagged human chromosome 11 for use as a resource for
MMCT.
The transfer chromosome 11 (556.1.5) into ovarian cancer cell line OVCAR3
generated a number of clonal cell lines. The origins of these can be seen in Figure
3.1.
Figure 3.1. The generation of OVCAR3 derived hybrid cell lines using MMCT. OH3 and
OHX are clonal derivatives of OVCAR3. OHX is generated from a xenograft of OH3.
Independent MMCT were carried out to form clonal hybrids.
To determine the extent of chromosome 1 lpl5 transferred into each of the hybrids,
microsatellite maps were generated. Of 14 microsatellite markers situated along
lip 15, only 8 were found to be polymorphic between the parental lines OVCAR3
and 556.1.5. Examples of chromosome transfer as detected by peak size differences
are seen in Figure 3.2.
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The regions of chromosome lip 15 transferred in the hybrid cell lines 11OH 1.1,
110HX1.1, 110H2.1, 110HX2.1, 110H2.2 and 110HX3.1 was determined using
these 8 polymorphic markers (Figure 3.3). The original microsatellite mapping of
these lines for llpl5 used only two markers so was not very comprehensive (see
Figure 1.4).
Hybrid cell-lines 11 OH1.1, 110HX1.1 and 110HX3.1 contain the whole lip 15
region which agrees with the original two marker data. 110H2.1, 110H2.2 and
110HX2.1 have only partial transfer. This fragmentation at 11 p 15 was not detected
in the preliminary maps. 110H2.1 and 110H2.2 were generated from the same Chr
11 transfer and show loss of the same regions and the same growth characteristics.
Further mapping has successfully minimised the areas along llpl5 which may
contain putative TSGs to pTel-Dl 1S932 and D11S569-D11S419.
3.2 Revertant hybrid mapping
Clonal hybrid cell lines llOHXl.l, 110HX2.1, 110H2.2 and 110HX3.1 were
passaged ten times the aim being to generate revertant clones which will have lost
the growth suppression due to loss of donated chromosome 11 regions (assisted by
Eric Miller). In all, from these cell lines, we generated 48 clones. It should be noted
that these clones have not yet been assessed for growth and tumorigenicity
characteristics, they are therefore only putative revertants.
Again, using the eight polymorphic markers, microsatellite maps were generated
showing the regions of transfer and by comparison to the parent hybrid, any regions



























Example traces of allele peaks from parental and hybrid cell-lines. Fam-labelled primers for
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Figure 3.3
The extent of chromosome 1 lpl5 transfer in clonal hybrid cell-lines generated by MMCT. A
white box= transfer of the 556.1.5 Chr 11 marker, a red box= endogenous OVCAR3 Chr 11.
Microsatellite loci and distances between these are seen on the left. Data for markers
D11S569 and D11S419 from original mapping.
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Revertant clones were generated from cell-lines 110HX1.1, 110HX2.1, HOH2.2
and 110HX3.1.
Mapping of the 1 lpl5 region in the passaged clones reveals few further losses of the
donated chromosome. 110HX2.1 parental line contains only the region spanning
D11S569-D11S419 of llpl5. Passaged clones from this line did not show further
losses at 1 lpl5. This line interestingly exhibits faster growth than the other two
110HX lines, suggesting that a growth suppressor may lie in those regions not
contained in this clone. D11S926 marker appears to be the only marker that is lost in
any of the passaged clonal derivative lines, with the exception of clone 110HX1.1
12. Seven 110H2.2 clones have lost D11S926 along with 4 110HX3.1 and 2
1 lOHXl.l clones.
The frequent loss of D11S926 in these clones may correlate with growth suppression
and these functional studies are still to be undertaken.
The microsatellite map of clone 1 lOHXl.l 12 closely resembles a 110HX2.1 clone
and it is likely that this clone has been mislabelled.
3.3 Further mapping of HOH2.1
MMCT hybrid 110H2.1 was chosen as the cell-line to be used in difference analysis
techniques with the aim of identifying genes associated with growth suppression.
When previously mapped with the two markers at llpl5.2, the hybrid showed
retention of this region. When I mapped further with the eight polymorphic markers
used in the revertant analysis, regions of loss between D11S932 and D11S926 and
also D11S926 to 1 lpl5.1 were detected. In order to refine this region a further 14
microsatellite markers were used. Again some of the markers were found not to be
polymorphic between OVCAR3 and the donor cell-line 556.1.5 so only 9 markers
were added to the map (Figure 3.5). Nineteen markers were mapped in all.
The regions of transfer in 110H2.1 span 9.9 MB from D1 IS 1363 to D11S4188 and 4
MB from D11S569 to D11S419. It is hypothesised that these regions may therefore


















































Figure 3.5 Extent of chromosome 1 lpl5 transfer in MMCT hybrid 110H2.1.
Distance between markers is seen on left. Markers run from telomere to centromere,
1 lp 15.5 to 1 lpl5.1. A white box= transfer, a red box= endogenous OVCAR3 Chr 11.
D11S569 and D11S419 determined previously.
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4. GENE EXPRESSION DIFFERENCE ANALYSIS:
UNVALIDATED PRODUCTS
89
4.1 Identification of differentially expressed genes
With the aim of identifying genes involved in the growth suppressed phenotype,
gene expression in microcell hybrid 110H2.1 was compared to parental clone OHN
using three difference analysis techniques. Transfer of chromosome 11 into hybrid
110H2.1 caused growth suppression both in vivo and in vitro. The products
identified as differentially expressed between this clone and OHN will therefore be
associated with the growth suppressed phenotype. The methods of DD-RT-PCR,
cDNA-RDA and Clontech HDFA were used to identify up and down regulated
genes.
Dr Grant Sellar and Genevieve Rabiasz carried out DD-RT-PCR and the subsequent
cloning and sequencing of differentially expressed products.
Dr Grant Sellar also performed the cDNA-RDA experiments which compare cDNA
samples prepared from two different sources (110H2.1 and OHN). The method
identifies those genes present in the tester population as opposed to the driver so
reciprocal experiments are needed to identify genes both up and down regulated. In
all, five experiments were done, three identifying candidate oncogenes and two
finding candidate TSGs that are down and up regulated in 110H2.1 respectively.
The final difference analysis method used in the comparison of 110H2.1 and OHN
was doing Clontech High Density Filter Array (HDFA) hybridisations. Three arrays,
each containing 1,176 oligonucleotide spots, were hybridised with RNA extracted
from OHN and 110H2.1.
4.2 DD-RT-PCR results
DD-RT-PCR products were subcloned and sequenced. In silico analysis of these
sequences was performed to determine identity, location and function of products.
Sequence matches were identified using online BLAST searches of the NR and
HTGS databases. As the Human genome sequencing project progressed, more of
these transcripts could be identified. The introduction of the NCBI Mapviewer also
allowed pinpointing of transcripts within the human genome. Using these resources,
the majority of transcripts were identified and all were subsequently positioned on
chromosomes. Cellular functions and alternate gene nomenclature were found using
OMIM at NCBI and the GeneCards database and subsequent links from this site. A
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summary of these in silico analyses is shown in Table 4.1. Overall, 47 transcripts,
representing 18 genes were identified as either up or down regulated in 110H2.1 as
compared to the parent line.
Of the 10 genes upregulated in the hybrid clone, one was located on chromosome 11
(KIAA0409).
ACCESSION NO GENE TIMES SEEN CHR FUNCTION
AL158802 NPAS-3/MOP6 1 14q12-13 Signalling
AA283103 KIAA0409 1 11 p15 Unknown
X67247 RPS8 10 1p34 Ribosomal protein
AA181431 Cytochrome c oxidase 3 8q Mt protein
AL519840 ZDHHC4 2 7p Unknown
various mouse 7 - -
AI381647 CGI-72 1 8q Unknown
BF590583 MRPL41 3 9q34 Ribosomal protein
BE898409 PSMD1 1 2q37 Protein degradation
AW591192 ZAK 1 2q31 Protein modification
ACCESSION NO GENE TIMES SEEN CHR FUNCTION
AF014807 CDIPT/PIS 3 16 Signalling
BE898762A/00662 MTCYTB 1 MT MT protein
AB015228 RALDH2 5 15q Protein modification
AC005823 ? 1 17q Unknown
BE671874 SKP2 1 5p Cell growth/cell cycle
AC083805 ? 1 12q Unknown
AX061637 HSPC194 3 6p22 Membrane bound
AJ243666 NICE-5 2 1q Protein degradation
Table 4.1 Genes a) up and b) downregulated in hybrid clone 110H2.1 as compared to OHN
as identified by DD-RT-PCR. GenBank accession number, gene name, chromosomal
location, number of times transcript was detected and cellular function shown.
4.3 cDNA-RDA results
Gel extracted and purified difference products were shotgun cloned into plasmid
pGEMt-easy. Having transformed competent cells, colonies were picked and inserts
sequenced using dRhodamine. In all, 572 were successful. I took this sequence data
and analysed the transcripts in silico, as described for the DD-RT-PCR products. A
large number of up and down regulated genes were identified from the 5 cDNA-
RDA experiments (Tables 4.2/4.3). Having collated the data, the 572 sequenced
products were found to represent 231 different genes that are either up or down
regulated in 110H2.1 (Chr 11 hybrid) with respect to OHN.
One hundred and four genes were identified as upregulated in 110H2.1. Of these, 9
were ribosomal proteins, 3 mitochondrial proteins, 22 of unknown function, 4
identified as mouse contaminants (due to the murine cotransfer with chromosome 11
from mouse donor line 556.1.5) and 66 characterised genes. Nine of the genes are
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located on chromosome 11. Twenty-eight percent of genes are seen twice or more
within the sequenced difference product transcripts.
One hundred and twenty seven genes were identified as upregulated in the oncogenic
parental line OHN. These consist of 23 ribosomal proteins, 8 mitochondrial proteins,
8 of unknown function and 88 characterised transcripts.
In all, more candidate oncogenes than TSGs were identified. However, three
experiments were done to identify genes upregulated in OHN resulting in 391
sequenced transcripts as compared to the 181 sequenced from the reciprocal two
experiments. It is therefore not surprising that we identified more genes that are
downregulated than upregulated in 110H2.1. The majority of genes are only
detected once within the sequenced transcripts with only 27% of genes detected
twice or more. Fifteen percent of all genes were identified by two or more of the
repeated RDA experiments. Curiously, SLPI was identified by all five RDA
experiments, regardless of direction of expression.
Those genes identified as upregulated in OHN consisted of 18% ribosomal proteins
and 6% mitochondrial products. Fewer ribosomal and mitochondrial products were
found to be upregulated in 110H2.1 (9% and 3%) suggesting that in general these
proteins are associated with proliferation. Novel and uncharacterised genes were
more commonly associated with growth suppression (21% vs 6%), probably because
proliferation associated genes are well annotated and have been more widely studied.
cDNA-RDA is known to produce false positives. In our experiments, thirteen genes
were found in both directions of subtraction. These are BCAT2, RPS16, RPL10,
RPLPO, RPS14, RPL27A, GNAS1, ENOl, SLPI, SPINT2, PSMA7, DLC1 and beta-
actin. These genes may not represent actual differentially expressed genes and would




PRODUCT FUNCTION CHR Times
seen
RDA exp.
X03559 FIATPASEI}/ ATP5B MT protein 12p 1 9A-SPIK
U68418 BCAT2 MT protein 19q 1 9A-SPIK
U78678 TXN2/Thioredoxin 2 MT protein 22q 1 9A-SPIK
NM 001020 RPS16 Ribosomal protein 19 1 9A
NM 000999 RPL38 Ribosomal protein 17q 1 9A
NM 000994 RPL32 Ribosomal protein 3p 1 9A
M73791 RPL10/QM Ribosomal protein Xq 1 9A-SPIK
M17885 RPLPO Ribosomal protein 12q 1 9A-SPIK
AF116710 PRO2640/RPS14 Ribosomal protein 5q 1 9A-SPIK
X69150 RPS18 Ribosomal protein 6p 1 9A-SPIK
U14968 RPL27A Ribosomai protein 11 p15 2 9A-SPIK
X73460 RPL3 Ribosomal protein 22q 1 9A-SPIK
NM 004494 HDGF/HMG1L2 Signalling Xq 2 9A
NM 000214 JAGGED1/HAG1/AGS Signalling 2Op 1 9A
NM 016592 NESP55/GNAS1/POH Signalling 20q 2 9A
NM 002087 Granulin/GRN/PCDGF Signalling 17q 1 9A
NM 005682 TM7XN1/GPR56 Signalling 16 23 9A, 9A-SPIK
AF147747 BOG25/SH3BP4 Cell cycle/Signalling 2q 1 9A-SPIK
AF025304 EPHB2/DRT Signalling 1p 1 9A-SPIK
L10612 MIF/GLIF Signalling 22q 1 9A-SPIK
D16227 BDP-1/Recoverin/HPCAL Signalling 2p 1 9A-SPIK
X76678 MAL/MTKL1 Signalling 2 1 9A-SPIK
X00588 EGFR Signalling 7p 1 9A-SPIK
L11285 MEK2/MAP2K2 Signalling 19p 1 9A-SPIK
AF297709 NTKL/P105 Signalling 11q12 1 9A-SPIK
U21909 COFILIN/CFL1 Cytoskeleton/Signalling 11q13 1 9A-SPIK
AK022227 GBL Signalling c16p 1 9A-SPIK
AK026462 PGPL Signalling Xp 1 9A-SPIK
NM_001064 Transketolase/TKT Metabolism/Protein modification 3p 3 9A
NM_003334 UBE1/GXP1/A1S9T Protein Modification Xp 3 9A, 9A-SPIK
NM_001084 PLOD3/LH3 Protein Modification 7q 1 9A
M98252 PLOD Protein Modification 1P 2 9A-SPIK
D29643 KIAA0112/DDOST Protein Modification 1p 1 9A-SPIK
E06719 P4HB/DSI/PDI Protein Modification 17q 1 9A-SPIK
NM_001961 EEF2/EF2 Translational elongation 19p 5 9A, 9A-SPIK
U77700 HSGCN1/KIAA0219 Translation regulation 12 3 9A
NM 017827 FLJ20450 ?Translation 19 1 9A
AF193054 PP3241/DDX27 Translation/Splicing 20q 2 9A-SPIK
NM_013282 ICBP90/UHRF1/TCF19 Transcription factor 6p 1 9A
U57316 GCN5L2/GCN5 Transcriptional activation 17q 1 9A
NM_001428 EN01 Transcription factor c1 2 9A
NM_006892 DNMT3B Methylation/Gene expression 20q 1 9A
NM_003072 SMARCA4/BRG1/BAF190 Transcriptional activation 19 3 9A, 9A-SPIK
NM 001312 CRIP2 Transcriptional regulation 14q 1 9A
AF108459 UBN1 Transcription factor 16p 1 9A-SPIK
NM_003064 SLPI Protease inhibitor 20q12 2 9A, 9A-SPIK
U78095 Bikunin/SPINT2 Protease 19 2 9A, 9A-SPIK
U44385 TIMP-2 Protease inhibitor 17q 1 9A
X64190 CAPNS1 Protein degradation 19q 1 9A-SPIK
AF054185 PSMA7 Protein degradation 20q 1 9A-SPIK
AB009398 PSMD13 Protein degradation 11 p15 1 9A-SPIK
AF007162 CRYAB Protein folding/ heat shock 11q22 1 9A-SPIK
U27515 MIP224/PSMC4 Protein degradation 19q 1 9A-SPIK
Table 4.2 Genes upregulated in 110H2.1- candidate TSGs. As identified by cDNA-RDA.
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ACCESSION PRODUCT FUNCTION CHR Times RDA exp.
NO seen
AB023154 KIAA0937 Unknown 11 8 9A, 9A-SPIK
AB002323 KIAA0325 Unknown 14 4 9A, 9A-SPIK
NM 006360 GA17 Unknown 11 p13 1 9A
AB028991 KIAA1068 Unknown 7p13 1 9A
AK022702 Timeless/TIM/HTIM Unknown 12q 9A-SPIK
BF115985 FLJ14775 Unknown 17 1 9A-SPIK
AB028965 KIAA1042 Unknown 3p 1 9A-SPIK
AF119848 PRO1580 Unknown 5q 1 9A-SPIK
AB040897 KIAA1464 Unknown 16q 1 9A-SPIK
AB033011 KIAA1185 Unknown 1 1 9A-SPIK
AB038651 LOC57106/KLP1 Unknown 19q 1 9A-SPIK
AF289485 MYG1/ C12ORF10 Unknown 12q 1 9A-SPIK
D38549 KIAA0068/CYF1P1 Unknown 15 1 9A-SPIK
AF175966 AMOTL2/LCCP Unknown 3q 1 9A-SPIK
AB002308 KIAA0310 Unknown 9 1 9A-SPIK
AB040924 KIAA1491 Unknown 9 1 9A-SPIK
AK025994 FLJ22341 Unknown 17q L 1 9A-SPIK
AF151912 CGI-54/PRO0989/BR-84 Unknown 20q 1 9A-SPIK
E27354 HM13/H13 Unknown 20q 1 9A-SPIK
AJ001258 NIPSNAP1 Unknown 22q 1 9A-SPIK
AB002313 KIAA0315/PLXNB2 Unknown 22q 1 9A-SPIK
AK025875 FLJ22222 Unknown ? 1 9A-SPIK
NM 001660 ARF4 Protein trafficking 3 1 9A
U32944 DLC1/PIN Protein trafficking 12q 1 9A-SPIK
AF002020 NPC1 Protein trafficking 18q 1 9A-SPIK
T10807 SLC1A5 Transporter 19q 1 9A-SPIK
AF051976 DFNB3/MY015 Cytoskeleton 17p 8 9A, 9A-SPIK
NM 001101 SACTIN Cytoskeleton 7p15 2 9A, 9A-SPIK
NM 005572 LAMIN A/C/LMNA Cell structure iq 3 9A, 9A-SPIK
AK000860 COR01B Cell structure 11q 1 9A
X51521 EzrinA/illin2A/IL2 Cytoskeleton 6q 2 9A-SPIK
M34482 CK8/KRT8/CARD2 Cytoskeleton 12q 4 9A-SPIK
AF216941 CLIC5 Cytoskeleton 6p 1 9A-SPIK
NM_000424 KRT5/EBS2 Cytoskeleton 12q 2 9A-SPIK
M11315 COL4A1 Structural protein 13q 1 9A-SPIK
M95178 ACTN1/Actinin Cytoskeleton 14q 1 9A-SPIK
AF202321 KRT19 Cytoskeleton 17q 1 9A-SPIK
M80899 AHNAK/Desmoyokin Cell differentiation 11 q12 1 9A
NM_006445 PRP8/DBP2 RNA splicing 6 1 9A
AB018331 KIAA0788 RNA splicing 7 2 9A
NM 001752 CAT/Catalase Cell protection/ cell stress 11 p13 1 9A
NM 001305 Claudin4/CLDN4/CPE-R Membrane protein 7 4 9A, 9A-SPIK
NM_016561 BFAR/LOC51283 Apoptosis regulator 16p 1 9A
M57638 ASL Urea cycle 7q 1 9A-SPIK
AF261085 GAPDH Metabolism 12p 1 9A-SPIK
M81735 POLD1 DNA replication 19q 1 9A-SPIK
NC_001501 MMLV Mouse contaminant - 8 9A
Z93724 MURINE Shuttle Vector Mouse contaminant - 3 9A
AF090190 MURINE KINESIN Mouse contaminant - 3 9A
NM_007472 MURINE Peroxiredoxin Mouse contaminant - 6 9A
Table 4.2 cont. Genes upregulated in 110H2.1- candidate TSGs. As identified by cDNA-
RDA. GenBank accession number, gene name, function, chromosome location, number of
times identified by RDA and experiment number shown.
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ACCESSION NO PRODUCT FUNCTION Times
seen
RDA exp.
AF172368/U09500 Mt cytochrome b/MTCYTB Mt Protein 4 5A,9B,9B-SPI
NM 005918 malate dehydrogenase 2/MDH2 Mt Protein 2 5A, 9B
U12694 cytochrome oxidase subunits l/ll/COII Mt Protein 5 5A,9B,9B-SPI
NM 001098 aconitase 2 /AC02 Mt Protein 1 5A
L06328/L08666 VDAC2 Mt Protein 1 9B-SPI
X83218 atp50/OSCP/TATPO Mt Protein 1 9B-SPI
J04469 CREATINE KINASE/CKMT Mt Protein 1 9B-SPI
NM 001190 BCAT2 Mt Protein 1 9B-SPI
NM 002952 LLREP3/RPS2/RPS4 Ribosomai protein 13 5A,9B,9B-SPI
NM 006013 QM/RPL10/NOV Ribosomal protein 1 5A
NM 001025 RPS23 Ribosomai protein 2 5A, 9B-SPIK
NM 001013 RPS9 Ribosomal protein 1 5A
NM 001032 RPS16 Ribosomai protein 3 5A, 9B-SPIK
NM 001009 RPS5 Ribosomal protein 2 5A, 9B-SPIK
NM 001002 RPLPO Ribosomal protein 5 5A,9B,9B-SPI
NM 000969 RPL5 Ribosomal protein 1 5A
NM 001006 RPS3A/MTFL Ribosomal protein 1 9B
AF161494 HSPC145/MRPL15 Ribosomal protein 1 9B-SPI
AF116710/M13934 RPS14/PRO2640/EMTB Ribosomal protein 1 9B-SPI
U12465 RPL35 Ribosomal protein 1 9B-SPI
X06617 RPS11 Ribosomal protein 2 9B-SPI
U14968 RPL27A Ribosomal protein 1 9B-SPI
D87735 RPL14/CAG-ISL7 Ribosomal protein 3 9B-SPI
M36072 SURF 3/RPL7A Ribosomal protein 1 9B-SPI
X67247 RPS8 Ribosomal protein 1 9B-SPI
AF325707 RPML2 Ribosomal protein 1 9B-SPI
U43701 RPL23A Ribosomal protein 1 9B-SPI
NM 000987 RPL26 Ribosomal protein 2 9B-SPI
NM 000976 RPL12 Ribosomal protein 1 9B-SPI
NM 000981 RPL19 Ribosomal protein 1 9B-SPI
NM 021104 RPL41 Ribosomal protein 2 9B-SPI
NM 002574 PRDX1/peroxiredoxin/NKEFA/PAGA Signalling 2 5A, 9B-SPIK
NM 006098 GNB2L1/RACK1 Signalling 7 5A,9B,9B-SPI
NM 000877 IL1R1 Signalling 1 9B
NM 000516 GNAS1/NESP55/CARD3/POH Signalling^ 4 9B.9B-SPI
NM 004039 annexin a2/ANXA2/LIP2/CAL1H Signalling 2 9B.9B-SPI
U61538 calcineurin b homol/CHP/P22 Signalling/ membrane traffic 1 9B-SPI
S80794/Z82248 YWHAH/14-3-3 ETA Signalling 1 9B-SPI
M84349 CD59/ PROTECTIN/MIC11 Signalling 1 9B-SPI
NM 012302 latrophilin/LPHH1/LEC1 Signalling 1 9B-SPI
NM_007273 REA/GEFSP2/SCN1A Signalling 1 9B-SPI
AB015226/NM 009022 RALDH2/ALDH1A2 Protein modification 50 5A, 9B
AB028981/XM 090586 KIAA1058 Protein modification 1 5A
NM 003333 UBA52/RPL40 Protein modification 6 9B.9B-SPI
XM 084111 RIBOPHORIN1/RPN1 Protein modification 1 9B-SPI
NM 001418 DAP5/NAT1 /EIF4G2 Translation initiation 4 5A, 9B-SPIK
AF267861 EF1A/EEF1A1 T ranslation 1 9B-SPI
X69150 RPS18/KE3 Translation initiation 4 9B-SPI
NM 003754 EIF3S5 Translation 1 9B-SPI
NM. 001959 EEF1B2 Translation 1 9B-SPI
U63131/NM 007065 CDC37 Cell cycle/ protein chaperone 1 5A
NM 006999/AF089896 TRF4-1/ POLS Cell cycle 1 5A
NM 005196/NM 016343 CENPF Cell cycle 2 5A, 9B-SPIK
J02763/M18981 ca Icycl i n/S 100A6/2A9/CACY Cell cycle 1 9B-SPI
D84296/D84294 TCC3/TPRDIII/DCRR1 Cell cycle 1 9B-SPI
Table 4.3 Genes upregulated in OHN - candidate oncogenes. As identified by cDNA-RDA.
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ACCESSION NO PRODUCT FUNCTION Times
seen
RDA exp.
X68060/NM 001068 topoisomerase MIS/ TOP2B Transcription 1 5A
NM 006800 MSL3L1 Transcriptional activation 5A, 9B
NM 005762 KAP1/TIF18/TRIM28 Transcriptional repression 1 5A
AB020692 KIAA0885/D1S155E/UNR Transcription 5A, 9B-SPIK
NM 003663 CGGBP1 Transcription 1 5A
U69127 FBP3/FUBP3 Transcriptional activation 1 5A
X77588/NM 003491 TE2/ARD1/DXS707 Nuclear organisation 1 5A
AF074723 MED6 Transcription 1 9B
NM 000970 TAXREB 107/RPL6 Transcription 9B.9B-SPI
AF0077044/NM 015972 RNApoh 16Ksubunit/LOC51082 Transcription 1 9B
NM 006711 RNPS1 Splicing/ transcription 1 9B
X74070 BTF3 Transcription factor 1 9B-SPI
M37197 CBF2 Transcription factor 1 9B-SPI
M11353/NM 002107 H3F3A/HISTONE H3 Nuclear organisation 1 9B-SPI
NM 014263 YME1L1/MEA Transcription 9B-SPI
NM 022731 NUCKS Transcription 1 9B-SPI
NM 005644 TAF2J/TAF12 Transcription 1 9B-SPI
NM 002512 NME2/NME23B Transcription 1 9B-SPI
NM 005517 HMG17 Transcription 1 9B-SPI
NM 005967 NAB1/NGF1A-BP Transcriptional repression 1 9B-SPI
NM 003286 topoisomerase I/TOP1 DNA structure/ transcription 1 9B-SPI
NM 014071 AIB3/RAPL50/NCOA6 Transcriptional activation 1 9B-SPI
NM 003064 SLPI/HUSI-1 Protease inhibitor 10 5A,9B,9B-SPI
NM 003470 usp7/HAUSP Protein degradation 1 5A
AF022815/NM 002792 xapc7/PSMA7 Protein degradation 9B-SPI
E12605/E12459 POLY UBIQUITIN Protein degradation 1 9B-SPI
X12548/NM 001610 acp2 Protein degradation 1 9B-SPI
AF097362/J 03909 ip-30/IFI30/GILT Protein degradation 1 9B-SPI
U78095 bikunin/SPINT2/HAI-2/KOP Protein degradation 1 9B-SPI
NM 016237 APC5/ANAPC5 protein degradation 2 9B-SPI
AF161425 HSPC307/DC2 Unknown 3 5A
AF077051/AB019392 PTD001/M9/HSPC029 Unknown 2 5A, 9B-SPIK
NM 012111 HSPC322/C140RF3/CEP52 Unknown 1 9B
NM 006070/AF143407 trk fused qene/TFG Unknown 1 9B
AF161519/NM 014187 HSPC171 Unknown 1 9B-SPI
AC006499 CB1 Unknown 93 5A, 9B
AC087369 CB2 Unknown 37 5A
AK001985 CB3 Unknown 1 5A
NM 018840/AF112213 RIP-5 Membrane traffic 1 5A
NM 004911 erp72/DCK Protein secretion 1 5A
NM 022449/AL136938 RAB17 Transcellular transport 1 9B-SPI
AJ251830/AF317550 PIGPC1/THW Transmembrane protein 1 9B-SPI
NM 006831 HEAB Protein transport 1 9B-SPI
NM 03746 dynein liqht polvpeptide/PIN/DLC1 Protein transport 2 9B-SPI
NM 006280 trap delta/SSR4 Protein transport 1 9B-SPI
X00351 8-actin Cytoskeleton 1 5A
V00599 tubulin 85 Cytoskeleton 3 9B-SPI
NM 021103/XM 002498 thymosin810/TMSB10 Cytoskeleton 1 9B-SPI
L54057 COACTOSIN-LIKE PROTEIN/LM04 Cytoskeleton 1 9B-SPI
NM 003234 TFRC/p90/CD71/TFR Iron transport 1 5A
NM 003610 MRNP41/RAE1 Nuclear metabolism 1 5A
Y00339/NM 000067 carbonic anhydrase II/ CA2 metabolism 5 5A,9B,9B-SPI
AF024631 ANG2 Angiogenesis 1 5A
NM 004499 ABBP1/HNRNP A/B RNA Binding 2 5A, 9B-SPIK
AF043338/NM 006273 Mt MCP3/ SCYA7 Invasion 1 5A
Table 4.3 cont.l Genes upregulated in OHN - candidate oncogenes. As identified by cDNA-
RDA.
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ACCESSION NO PRODUCT FUNCTION Times
seen
RDA exp.
NM 001428 alpha enolase/ENOI metabolism 4 5A,9B,9B-SPI
AL049733 tNOX/APK1 ANTIGEN/COVA1 Cancer antigen 1 5A
NM 006802 SF3A3/PRP9/SAP61 Splicing factor 1 5A
NM 000071 cystathionine ft synthase/CBS/HIP4 Homocysteine metabolism 1 5A
NM 003217 TEGT Apoptosis 1 5A
AF028832/X15183 HSP90/HSPCA/LAP2 Stress response 2 9B
NM 005566 LDHA/LDH1 metabolism 2 9B
AF216292 GRP78/HSPA5/BIP Stress response 1 9B
U45955 M6B1/GPM6B Development 1 9B-SPI
AF107405 SFRS3/SPP20/X16 Splicing 1 9B-SPI
U79278/NM 005742 P5/D6S2650E Protein folding 1 9B-SPI
XM 007502 HNRPC Splicing 1 9B-SPI
AL035456 LOC200247 Stress response 1 9B-SPI
NM 020983 ADCY6/KIAA0442 cAMP biosynthesis 1 9B-SPI
Table 4.3 cont. 2. Genes upregulated in OHN - candidate oncogenes. As identified by
cDNA-RDA. GenBank accession number, gene name, function, number of times identified
by RDA and experiment number shown.
4.4 HDFA results
I cultured and counted the 110H2.1 and OHN cells, and sent them to Clontech for
hybridisation onto the cDNA arrays. The three arrays used were the Human 1.2k-I
and -II arrays and the Human Cancer array.
From the arrays, 230 genes were found to be upregulated in 110H2.1 and 384 were
downregulated. In order to minimise this data set into a reliable number of candidates
cut-off values were applied. An expression difference of >3-fold on the array and a
difference of 50 or more units of signal intensity were used. Hybridisation of the two
human 1.2k arrays however was poor so few genes met these criteria. For those
genes upregulated in 110H2.1 on these arrays, a cut-off of >2-fold was applied.
These cut-off values minimised the data set into a workable number. In all, 45 genes
were upregulated in 110H2.1 and 28 clones were downregulated, with two
representing the same gene but on different arrays (Tables 4.4/4.5).
Of the 45 genes upregulated in hybrid 110H2.1, four are found on chromosome 11.
The fold differences range from 9.8 to 2.1 fold with the vast majority of genes being
upregulated by <5-fold. All genes are characterised and none are ribosomal or
mitochondrial protein encoding. This is most likely due to the selection of genes
contained on the chips.
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ACCESSION NO PRODUCT ROLE CHR RATIO ARRAY
J05593 TIMP2 Protein degradation 17q25 8.9X Cancer 1.2k
M62403 IGFBP4 Cell growth/signalling 17g12 7.3X Cancer 1.2k
M99061 KRT2E Cytoskeleton 12g11 7.OX Cancer 1.2k
S85655 PHB Cell qrowth 17q21 6.3X Cancer 1.2k
X00588 EGFR Signalling 7p12 6.3X Cancer 1.2k
M63959 LRPAP1 Cell growth 4p16 5.5X Cancer 1.2k
X16707 FRA1 Transcription factor 11g13 5.3X Cancer 1.2k
U40434 CAK1/MSLN Cellular adhesion 16p13 5.3X Cancer 1.2k
M98776 KRT1 Cytoskeleton 12g12 5.OX Cancer 1.2k
X53587 ITGB4 Signalling/ cell adhesion 17g25 4.9X Cancer 1.2k
X94991 ZYXIN Signalling 7q34 4.7X Cancer 1.2k
M11233 CTSD Protein degradation 11 p15 4.7X Cancer 1.2k
X67683 KRT4 Cytoskeleton 12q13 4.4X Cancer 1.2k
M74387 L1CAM Cell adhesion Xg28 4.3X Cancer 1.2k
D13889 ID-1 Transcription 20q11 4.3X Cancer 1.2k
L11285 MEK2 Signalling 7g32 4.2X Cancer 1.2k
U17077 BENE Membrane protein 2g13 4.1X Cancer 1.2k
D84064 HGS Signalling 17q25 3.7X Cancer 1.2k
X61587 RHOG Cell cycle/ signalling 11 p15 3.6X Cancer 1,2k
U19796 P15/MAAT1 Melanoma antigen 16p13 3.5X Cancer 1.2k
X13293 B-MYB Transcription/ cell cycle 20q13 3.5X Cancer 1.2k
U58048 PCOLN3 Protein degradation 16g24 3.4X Cancer 1.2k
M59371 ECK Signalling 1p36 3.4X Cancer 1.2k
U33053 PRK1 Signalling 19p12 3.4X Cancer 1.2k
U18018 ETV4 Transcription factor 17g21 3.1X Cancer 1.2k
Y07604 NME4 Nucleoside metabolism 16p13 3.OX Cancer 1.2k
U93236 MENIN Transcription 11g13 3.OX Cancer 1.2k
X56681 JUN-D Transcription factor 19p13 3.OX Cancer 1.2k
L08096 TNFSF7 Cell growth/ signalling 19p13 9.8X Human 1.2k-l
M80397 POLD1 DNA synthesis 19q13 4.3X Human 1.2k-l
M81934 CDC25B Cell cycle 20p13 3.8X Human 1.2k-l
M11886 HLAC Immune response 6p21 3.8X Human 1.2k-l
X58079 S100A1 Signalling /cell structure 1g21 3.4X Human 1.2k-l
M96577 RBBP3/E2F1 Transcription factor 20q11 3.3X Human 1.2k-l
AF060515 CYCLIN K Transcription 14g32 3.OX Human 1.2k-l
M86400 YWHAZ Signalling 2p25 2.9X Human 1.2k-l
L27211 CDKN2A Cell growth 9p21 2.7X Human 1 2k-l
M92381 TMSB10 Cytoskeleton 2p11 2.4X Human 1.2k-l
U05340 CDC20 Cell cycle 1p34 2.4X Human 1.2k-l
M73482 NMBR Signalling 6g21 2.1X Human 1.2k-l
M29874 CYP2B6 Electron transport 19g13 4.7X Human 1.2k-ll
U66199 FGF-11 Signalling 17g21 2.3X Human 1.2k-ll
U53476 WNT7A Signalling 3p25 2.2X Human 1.2k-ll
U03865 ADRA1B Signalling 5g33 2.1X Human 1.2k-ll
L19711 DAG1 Cytoskeleton 3p21 2.1X Human 1.2k-ll
Table 4.4. Genes upregulated in 110H2.1 - candidate TSGs. As identified by HDFA.
GenBank accession number, gene name, cellular function, chromosomal location, fold
upregulation and array title all shown.
Twenty-seven different genes were identified by HDFA as being upregulated in
OHN. Of these, the expression differences range between 17.0 and 3.0 fold. There
are fewer genes upregulated in OHN than down regulated but that may be due to the
differences in cut-offs used to identify expression changes (3-fold Vs 2-fold).
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U35048 TCS22 Transcriptional repressor 17.OX Cancer 1.2k
M11810 OAS1 Translation inhibition 7.4X Cancer 1.2k
X05323 OX2 Membrane glycoprotein 7.4X Cancer 1.2k
Z17227 IL10RB Signalling 5.1X Cancer 1.2k
M65062 IGFBP5 Cell growth/ signalling 4.9X Cancer 1.2k
U69161 CC3/TIP30 Apoptosis 4.7X Cancer 1.2k
U51004 PKCI1/HINT Signalling 4.6X Cancer 1.2k
M3410 IGFBP2 Cell growth/ signalling 4.2X Cancer 1.2k
3.7X Human 1.2k-l
X17644 GSPT1 Cell cycle 4.1X Cancer 1.2k
M12623 HMG17 DNA structure/ transcription 4.OX Cancer 1.2k
U18321 DAP3 Transcription / apoptosis 4.OX Cancer 1.2k
U83117 SUM01/UBL1 Protein degradation 3.8X Cancer 1.2k
M27364 EEF1A1 Translation 3.8X Cancer 1.2k
L22253 9G8/SFRS7 Splicing 3.6X Cancer 1.2k
M60974 GADD45A Stress response 3.5X Cancer 1.2k
J03824 UROS Haem production 3.5X Cancer 1 2k
AF015592 Cdc7 Cell cycle 3.3X Cancer 1.2k
U22431 HIF1A Transcription factor 3.3X Cancer 1,2k
D14878 D123 Unknown 3.2X Cancer 1.2k
X52946 PTN Signalling 3.1X Cancer 1.2k
S74678 HNRNPK Cell cycle/ DNA structure 3.1X Cancer 1.2k
D38551 RAD 21 Cell cycle 3.OX Cancer 1.2k
M74816 CLU Apoptosis 3.7X Human 1.2k-l
X66945 N-Sam Signalling 3.6X Human 1.2k-l
U71207 EYA2 Development 4.5X Human 1.2k-ll
U10492 MEOX-1 Transcription 3.1X Human 1.2k-ll
X78669 ERC-55/RCN2 Signalling 3.OX Human 1.2k-ll
Table 4.5. Genes upregulated in OHN - candidate oncogenes. As identified by HDFA.
GenBank accession number, gene name, cellular function, fold upregulation and array title
all shown.
4.5 Comparison of genes identified by difference analysis.
Comparison of the products from each of the difference analysis techniques shows
some genes have been identified as differentially expressed by two independent
methods. None of the genes were identified by all three techniques.
Four products were identified as differentially expressed by both DD-RT-PCR and
cDNA-RDA; MTCYTB, Cytochrome C oxidase (COII), RPS8 and RALDH2.
Confusingly, there is a discrepancy between techniques in the direction of expression
difference for RSP8 and COII. However, the fact that two independent methods have
identified MTCYTB and RALDH2 as upregulated in OHN gives support to them as
true candidate oncogenes.
There was no overlap of products between DD-RT-PCR and HDFA but this may be
because so few genes were identified by DD-RT-PCR. The arrays represent a limited
set of genes so this may further limit overlap of the techniques.
Of the 45 genes identified as associated with growth suppression by HDFA, four
were also detected as upregulated using cDNA-RDA. These are TIMP2, EGFR,
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MEK2 and P0LD1. Only one gene was identified as upregulated in OHN by both
cDNA-RDA and HDFA and that is the translation elongation factor EEF1A1.
Thymosin beta 10 transcripts were identified by cDNA-RDA as more abundant in
OHN. A 2.4-fold decrease in expression, however, was seen using HDFA. This
discrepancy may be due to differences between the techniques.
To summarise, three difference analysis techniques have been used to identify, in
total, 153 up and 157 down regulated genes in the growth suppressed microcell
hybrid 110H2.1. Due to the false positive rates of the methods, these products need
to be validated for expression differences between OHN and 110H2.1.
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5. VALIDATION OF DIFFERENTIALLY EXPRESSED GENES
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All three difference analysis methods are liable to identify false positive genes. In
order to calculate the false positive rates and determine those genes that are truly
differentially expressed, further validation of expression is required. Of the 321
transcripts identified as differentially regulated from the three difference analyses,
178 were further validated. Both Northern blotting and quantitative RT-PCR were
used for validation. Genes were chosen for validation in different ways depending
upon the method by which they were identified. Those genes which were identified
as 'interesting', that is any which were previously associated with cancers, any
positioned on chromosome 11 and others with interesting cellular functions such as
roles in apoptosis and cellular proliferation were taken forward from DD-RT-PCR
and cDNA-RDA. Genes from the HDFA hybridisations were chosen by strict cut-off
values of >3-fold difference (>2-fold for genes up in 110H2.1 on Human 1.2K
arrays) and a difference of 50 or more units of signal intensity. Some products were
identified by more than one method but only validated once. A number of other
products were not validated due to failure of the PCR primers on the Light Cycler.
5.1 Expression validation: Northern Blotting
Initially, products identified by cDNA-RDA were validated using Northern blotting.
Only those which were upregulated in OHN were tested. Examples of gene
expression on Northern blots are seen in Figure 5.1. Products were chosen for
validation by Northern Blotting based upon preliminary semi-quantitative RT-PCR
analyses. Ten probes were generated from the sequenced transcripts and hybridised
to membrane strips carrying OHN and 110H2.1 total RNA. Of these 10 transcripts, 3
were validated as having a >2-fold difference in expression, as a suitable arbitrary
cut-off, in using densitometry (Table 5.1). KIAA1058, HSPC307 and RALDH2 had
















Figure 5.1 Example Northern Blots. Expression of CDC37 and RALDH2 in OHN and
110H2.1 cell-lines.
Accession No Product Function Fold difference
NM 006013 QM Ribosomal Protein 1.70
AB028981/XM 090586 KIAA1058 Protein Modification 2.17
NM 001418 DAP5 Translation initiation 1.06
NM 003610 RAE1 Nuclear Metabolism 1.38
- RDA43 Unknown 1.79
NM 004499 ABBP1 RNA binding 1.25
AF161425 HSPC307 Unknown 3.88
AK001985 CB3 Unknown 1.22
U63131 /NM_007065 CDC37 Cell cycle/ protein
chaperone
1.35
AB015226/NM 009022 RALDH2 Protein modification 10.53
Table 5.1. Transcripts examined for expression in OHN and 110H2.1 by Northern blotting.
Accession number, product, role and fold-difference is shown. RDA43 is a cDNA-RDA
product with no matches to the genome databases. Differences determined by densitometry.
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5.2 Expression validation: Quantitative RT-PCR
Subsequently, the method of quantitative RT-PCR using a Light Cycler was
established in our Lab. This method was used in preference to Northern blotting, as
it is easier and quicker to perform and is more sensitive in determining expression
differences.
Seventy-eight genes down regulated with respect to growth suppression and 100 up
regulated candidate TSGs were validated using quantitative RT-PCR. This represents
48% of down and 63% of all upregulated genes originally identified by the three
difference analysis methods. I validated 72 of these candidate genes by Light Cycler,
with the remainder being assayed by Dr Euan Stronach and Charlie Massie.
An example Light Cycler output showing expression of PSMD13 and beta actin in
OHN and 110H2.1 is seen in Figure 5.2.
For each of the difference analysis methods, the rate of false positives was high. DD-
RT-PCR identified only one validated gene, RALDH2. cDNA-RDA detected the
most candidates and 10% of those tested were validated by Light Cycler as
differentially expressed. Just over 9% of genes found by HDFA hybridisation were
verified. This data shows the importance of further validation of products identified
by all difference analysis techniques. Table 5.2 summarises the number of genes





































Figure 5.2 Light Cycler output graphs for expression of beta-actin and PSMD13 in OHN and
HOH2.1. a) Graph of expression of PSMD13 in triplicate samples of OHN and 110H2.1 as
compared to known standards of 109, 107 and 105 copies of the starting template. A clear
difference between the cell-lines is seen with higher expression in 110H2.1. b) Graph of
expression of beta actin in OHN and 110H2.1 as compared to standards. Expression is the








Products identified as upregjulated in hybrid 1101 TSGsJ
DD-RT-PCR 10 8 0
cDNA-RDA 104 63 8
HDFA 45 29 4
Products identified as downregulated in 110H2.1 (candidate oncogenes)
DD-RT-PCR 8 6 1
cDNA-RDA 127 48 3
HDFA 27 24 1
Table 5.2 Summary of products identified, tested and validated from all three difference
analysis techniques as differentially expressed between OHN and 110H2.1.
Twelve transcripts were validated as upregulated in 110H2.1, and so were associated
with growth suppression, representing only 12% of all genes tested by Light Cycler.
These are all different genes, of which 11 have been characterised. One of these 11
represents a mouse gene that is present as contamination from the MMCT process
(MMLV). Three transcripts are structural keratins and four are localised to
chromosome 11. Two of the genes have been identified by two independent
experiments as being upregulated in 110H2.1 (TIMP2 and EGFR).
Five transcripts, representing four different genes were validated as potentially
oncogenic. Two of these sequenced products, identified from both cDNA-RDA and
DD-RT-PCR, are transcribed from the chromosome 15 gene RALDH2. Two more,
both discovered by cDNA-RDA, are novel transcripts that I have named CB1 and
CB2. The final product is a characterised gene IGFBP2. These five transcripts
represent only 6% of the genes tested by Light Cycler.
The sixteen genes validated by quantitative RT-PCR as differentially expressed
between OHN and 110H2.1 are shown in Table 5.3.
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Accession Gene Function Expression Chromosome Method
number difference location
Products Validated as upregulated in 110H2.1 (candit
U17077 BENE Integral membrane
protein
2.2 2q13 HDFA
X00588 EGFR Signalling 2 7p12 HDFA/
cDNA-RDA
AB009398 PSMD13 Proteasome subunit 2.3 11 p15.5 cDNA-RDA
M11233 CTSD Lysosomal aspartyl
protease
2.4 11 p15.5 HDFA
U14968 RPL27A Ribosomal protein 2.3 11 p15.4 cDNA-RDA
AF007162 CRYAB Heat shock protein 5.2 11q23 cDNA-RDA
NM 000424 Keratin 5 Structural protein 3.1 12q 13 cDNA-RDA
M34482 Keratin8 Structural protein 2.5 12q 13 cDNA-RDA
AF202321 Keratin 19 Structural protein 2 17q21 cDNA-RDA
E27354 HM13 unknown 2.1 20 cDNA-RDA




- MMLV Artefact of MMCT 00 - cDNA-RDA





NM_000597 IGFBP2 Insulin-like growth factor
binding protein
2.4 2q33-q34 HDFA
AC006499 CB1 Unknown -200 4p16 cDNA-RDA
NT_023736 CB2 Unknown 1290 8p23 cDNA-RDA
Table 5.3 Validated differentially expressed genes between OHN and 110H2.1. Accession
number, cellular function, chromosomal location, fold-difference and method by which each
gene was identified are listed.
5.3 Summary of gene validation
Sixteen genes have been validated, from 178 tested, as differentially expressed
between the hybrid clone 110H2.1 and parental line OHN.
Two methods of quantitative validation were used. There were discrepancies
between Light Cycler and Northern data for two genes, KIAA1058 and HSPC307.
These transcripts were found to show less than 2-fold expression difference by Light
Cycler suggesting that the Northern data is only reliable for larger differences.
Of the fifteen validated human genes, four were down regulated upon introduction of
chromosome 11. Three of the four candidate oncogenes are overexpressed by over
200-fold. These changes are markedly different to the small expression differences
seen for candidate TSGs. Generally, the magnitude of decrease in expression of
TSGs in tumours is however invariably less than the magnitude of induction seen for
oncogenes.
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All of the genes associated with growth suppression, that is the eleven human
candidate TSGs, have small fold-differences between 110H2.1 and OHN. This
suggests that slight alterations in gene expression of a larger number of genes are
enough to bring about a phenotypic change. With the introduction of chromosome 11
into OVCAR3 we would expect genes located on this chromosome to be induced
rather than suppressed. There are however seven non-chromosome 11 positioned
genes which are increased in the suppressed hybrid 110H2.1 supporting the theory
that genes are induced rather than repressed upon instigation of growth suppression.
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6. VALIDATED CANDIDATE TUMOUR SUPPRESSOR GENES
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6.1 Gene expression of candidate TSGs
6.1.1 Expression of candidates in ovarian cell-lines and primary tumours
Of 145 genes identified as upregulated in the MMCT hybrid 110H2.1, and therefore
associated with growth suppression, only 12 were validated as true alterations by
quantitative RT-PCR. This represents only 8.3% of all candidates. Of these validated
12 genes, four (33%) were positioned on chromosome 11 (Figure 6.1). The
validation enriched for genes that reside on chromosome 11, in particular at 1 lpl5.
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Figure 6.1 Chromosome positions of upregulated genes identified by difference analysis
techniques before and after Light Cycler validation.
Our interest is in the identification of TSGs on chromosome 11 so the four
differentially regulated genes located on this chromosome were further studied.
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Evidence for a wider role in ovarian cancer for these genes required confirmation of
their downregulation in a panel of cancer cell-lines and primary human ovarian
tumours (HOV). A panel of 15 ovarian cancer cell-lines, 5 other cancer cell-lines and
18 HOVs were analysed for expression of each of the four chromosome 11 genes by
quantitative RT-PCR (done by Dr Euan Stronach). A normal OSE sample Lil was
also used to determine normal epithelial expression of the genes. Light Cycler
analysis was performed with OHN and 110H2.1 in each run so results could be
standardised between them. All cDNA samples were also standardised for actin
ratios to ensure quantitative analysis.
Beginning with the most telomeric gene, PSMD13, expression in normal OSE
sample Lil was higher than any of the ovarian cancer cell-lines (Figure 6.2). Breast
cancer cell-lines MDA and ZR75 both showed low expression but could not be
corrected to its normal tissue as no such sample was available. Colon cancer cell-
lines had high expression, up to >8-fold higher than the ovarian cancer lines. Only 4
HOV tumours showed a lower expression than Lil. Stromal expression may account
for the high expression in the other 14 tumours.
Moving down the chromosome, CTSD shows much lower expression in all samples
than in normal OSE, including all of the HOVs (Figure 6.3). The ovarian cancer cell-
lines with highest expression are 59M and SKOV3. This is the only gene that shows
a lower expression in all HOV samples and cell-lines than OSE.
Ribosomal protein RPL27a at 11 p 15.4 is expressed in a similar manner to PSMD13
(Figure 6.4). All but one of the ovarian cell-lines (PE04) are expressed at a lower
level than the normal OSE. Again the HOV samples have varied expression, possibly
due to stromal expression. Expression of RPL27a is very high in the colon cancer
cell-lines.
Finally at llq22-23, CRYAB is expressed at low levels in all ovarian cancer cell-
lines and expression is almost non-existent in the other cancer lines (Figure 6.5).
HOVs samples vary widely in expression of the gene from 10-fold less to 5-fold




















































Figure6.2ExpressionofPSMD13inapan lc nc rll-lin sdHOVs. Greenbars=HOVtumours,luenon- variancancerell-li es,gr yb rovariani ,dorm lOSEa originalOHNand110H2.1lines.Expr s ionr lativetnorm lSE( 0%).
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Northern blotting of the three genes located on chromosome llpl5 on total RNA
extracted from a panel of ovarian and other carcinoma cell-lines, as performed by
myself, showed none of these genes have alternative isoforms, so none under go
alternative splicing. Expression of the genes on the Northern blots correlated
reasonably well with data from the quantitative RT-PCR method (Figure 6.6). For all
of the cell-lines, Light Cycler quantification appeared to be more sensitive in
detecting levels of expression. Overall, Light Cycler RT-PCR is more accurate and
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Figure 6.6.
Expression of candidate TSGs on a panel of ovarian cell-lines using two quantitative
techniques. Red bars = expression determined by Light Cycler RT-PCR, Blue bars =
Northern blotting. Expression shown as LoglO of percentage relative to OVCAR3/OHN
expression.
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6.1.2 Clinicopathological associations with candidate TSG expression
The relationship between expression of the four chromosome 11 genes in the 18
HOV samples and various clinicopathological variables was examined.
Arbitrary cut-offs of gene expression were determined for each clinicopathological
variable. This therefore weakens the significance of the statistics derived from this
data.
CTSD expression below 6% of normal OSE was found to correlated significantly
with adverse survival (Figure 6.7). Median survival was 28 and 16 months
respectively for patients with CTSD expression above or below 6% of normal OSE
(p=0.0107). An expression level below 20% normal OSE for CRYAB also
correlated with adverse survival with median survival at 25 months for high
expression and 9 months for low expression (p=0.0126)(Figure 6.8). Fishers exact
test showed that decreased expression of CTSD to below 20% of normal OSE level
was associated with a high tumour grade (p=0.0179). CRYAB expression below
50% of normal OSE level was associated with non-serous tumour histology
(p=0.0023). No other significant associations between expression level and tumour





























Figure 6.7 Kaplan-Meier survival curve for CTSD expression. Decreased expression,
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Figure 6.8 Kaplan-Meier survival curve for CRYAB expression. Decreased expression,
relative to normal OSE, of CRYAB is associated with adverse survival (Log Rank
p=0.0107).
Within the panel of cell-lines and HOV tumours, expression of PSMD13 and
RPL27A was seen to be correlated very significantly (p<0.001) (Figure 6.9). This
correlation is also detected on the Northern cell-line panel. Neither of the genes
correlates with the expression patterns of CRYAB or CTSD.
The correlation between PSMD13 and RPL27A extended to colon and breast cancer
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Figure 6.9 LoglO RPL27a Vs LoglO PSMD13 expression in a panel of HOVs and cell-lines.
Correlation is significant (p<0.001).
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6.2 Protein expression for candidate TSGs
Of the four chromosome 11 genes, we acquired antibodies for three. The antibody
against PSMD13 was very poor and designed to identify the protein from a purified
proteasome fraction and I found it very troublesome on whole cell-line lysates. At all
dilutions, the background was very strong. Those bands that were seen appeared to
be non-specific and a correct sized protein could not be detected.
Commercial antibodies were available for both CTSD and CRYAB. The antibody for
CRYAB was unsuitable for IHC and has currently not been optimised for Western
Blotting. The antibody for CTSD, which detects both the 52 kDa pro CTSD protein
and the mature cleaved 34 kDa protein, was successfully optimised for western
blotting and IHC.
I assayed CTSD protein expression in a panel of 16 ovarian cancer cell-lines, 3 other
cancer lines and 3 breast cancer cell-lines that have been treated by estrogen
(acquired from Dr Amanda O'Donnell). Western blots for CTSD are seen in Figure
6.10. Three distinct bands are seen on the blots at 52 kDa, 34 kDa and approx. 30
kDa. The larger two bands are the pro CTSD protein and its mature cleaved product.
The smaller band is an unknown protein.
At a longer exposure all samples showed some expression of the mature CTSD
protein, although this was very weak for PE016 and K562. 52kDa bands are
eventually detectable for all of the estrogen induced cell-lines. OVCAR5, PE04 and
SKOV3 also show expression of the pro CTSD protein. The expression difference
between OHN and 110H2.1 varied per exposure due to saturation of the bands. The
average fold difference from the three gels between OHN and 110H2.1 is 3.26-fold.
This number may be skewed from the 2.5-fold ratio found at the mRNA level due to
the first blot that showed a difference of about 8-fold. The other two blots
demonstrated a correlation for CTSD protein and RNA differences between OHN
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Protein expression of CTSD correlated well with mRNA expression for most of the
ovarian cell-lines (Figure 6.11). Only two samples vary widely between RNA to
protein, PE016 and A2780. This is probably due to the very low levels of RNA and
protein detected. The difference between the expression levels is small but relative to
the actual expression it appears to be large. The strong correlation between CTSD
protein and RNA expression shows that data derived by Light Cycler analysis is






















Figure 6.11 Comparison of CTSD protein and mRNA expression in 14 ovarian carcinoma
cell-lines. Red bars = mRNA expression as determined by quantitative RT-PCR, blue bars =
Protein expression on Western blot.
6.3 Immunohistochemical analysis of CTSD protein expression
The CTSD antibody was also optimised for use in immunohistochemistry, on fixed
paraffin embedded sections. A series of 48 ovarian tumours and 5 normal Ovarian
samples were treated with the CTSD antibody to detect localisation and intensity of
protein staining. Clinicopathological characteristics of the 48 tumour samples are
seen in Table 6.1. Mean survival is 1746 days and ranges from 38-4043 days.
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After staining, expression of CTSD protein was examined for each section by Dr
Owatif Al-Nafusi and scored according to intensity. The range of score was from 0-3
for the tumour samples with a low score representing low protein expression. All 5
normal ovary samples showed expression of 2/3 within the OSE with a granular
cytoplasmic distribution of the protein. Cellular compartment location for the
tumours was also noted. Nine tumours showed a more diffuse cytoplasmic staining
pattern suggesting release of the protein from within these granular spots. The
precise organelle responsible for these granules is unknown.















Table 6.1 Clinicopathological characteristics of Patient samples used in CTSD IHC study.
Thirty-three tumours had decreased protein expression (score si) as compared to
normal OSE. Decreased expression of CTSD in these 33 tumours does not associate
with any clinicopathological parameters. Very low expression of CTSD (score s0.5)
was associated with a serous histology (p=0.0169). There were no associations of
CTSD protein expression with Grade, FIGO stage or with debulk status.
Survival analysis showed a trend towards the association of very low expression
(score s 0.5) with adverse survival (Log rank p=0.0847) (Figure 6.12). A larger set
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Figure 6.12. Kaplan-Meier survival curves for protein expression of CTSD in patient
samples. Survival comparison between protein expression of score 0.5 and al. Log rank test
p=0.0847.
6.4 Functional studies using sense and antisense candidate TSG transfection.
Primers were designed which encompassed the complete cDNA coding regions for
the four chromosome lip TSG candidates. These were ligated into the plasmid
pcDNA3-Zeo that carries a Zeo resistance gene. These plasmids, in the sense and
antisense orientations, were transfected into OVCAR3 derived clonal line OH1. Zeo
resistant clones were derived from three independent transfections. To date, clones
have been generated to contain, independently, the full-length coding regions for
PSMD13, CTSD and RPL27A.
Once generated, clones were assayed for insert presence and direction. I produced 4
RPL27A sense clones and 8 RPL27A antisense clones. Transfections of PSMD13
were less successful and only 1 sense and 2 antisense clones were generated. CTSD
clones are yet to be assayed for inserts.
The next step was to determine if these inserts are expressed. This was done using
primers within the sequence transcribed from the plasmid. SP6/T7 primers, which
bind only to the transcript from the plasmid, were used to distinguish between
















Figure 6.13 Primers used to determine insert orientation. Combinations of Insert and plasmid
specific primers are used to show insert expression.
cDNA generated from the RPL27A and PSMD13 sense and antisense transfected
clones were assayed for insert expression. Only one PSMD13 antisense clone and no
sense clones, expressed from the plasmid. I did however, successfully generate
RPL27A 4 sense and 7 antisense expressing clones. Expression levels varied
between these clones suggesting some plasmids were more efficient at transcribing
than others (Figure 6.14).
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Figure 6.14 Insert expression in RPL27A sense and antisense transfected clones. Plasmid
and insert specific primers used in combinations to determine orientation and expression of
inserts in clones. Plasmid only clones show no expression as expected.
The most important question is whether there are any changes in endogenous
expression due to the addition of these plasmids. In theory, if antisense transcripts
are knocking out endogenous expression then this should be detected as a decrease in
expression as compared to the sense transfected and parental cells. Endogenous
expression was determined by RT-PCR using reverse primers designed to those 5'
sequences not included in the plasmid.
The sense and antisense clones did not however show any differences in expression
of RPL27A. A more quantitative approach may however be required to determine
small differences in expression, alternatively further transfections or a different




Four products were validated by Light Cycler quantitative RT-PCR as
downregulated upon introduction of chromosome 11 into OVCAR3. Only two of
these, RALDH2 and IGFBP2 have been previously characterised as transcribed
genes. Novel transcripts CB1 and CB2 have been positioned on the NCBI map
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Figure 7.1 Chromosomal positioning of CB1.
Product CB1 maps to hypothetical protein LOC133258. The potential roles of genes are seen
on the right. The red box = position of CB1 sequence. Distance along the Chr 4 seen right of
the ideogram.
CB1 and CB2 do not match to known gene exons however suggesting that although
they are high abundance transcripts they may not be translated. This is further
supported when the sequences are translated using the expasy translate tool
(www.ca.expasy.org). The outputs show stop codons dotted through out the
postulated protein sequence, in all three codon frames and both 5'-»3' and its
reverse. Quantitative RT-PCR showed these products to be substantially
downregulated, by 200-1300 fold in the growth suppressed clone 110H2.1.
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Figure 7.2 Chromosomal positioning of CB2.
Product CB2 maps between hypothetical genes LOC137239 and LOC169000. The potential
roles of genes are seen on the right. The red box = position of CB2 sequence. Distance along
the Chr 8 seen right of the ideogram.
7.2 Expression of candidates in cell-lines and tumours
Semi-quantitative RT-PCR on a panel of ovarian cell-lines showed that CB1 is only
expressed in the line OVCAR3. This product if therefore non-representative of
ovarian carcinoma cell-lines and unlikely to be involved in ovarian cancer
progression. Also, Northern blotting with a CB1 probe on mRNA and total RNA
from OHN and 110H2.1 showed no bands. Northern blotting does not appear to be
sensitive enough to detect this transcript. Northern blotting with a probe for CB2,
again on mRNA and total RNA, showed a very feint product on total RNA alone (not
shown). These results suggest that neither CB1 or CB2 are present in the mRNA
population and unlikely to be transcribed.
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Of the four candidate oncogenes identified and validated, three are altered in
expression by >100-fold. These products, CB1, CB2 and RALDH2, were identified
by the so-called open systems of difference analysis; DD-RT-PCR and cDNA-RDA.
As for the TSG candidate analysis, RALDH2 and IGFBP2 were assayed for
expression across a panel of ovarian cancer cell-lines and HOV samples for further
validation of actual association with ovarian cancer progression. CB1 and CB2 were
not analysed as they are not likely to be translated into functional proteins.
RALDH2 was validated to be overexpressed 200-300 fold in the OVCAR3
derivative OHN. It was expected that this gene would be highly overexpressed in the
majority of other ovarian lines and HOV tumours. Expression of RALDH2 was
however in all but one cell-line seen to be lower than in the normal OSE (Figure 7.3).
OHN (OVCAR3) expression is over 6000% relative to Lil (normal OSE) so is not
represented on the graph. The breast cell-lines MDA and ZR75 had little expression
and the colon lines had similar levels to those seen in the normal OSE sample Li 1.
Only six HOV samples showed a higher level of expression than the OSE.
Expression of RALDH2 in OHN is over 100 fold higher than in any other sample
analysed quantitatively.
IGFBP2, identified by HDFA hybridisation, has a 2.4-fold change in expression
between OHN and 110H2.1. Of the panel of cell-lines, none showed higher
expression than the normal OSE (Figure 7.4). Only 4 of the 17 HOV tumour
samples showed elevated expression over the normal OSE. One of these samples had
an increase in expression of IGFBP2 of 6-fold. The level of expression in OHN is
only 22% of Lil. If this gene were truly oncogenic, I would expect expression in




Figure7.3RALDH2expressioninapan lofcell-linesndHOVtumours. Greenbars=HOVtumours,luenon- variancancerell-lines,gr yrovariandorm l OSEandoriginal110H2.1line.Expressionr lativetnormal( 0%).





































OOCniOCOCMOOJCNCOOOT- Jl D i-T-cNcoiococot^t^ooojcr>ao >>>>>>>>>>> ooooooooooo xxxxxxxxxxx
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7.2.1 Clinicopathological associations with candidate oncogene expression
No clinicopathological associations were found between RALDH2 and IGFBP2
expression and stage, grade, and histology. The only trend towards an association
with adverse survival is for RALDH2 expression >80% normal OSE level
(p=0.1303) (Figure 7.5).
Figure 7.5 Kaplan-Meier survival curve for expression of RALDH2 above and below 80%
normal OSE levels. Log rank p=0.1303.
7.3 Protein expression of candidate oncogenes
Of the two characterised genes, RALDH2 and IGFBP2, only IGFBP2 has
commercially available antibodies. Two antibodies were tested on IHC and neither
could be optimised. The Upstate Biotechnology UK antibody was also tested on
cell-line lysates by western blotting. This antibody however produced multiple non¬
specific banding on the gels. Intense optimisation of this antibody would be needed
for it to be used quantitatively.
7.4 In vitro antisense knockout of RALDH2 and IGFBP2
If these genes are functionally active in the carcinoma cell-lines then removal of
these RNAs by antisense knockout might slow growth and tumorigenicity
characteristics of the cells.
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Sense and antisense constructs were generated by ligating partial cDNAs into
pcDNA3.
A 499bp fragment of RALDH2 cDNA was ligated into plasmid pcDNA3-neo and
sense and antisense orientation constructs were transfected into OVCAR3 clonal line
OH1. After selection with G418, clones resistant to the antibiotic were selected and
grown-up with DNA and RNA made from each. Two primer sets were used to
determine expression of the insert and endogenous expression of the gene, with the
aim being to identify clones having partial knockout of RALDH2 expression.
I was successful in generating clones with insert expression and subsequent partial
endogenous knockout, showing that this method of transfecting in antisense clones
does work. Initial in vitro growth studies showed mixed results. Sense and antisense
transfected clones grew with unexpected variability. There were varied growth rates
for both the sense and antisense clones. Those antisense clones with knockout did not
necessarily grow slower than the sense controls.
A example graph of RALDH sense and antisense clone growth rates is seen in Figure
7.6. As seen, growth rates for the antisense clones are not slower than for the sense
clones suggesting that knockout of RALDH2 caused no functional effect in these
cell-lines. Parental line OH1 appears to grow slower than any of the transfected
clones. The OH1 cells used however had been passaged on fairly rigorously so may
no longer be representative of the OVCAR3 parent.
Antisense transfection experiment appears to suggest that knockout of RALDH2 has
no functional consequences on clone phenotype. This data supports the cell-line
expression data, leading us to believe that RALDH2 overexpression may represent
merely a contextual artefact ofOVCAR3.
In light of the results from RALDH2 functional experiments, IGFBP2 sense and
antisense knockouts were not performed on that basis of similar cell-line panel
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8. LOH ANALYSIS OF CHROMOSOME llp!5
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Loss of heterozygosity has been detected at chromosome 11 p 15 in multiple tumour
types including ovarian carcinoma (as reviewed in introduction). In order to
minimise the regions of deletion on lip 15, identify potential tumour suppressor
genes and place these in relation to genes identified by our functional approach,
further LOH mapping was carried out.
Forty-four polymorphic markers along 1 lpl5 were identified and optimised for PCR
conditions. Of these, two markers could not be successfully optimised (D11S1348
and D11S4189). A further two markers were found to be non-polymorphic on our
panel of blood-tumour pairs (D1 IS 1318 and IGF2). D11S4194 was removed from
the study as it was subsequently positioned outwith 1 lpl5. Therefore the study used
39 polymorphic markers.
The aim was to identify as many markers along the lip 15 region as possible to
create a precise map of LOH, therefore markers were chosen anywhere along this
region so they are not necessarily well spaced. The largest distance between any two
markers is 2Mb and the smallest 10Kb. Markers were identified from the UCSC
Genome Map and NCBI Mapviewer with links to the STS and GDB databases (See
Table 2.2).
8.1 Individual Marker Analysis.
A total of 87 matched tumour-normal pairs were used in the study, extracted from a
combination of fresh and paraffin embedded samples. Normal samples were
extracted from blood samples, normal omentum, normal uterus or paired normal
ovary. All tumour samples were from epithelial ovarian cancers.
Details of the clinicopathological features of the patients used in the study are found
in Table 8.1. The retrospective set is over represented in terms of the less commonly
occurring early stage (FIGO I/II) carcinomas. Patients with follow-up of >2 years
were used in survival analyses.
All pathology was routinely reviewed through the South-East Scotland
multidiscipline gynaecological oncology meetings.
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Table 8.1 Clinicopathological information of the 87 patient samples of EOC used in
the microsatellite LOH mapping of 1 lpl5.5.
LOH analysis was carried out for all 39 markers with as many of the 87 samples as
possible. It was found that two of the markers (D1 IS 1310 and D1 IS 1791) could not
be optimised for PCR on the paraffin embedded DNA. There were also 'difficult'
samples that for a number of markers could not be amplified for analysis, probably
due to DNA degradation. These samples are labelled as "not determinable".
LOH results for blood tumour pairs were analysed and the R-value, a ratio of the two
peaks, was generated for each pair. Example peak traces can be seen in Figure 8.1.
A cut-off of 0.6, or 40% loss, was chosen based on recent discussion in the literature
(Tomlinson et al., 2002). This cut-off value allowed detection of markers with
variable LOH rates which for 12 markers was above the LOH threshold of 35%

































Figure 8.1 Example Gene Scan traces of allele patterns for markers D11S922, D11S2071
and D11S1338. The top pairs show blood and tumour samples with no loss. The bottom pair
show allele loss in the tumour sample as indicated by an arrow.
To summarise the LOH data, 91% (79/87) of all samples had evidence of loss of 1 or
more markers along 1 lpl5. Only 9% (8/87) had no loss at all. Twenty-one samples
appear to have LOH of the majority of the llpl5 region (at least 80% loss). This
high rate of whole arm allele imbalance (24%) suggests that loss of the whole region
is a common mechanism for the LOH observed.
There are 12 markers which show an overall LOH rate of >35%. A graph of the LOH
rates pinpoints these markers (Figure 8.2).
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The overall LOH for each of the clinicopathological subgroups, per marker, is
represented in Figure 8.3. There appears to be a trend along the chromosome arm for
increased LOH in late stage tumours and high grade. There is also an apparent
association with a non-mucinous histology.
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8.1.1 Clinicopathological correlations.
All 39 markers were assessed using a two-tailed fishers exact test for correlations
with stage, grade, histology and debulk status. At a significance cut-off of p=0.05,
18 markers showed an association with one or more of these variables. A more
stringent cut-off of p=0.01 associated only 6 markers with variables, the most
common being advanced stage.
8.1.2 Allele loss and histology
There are few markers that show biased LOH in histological subtypes (Figure 8.4).
At p<0.01, only one marker associated with a histopathological subtype. Marker
D11S4188 was associated with a non-mucinous histology (p=0.0046). There were
trends towards significance for a number of other markers (Table 8.2).






D11S1363 Non-Clear cell p=0.0243
D11S4184 Endometrioid p=0.0366
D11S4177 Non-clear cell p=0.0435
D11S4193 Non-clear cell p=0.0452
D11S4188 Non-mucinous p=0.0473
Table 8.2 Microsatellite markers associated with Histology. Fisher's exact test used to
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8.1.3 Allele loss and FIGO stage
LOH at many individual loci associate with late stage suggesting loss of the whole
region may occur in late stage tumours (Figure 8.5).
Using a more stringent cut-off of p=0.01, 6 markers remain associated with late stage
supporting the above theory. These markers cluster from D11S932-D11S4170 at
1 lp 15.4-p 15.2 (Table 8.3). Three markers that do not show this bias towards
increased loss in late stage tumours are D11S1338, D11S1794 and D11S921.









Table 8.3 Microsatellite markers associated with adverse stage (FIGO III/IV). Fisher's exact
test used to calculate significance. * indicates p<0.01.
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8.1.4 Allele loss and differentiation status
Only one marker associates with a poor differentiation status D11S4188 (p=0.0055)
(Table 8.4). D11S1331 (p=0.0230), D11S4138 (p=0.0201) and D11S1888
(p=0.0467) all show a trend towards high grade. These few associations suggest that
loss of the complete region is not associated with a poor differentiation status (Figure
8.6).





Table 8.4 Microsatellite markers associated with differentiation status. Fisher's exact test
used to calculate significance. * indicates p<0.01.
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8.1.5 Survival analysis
Taking a cut-off of p<0.05 as significant, none of the 39 markers associates with
survival when those patients with LOH and follow-up of >2 years are analysed
(Table 8.5). There are however two markers with p values very close to significance,
D11S4121 and D11S4188.





Table 8.5 Correlation of marker LOH with adverse survival
LOH at D11S4121 is almost significantly associated with adverse survival (Figure
8.7). The median survival for those with LOH was 4 years as compared to 8.3 years
for those with no LOH. At 5 years, patients survival with LOH was only 30% versus
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Figure 8.7
Kaplan-Meier survival curve and log-rank analysis for association with D11S4121 status.
Allelic loss at D11S4188 and survival was also correlated very near to significance
(Figure 8.8). Patients with LOH at D11S4188 showed an approx. 28% survival rate
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as compared to 70% for those without. The median survival of patients with LOH at
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Figure 8.8
Kaplan-Meier survival curve and log-rank analysis for association with D11S4188 status.
8.1.6 Analysis of LOH along llpl5 - overview
High levels of LOH (>35%) were detected for 12 markers of 39 along chromosome
llpl5. Figure 8.9 shows a scale diagram of marker positions along 1 lpl5 from
telomere to 1 lpl5.1. Marker positions, distance between markers, LOH rate,
histopathological correlations, mean peak ratios (R value) and determined
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Figure 8.9.1 Diagram of marker locations along 1 lp 15. On the left are the
markers and distances between them from telomere to centromere on llpl5.
Locus LOH rate, histopathological correlations, R value and heterozygosity rate




















LOH % Histopathological Correlations Mean r value Heterozygos
1329 29% (18/63) none 0.3 0.79 (0.7704)
COCOT—I 25% (15/60) none 0.31 0.82 (0.7915)
1349 31% (24/78) non-mucinous p=0.0149, non-clear cell p=0.0149, stage p=0.0015 0.33 0.90 (0.8412)
1315 31% (18/58) stage p=0.0091 0.4 0.67 (0.5549)
1334 26% (17/66) stage p=0.0255 0.3 0.76 (0.8001)
4116 28%(19/68) stage p=0.0072 0.32 0.80 (0.8027)
1794 37% (22/59) none 0.31 0.74 (?)
926 26% (19/72) none 0.35 0.83 (0.74)
1307 25% (11/44) none 0.35 0.51 (?)
4170 24% (16/67) stage p=0.0009 0.35 0.78 (0.78)
861 32% (24/76) none 0.32 0.87 (0.70)
4193 32% (18/57) non-clear cell p=0.0452, stage p=0.0105 0.29 0.66 (0.5218)
4121 32% (22/68) stage p=0.0220 0.31 0.78 (?)
1791 33% (7/21) none 0.31 0.53 (?)
921 37% (22/60) none 0.33 0.74 (0.7076)
902 18% (14/77) none 0.37 0.89 (0.8058)
4138 33% (21/63) non-mucinous p=0.0234, stage p=0.0149, grade p=0.0201 0.36 0.77 (0.8221)
-1888 31% (20/64) non-mucinous p=0.0473, grade p=0.0467 0.35 0.83 (0.79)
1310 36% (9/25) none 0.37 0.57 (?)
COO)©■St! 33% (16/49) none 0.31 0.78 (0.9124)
Figure 8.9.2 Diagram of marker locations along llpl5. On the left are the markers and
distances between them from telomere to centromere on 11 p 15. Locus LOH rate,
histopathological correlations, R value and heterozygosity rate (expected rate in brackets)
shown. Correlations p<0.01 are in bold.
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8.2 Minimising Regions of Loss on llpl5.
Of the eighty-seven tumours used in our study, 45 samples showed partial loss along
the chromosome at four or less regions. Seventeen tumours had LOH at only one
region, the rest of the chromosome being heterozygous or uninformative. A further 8
tumours showed loss of two distinct regions. Thirteen and eight had allele imbalance
at three and four areas respectively.
As previously mentioned, 21 samples lost the majority of 1 lp 15 and 8 had no loss at
all. The remaining 13 showed patterns of loss known as harlequinning. These
samples have bands of loss and retention all the way down the chromosome arm and
are difficult to interpret for distinct regions of loss.
Figure 8.9 shows those 45 samples with partial losses. Deletions are shaded and
where a locus is uninformative and separates loss from a heterozygous marker, this
locus is included in the deletion. Analysis of the 45 samples with partial loss
identified eight or nine potential shortest region of loss (SRO's). All are supported by
patient samples with only one or two areas of allele loss.
The minimal regions identified encompass from 77KB to 1927KB. Of the 19.7MB
spanned by the 39 markers, these SROs represent 7.5MB, minimising our candidate
















































■ HF□ □ □




























































































Figure8.10.Minimalregionsoflossi patientsa pl .Awhiteb x=retentionl cu ,ha dx=unifo ma ive,l ckLOH Greya easshowregionsoflos ,rangingfr me(eft)turri h ).Blsh dismi imall s ,highlig t dbyl n
8.3 Genes within minimal regions of loss
Chromosome llpl5 is very gene rich and the SROs contain varied numbers of
candidate genes from 4 to 21 (Figures 8.11-8.13). Of the 160 genes contained within
this entire region, our SROs contain 56% of these genes, minimising the number of
candidates to 89.
The eight distinct regions are focussed around markers with particularly high LOH
rates, apart from region VI, with a lower LOH rate of 33%. The smallest SRO,
Region I, spans from D11S4177 to D11S2071 and contains the gene PSMD13,
which was identified by cDNA-RDA to be upregulated in the growth suppressed
clone 110H2.1 (Figure 8.11). Region II spans from the H-RAS gene to D11S922 and
again this region contains a candidate TSG identified from our difference analysis
experiments, CTSD. Region III spans from D11S4088, a marker with high LOH, to
D11S4146. This region contains three genes previously associated with cancer
progression, including the well studied CDKNlC/p57Kip. Region IV spans from
D1 IS 1338, which has a very high LOH and an apparent association with early stage,
to D11S1331 (Figure 8.12). The high LOH rate at D11S1338 suggests this marker
lies very near an important cancer-associated gene. Spanning from D11S4149 to
D11S1329, region V is the largest of our regions, however due to the very significant
associations of D11S4188 with stage, grade and histology, this strongly suggests the
positioning of a TSG near to this marker.
Region VI is a small region containing only four known genes, spanning form
D11S1334 to D11S1794 (Figure 8.13). The high LOH rate of 37% at D1 IS 1794,
positioned within the gene ARNTL, indicates this gene may play a role in the
progression of ovarian cancers. Regions VII and VIII, spanning from D11S861-
D11S4193 and D11S4121-D11S1791 respectively, both encompass markers that do
not reach the arbitrary LOH threshold of 35%. The regions have however been lost
in multiple samples suggesting a role for one of the included genes in a small number
of cancers. Finally region IX, spanning D11 SI888 to D11S4096 contains 16 known
genes, including candidate cancer associated gene TSG101. This region focuses
around the marker D1 IS 1310, situated within an intron of the DELGEF gene (a gene
involved in deafness).
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Candidate oncogenes and TSGs within these SROs are highlighted. Loss of the TSGs
has previously been implicated in various cancers. These oncogenes are shown
because they may be excluded from the 89 genes within the regions as they are
unlikely to act as TSGs.
LOH rates for the individual regions range from 35% to 49%. Of the nine individual
regions pinpointed in Figures 8.10-12, 6 have an LOH rate of >40%.
Clinicopathological associations were calculated for each of the regions (Table 8.6).
Of the nine regions, 5 are associated with clinicopathological variables. None are
associated with survival. It is interesting to see that although some of the markers
contained in the SROs have strong individual associations with variables, when they
are included into a region these correlations are lost. This, to me, provides more
support that gene(s) of interest may lie very near to those markers with significant
associations.
Region Defining Markers LOH rate Histopathological associations
i D11S4177-D11S2071 46% Non-clear cell p=0.0305, endo and serous p=0.0347
II H-RAS-D11S922 46% Non-mucinous p=0.0349
in D11S4088-D11S4146 49% None
IV D11S1338-D11S1331 43% Debulk status p=0.0395
V D11S4149-D11S1329 47% Non-mucinous p=0.0294
VI D11S4116-D11S1794 37% Non-mucinous p=0.0467
VII D11S861-D11S4193 35% None
VIII D11S4121-D11S1791 38% None
IX D11S1888-D11S4096 42% None
Table 8.6 Clinicopathological associations of 1 lp 15 SROs. Region number, span, overall



























Figure 8.11 Genes within SROs, regions I-III. Taken from UCSC Genome Browser - June
2002. Distances between markers are shown. Green boxes show genes identified by our
difference analysis techniques. Red boxes show oncogenes previously implicated in cancers.



































































Figure 8.12 Genes within SROs, regions IV and V. Taken from UCSC Genome Browser -
June 2002 Distances between markers are shown. Red boxes show oncogenes previously



















































































Figure 8.13 Genes within SROs, regions VI - IX. Taken from UCSC Genome Browser - June
2002. Distances between markers are shown. Red boxes show oncogenes previously
implicated in cancers. Blue boxes show implicated TSGs.
There are markers that lie outwith these eight regions of loss which are strongly
correlated with clinicopathological features. Markers D11S932, D1 IS 1349,
D11S1315 and D11S4170 are all correlated with advanced FIGO stage with a
significance of about p=0.001.
Whether these associations are due to markers being near to candidate TSGs or as a
result of the whole arm loss which has been commonly seen was analysed. By
removing 21 samples that have whole arm loss from our data set, many markers lost
their associations with advanced stage (Table 8.7).
Loss of markers outwith the nine identified SROs may be lost as part of complete
1 lp LOH rather than being lost individually or in a discrete region. Those markers
that showed clinicopathological associations often lose these when samples with
complete region LOH are removed. This suggests that the mechanism of LOH at
these loci may be due to whole arm allele loss. Markers within SROs also lose
certain clinicopathological associations but there are patient samples only with loss










































Table 8.7 Clinicopathological associations with marker LOH. Patient samples with complete
1 lpl5 region LOH have been removed from analysis. Two-tailed Fisher's exact test used.
8.4 LOH at llpl5- a literature review
As discussed in the introduction, many groups have carried out LOH studies on
chromosome 1 lp in multiple cancer types. The main areas of interest are at 1 lpl5.5
and 1 lpl3 so these are the most commonly studied areas.
A comparison of our identified regions of LOH along 11 p 15 and those previously
reported in Breast cancer, Lung cancer and Wilm's tumours is shown in Figure 8.14.
Direct comparison of these studies is complicated because most authors used
different markers, as well as a different number and order of markers. In order to
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overcome these problems I have plotted the markers used in the most up to date
order possible.
Many of these studies used a minimal number of microsatellite markers with the
maximum, to date, being 17 in breast cancer. Those markers used also span short
regions of 1 lp 15, focussing around the 11 p 15.5 region spanning D11S1363-
D11S932. There are three common regions of LOH detected in these tumours. The
first spans between D11S2071 to just distal of D11S922. The second region is
focussed around the area from D11S4088 to D11S4181. The third region common in
breast cancer, Wilm's tumour and in our ovarian samples is centred on the marker
D1 IS 1338. Only three studies, of the nine, use markers that are centromeric of this




































































































































Figure 8.14 Regions of LOH on llpl5 in cancers. Author name, cancer type and year
shown. Number in brackets is number of markers used in study. Grey area shows region
encompassed by markers. Coloured blocks are regions of LOH. Markers seen on LHS, those





Independent transfers of neo tagged chromosome 11 into the ovarian cancer cell-line
OVCAR3 generated a series of growth and tumorigenicity suppressed clones.
Microsatellite mapping of MMCT hybrids 11 OH 1.1, 110H2.1, 110H2.2,
110HX1.1, HOHX2.1 and 110HX3.1 with a further eight markers was done to
determine the extent of chromosome 1 lpl5 transferred in these clones. This mapping
showed that all clones, except 110HX2.1 had transferred at least the ~9.3Mb region
at 1 Ipl5.5-pl5.4 and also the ~2.6Mb region surrounding marker D11S926 at
I lpl5.2. This further mapping minimised the regions in which potential TSGs could
lie. A highly tumorigenic xenograft of OVCAR3 generated the line OHX. This
underwent independent chromosome 11 transfers to generate the 11 OHX series.
Clone 110HX2.1 was found to have a less suppressed phenotype than the other
IIOHX clones. This clone showed transfer of only the region at D11S926,
suggesting that one or more genes involved in the growth suppression lies out-with
this transferred region to account for the phenotypic differences seen between clones.
This would point to the more telomeric region, at 1 Ipl5.5-pl5.3, as harbouring
functional TSGs.
The traditional approach of minimising candidate TSG harbouring regions following
on from MMCT is to perform revertant analysis of the hybrids. Revertants are
hypothesised to have lost sections of the transferred chromosome, which carry TSGs,
and therefore re-acquire the parental tumorigenic phenotype.
Our initial strategy in identifying these TSG loci was therefore to passage some of
our clones ten times with the aim of generating revertants. From four of the hybrids,
11OHX 1.1, 110HX2.1, 110HX2.2 and 110HX3.1, we generated 48 passaged
clones. These were densely microsatellite mapped at 1 lpl5 and then compared with
the parental hybrids to determine regions of chromosome loss. We found that the
majority of clones did not lose any of the eight 1 lpl5 markers used. Fourteen clones
did however lose the marker D11S926 on the transferred chromosome, positioned at
llpl5.3. These clones would need to be functionally assessed for growth
characteristics to determine whether the loss of this region leads to an altered growth
phenotype.
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Through further mapping of the MMCT hybrids we were able to determine the
region of chromosome llpl5 transferred within each clone. This mapping allowed
us to minimise the candidate 1 lpl5 TSG harbouring regions to two areas spanning
ptel-Dl 1S932 and D11S569-D11S419 (Figure 9.1).
We did not find sufficient information from the revertant mapping method to identify
minimal candidate TSG containing regions. This standard approach was therefore
unsuccessful for us so an alternative was needed, and led to the use of difference
analysis methodology. We carried out cDNA-RDA to compare expression
differences between the hybrid 110H2.1 and a parental derivative OVCAR3. The
revertant analysis and cDNA-RDA were carried out in parallel in anticipation of
these problems.
Revertant analysis has been relatively unsuccessful in minimising regions, although
there are notable exceptions. For example the prostate cancer associated metastasis
suppressor KAI1 was identified by this method (Kawana et al., 1997). This
technique has proven successful in that we were able to generate revertants with
chromosome loss at 1 lpl5, so if time allowed I may choose to continue with further
revertant analysis. Initially, I would repeat the passaging and use all of the hybrid
clones, including 110H2.1, probably passaging fifteen or more times as we have
seen that chromosome loss after only ten passages is rare. I would also use more
microsatellite markers, as there may actually be small fragments of loss that we have
not detected using only eight markers. If this were successful the next step would be
to transfer small subchromosomal fragments of DNA, which map to those regions of
loss associated with reversion.
If a small region harbouring only a few candidate genes was found, those candidates
within this interval would then be analysed for expression in tumours and further

























Figure 9.1 Chromosomal regions harbouring candidate 11 p 15 TSGs. Red boxes indicate the
regions transferred. Markers in Italics were previously mapped.
As the hybrid 110H2.1 was chosen for use in the difference analyses, I decided to
fine map 1 lp 15 in this clone. In all, 19 polymorphic markers spanning 19.1Mb from
ptel-11 p 15.1 were mapped, with interval spacing of between 200Kb and 3Mb. I
found that the complete 1 lptel-1 lpl5.4 (D1 IS 1363-D11S4188) region was retained,
as was 2.8Mb section from D11S4116-D11S419 (pl5.2) (see Figure 3.5). Therefore
if there are any functional 1 lpl 5 TSGs, they must reside within these regions.
168
9.2 Difference analysis methods.
The comparison of gene expression between ovarian cancer cell-line OHN and Chr
11 transferred hybrid 110H2.1 was performed using three difference analysis
techniques, DD-RT-PCR, cDNA-RDA and HDFA.
DD-RT-PCR, as a method, produced the fewest differentially expressed candidate
genes. In all the technique identified 18 products with altered expression between
OHN and 11OH2.1. The second method is cDNA-RDA, which couples subtractive
hybridisation with kinetic enrichment. cDNA-RDA was carried out five times, two to
identify candidate TSGs and three in the reciprocal direction to identify those genes
upregulated in OHN and potentially oncogenic. Products from cDNA-RDA were
subcloned into bacterial plasmids and individual colonies picked for sequencing. The
number of independent transcripts that can be identified should increase with the
number of colonies sequenced. We sequenced, in total, 572 transcripts that
represented 231 individual genes.
The final method used was the hybridisation of OHN and 110H2.1 RNA to Clontech
1.2K arrays. Three arrays were hybridised, each carrying 1,176 clones. Prior to
validation, differentially expressed products identified by these arrays were subjected
to strict inclusion criteria, which minimised the data set to a total of 72 genes.
DD-RT-PCR and cDNA-RDA are examples of open systems of expression analysis,
that is they are capable of identifying all genes within a transcriptome that may be
differentially expressed, including novel ones (Green et al., 2001). It is not therefore
surprising that these methods each pinpointed novel genes. A microarray is limited
by its clone content and is therefore a closed system. One advantage of the
microarray system however, is that all genes contained on the chip are assayed
whether differentially expressed or unaltered. As we are aiming to identify genes
which are differentially regulated along one chromosome this is useful as those
chromosome 11 genes which do not show expression differences can be disregarded
as candidates.
Considering that, in all, 310 individual genes were identified as differentially
expressed, overlap between the methods was minimal. No genes were identified by
all three methods. Only 10 genes were identified by two independent methods.
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Due to the false positive rates reported for these difference analysis methods, further
validation using quantitative RT-PCR was performed for the majority of the
identified candidates. Of the 321 genes in total, 178 were assessed for validity by
quantitative RT-PCR. Genes to be validated were chosen due to their cellular
function, abundance of transcripts (in the case of cDNA-RDA) and importantly their
position within the genome. All chromosome 11 genes identified as upregulated in
growth suppressed hybrid 110H2.1 were subjected to Light Cycler quantitative RT-
PCR.
Of the 178 genes assayed (100 up and 78 downregulated), only 17 were confirmed to
be differentially expressed >2-fold between OHN and 11OH2.1. Of these two
represent the same gene and one is a mouse contaminant from the chromosome
transfer method. This murine sequence, MMLV, was found by cDNA-RDA and
served as a useful positive control for the cDNA-RDA method. Other murine
transcripts were identified by DD-RT-PCR but not further validated. HDFA
represents only human sequences so murine transcripts are not assayed.
9.2.1 Validated Candidate TSGs
Eleven human genes were found to be upregulated in response to transfer of
chromosome 11 into 110H2.1. These include three structural keratins and four
chromosome 11 products. A substantial enrichment in chromosome 11 candidates
was seen after Light Cycler validation. The non-chromosome 11 located products fall
into two functional categories. These are proteins involved in cellular structure and
then those associated with the normal trafficking and degradation of proteins. These
non-chromosome 11 products are downregulated in response to the chromosome
transfer and could well be involved as downstream factors in the growth suppression
phenotype.
9.2.2 Genes with roles in cellular structure
Disruption of genes involved in cell structure within tumours may promote invasion
and metastasis. Tumour invasion involves in the upregulation of cell surface
receptors, intercellular adhesion molecules and signalling proteins (Skubitz, 2002). A
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metastatic cell may also increase expression of genes that degrade the existing ECM,
such as matrix metalloproteases and collagenases.
Our difference analysis techniques identified three upregulated keratins, KRT5,
KRT8 and KRT19. The upregulation of these genes may effect an increase in cell
structure and stability.
Keratins 8 and 19 are expressed normally in simple epithelial cells suggesting that
the reversion back to a more OSE-like state, such as in the 110H2.1 cell-line, may
cause their upregulation. KRT8 and KRT 19 are positively co-expressed according to
the SAGE and NCI60 data available from CGAP (http://cgap.nci.nih.gov/). Keratin 5
is involved in the regulation of cell size and shape and it has been reported as
decreased in expression between rat normal bladder cells (100%) and highly
metastatic bladder cell lines (20%) supporting the expression difference we have
found (Nan et al., 1993). CGAP data shows an association of KRT5 co-expression
with SLPI, a gene commonly over expressed in ovarian tumours. This association
suggests that expression of KRT5 may simply be an effect of the growth alteration
rather than a direct cause, which is consistent with our observation.
Tumour cells have highly upregulated levels of matrix metalloproteases (MMP)
which promote degradation of the ECM and assist in cell motility and metastasis
(fantastic review- (Egeblad and Werb, 2002)). MMPs are upregulated in multiple
tumour types including ovarian cancer (Herrera et al., 2002). We identified TIMP2,
which is an inhibitor of matrix metalloproteases, particularly MMP2 (Wang et al.,
2002). TIMP2 has been shown to inhibit invasion in cells derived from a serous
ovarian tumour, probably acting by inhibition of MMP2 (Yoshida et al., 2001). In
ovarian cancer effusions, that is cells which have migrated away from the main bulk
of the tumour, TIMP2 expression is decreased with a concomitant increase in
MMP2, strongly suggesting that loss of TIMP2 is involved in the invasive phenotype
(Davidson et al., 2001).
We also identified EGFR as upregulated in the growth suppressed hybrid. This
discovery is paradoxical as EGFR is frequently found to be upregulated in tumours
and is known to stimulate tumour growth and invasion. A decrease in EGFR
expression decreases adhesion on laminin-1, which would promote invasion, but
conversely lowers MMP9 activity (Alper et al., 2001). The introduction of
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chromosome 11 into the suppressed hybrid causes increase in expression of EGFR
but the mechanism is, at this point, obscure. CGAP data show a positive correlation
of EGFR expression with the expression of chromosome 1 lpl5.5 gene LMOl (LIM
domain protein). It may be the introduction of a functional LMOl that is increasing
expression of EGFR.
KRT8, KRT19 and TIMP2 have been identified as differentially expressed in ovarian
cancers by expression analyses previously (see Figure 1.3). KRT8 is normally
reported as upregulated in ovarian tumours rather than the decrease in expression that
we have detected. KRT19 and TIMP2 have been seen as up and down regulated
depending upon the experimental situation. This variation may be due to the use of
different techniques and samples. We can however say that in this context, these
genes are upregulated with growth suppression.
9.2.3 Genes involved in Protein degradation/trafficking
Proteins involved in the degradation and trafficking of specific molecules are vital
for normal cell cycle regulation.
HM13/SPP is a protease involved in the proteolysis of signal peptides after cleavage
from a preproprotein. It acts as a presenilin-type aspartyl protease (Weihofen et al.,
2002). Signal peptide peptidase activities are associated with cell regulation and
signalling. SPP is also vital in antigen processing for MHC immune response
(Weihofen et al., 2002). Loss of this protein in tumours may hypothetically allow the
cancer to evade the host immune defences or have a role in the dysregulation of cell
signalling. SAGE data from the CGAP project shows a significant decrease in
expression of SPP in ovarian tumours as compared to their normal counterpart by
virtual Northern.
BENE encodes a proteolipid involved in raft mediated trafficking in endothelial cells
(de Marco et al., 2001). BENE is involved in raft reorganisation and may be
important in the transport of GPI anchored proteins between the plasma membrane
and the internal compartments (Alonso and Millan, 2001). MAPK and PLCy
signalling cascades initiate within these lipid rafts. BENE also interacts with
candidate TSG Caveolin-1 and co-localises with CD59, interestingly encoded from a
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gene on 1 lpl3 (Wiechen et al., 2001). It could be hypothesised that loss of BENE in
tumours alters signalling and intracellular transport.
Neither SPP nor BENE have been described as downregulated in ovarian tumours
previously.
9.2.4 Chromosome 11 candidates
Four genes were validated as candidate Chr 11 TSGs. These are PSMD13, CTSD,
RPL27A and CRYAB. Interestingly three of these genes are positioned at 1 lp 15,
which has been shown to have high rates of LOH (as reviewed in introduction-
section 1.7). All four genes lie within the region of Chr 11 transferred into 110H2.1.
9.2.4.1 Proteasome subunit PSMD13
PSMD13 is a 19S proteasome subunit and forms part of the lid structure of this
complex (Figure 9.2). The 19S subunit acts to regulate the function of the 20S
proteasome and is essential for the degradation of multiubiquitinated proteins.
PSMD13 has a yeast homologue named Rpn9 which is needed for stability/efficient
assembly of the 26S proteasome (Takeuchi et al., 1999). The protein also appears to
be important in the degradation of multiubiquitinated proteins through its recruitment
of subunit 5a to the 19S proteasome and may also be required for efficient heat
shock response. A temperature sensitive mutant of Rpn9 arrests at G2/M when at the
permissive temperature (Takeuchi and Toh-e, 2001). Loss of this protein in yeast
causes the slow degradation of Pdslp for which the human homologue is the
oncogene PTTG (Zou et al., 1999).
The 19S lid-complex consisting of twelve protein subunits can act independently of
Rad23 in Nucleotide excision repair (NER) (Russell et al., 1999). The loss of






Figure 9.2 Structure of the 26S proteasome. The 26S proteasome degrades
multiubiquitinated proteins and consists of one 20S subunit and two 19S regulatory subunits.
The 19S subunit is made up of a lid and a base complex. PSMD13 is a component of the 19S
lid.
The yeast rpn9 subunit interacts with multiple proteins, including other 19S subunits,
DNA repair proteins and replication associated proteins (Figure 9.3). Many proteins
interact with multiple subunits of the 19S proteasome such as repair protein Rad23
and deubiquitinase USP6. There are however proteins which appears to interact with
Rpn9 exclusively, of all the proteasome subunits. Interestingly these proteins are
involved in transcription, DNA repair and more curiously the aromatase cytochrome
CYP19/AR01.
The effects of these interactions are however unknown. Aromatase is essential for
the production of estrogen from its precursors. In breast cancers aromatase inhibitors
are seen to decrease proliferation and activate apoptosis (Sasano et al., 1999).
Overexpression in mice of the aromatase transcript causes increased hyperplasia in
mammary glands as well as an associated decreases in apoptosis and in expression of
19Sbase fi.Qlj ^
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TSGs p53 and Rb (Kirma et al., 2001). If Rpn9 has a negative regulatory effect upon
aromatase activity it could be postulated that knockout of expression would be
advantageous for the tumour. Another interesting protein with which Rpn9 interacts
is Ribonucleotide Reductase, Ml (RRM1) which in humans also lies on llpl5.5.
The activity of RRM1 correlates significantly with the rate of DNA synthesis and is
constitutively expressed in cycling cells.
The human form of PSMD13/p40.5/TSAP13 has been identified as downregulated
with decreased tumorigenicity/increased apoptosis as instigated by p53/p21waf
signalling in the cell-line K562 (Roperch et al., 1999). The 19S subunit regulates
activity of the whole 26S proteasome complex and has other nonproteolytic
functions within the cell. It has been seen to play a role in efficient activated, not
basal, transcription (Ferdous et al., 2002). The human PSMD13 gene is not well
characterised in the literature and its loss has not previously been implicated in
cancer progression.
The interaction between PSMD13 and other proteins, as seen in yeast and humans,
suggests that it may have a non-proteolytic role in the cell. Transcription, DNA
repair, DNA replication, estrogen regulation and heat shock response are all
pathways in which
this protein may normally function. Its disruption in ovarian cancers may cause
dysregulation of these cellular pathways. Further validation of PSMD13 gene
expression in a panel of tumours and cell-lines confirmed loss of expression in all
ovarian cancer cell-lines as compared to normal OSE. Of 18 primary HOV tumours,
decreased expression was detected in four (22%).
The transfection of full-length PSMD13 into an OVCAR3 clonal line was




Figure 9.3 PSMD13 (Rpn9) protein interactions in yeast. Taken from http://genome-
www.stanford.edu/Saccharomyces/. All proteins shown interact with PSMD13 (Rpn9).
RAD23, FLJ11848 and USP6 also interact with other components of the 19S proteasome.
9.2.4.2 Protease Cathepsin D; CTSD
Moving down the chromosome, CTSD, at 1 lpl5.5, encodes for a lysosomal aspartyl
protease. Unlike PSMD13, the human form of this gene has been widely studied,
particularly for its involvement in the progression of breast and ovarian cancers.
Historically, in ovarian cancers, expression of CTSD was determined to be a poor
prognostic factor of survival (Scambia et al., 1991; Scambia et al., 1994; Shaheen et
al., 1995). These observations correlated with the consistent view that CTSD
expression is a prognostic factor in breast cancers (Fitzgibbons et al., 2000). More
recent IHC studies, however, have shown expression of CTSD in the epithelial cells
and stroma of tumours as a favourable prognostic factor for survival in advanced
EOC (Baekelandt et al., 1999b). Furthermore, overexpression of CTSD inhibits
growth of colon, liver and ovarian cancer cell-lines in vitro (Wu et al., 1998).
Knockout of CTSD in mice showed it to be essential for the degradation of proteins
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involved in cell growth and tissue homeostasis (Tsukuba et al., 2000). Secretion of
CTSD in prostate carcinomas cells has also been shown to induce production of
angiostatin, a potent angiogenesis inhibitor (Morikawa et al., 2000).
CTSD is a mediator of IFN-y and TNF-a induced apoptosis (Wu et al., 1998). This
activity is associated with an increase in p53 activity and transcription (Kagedal et
al., 2001). p53, estradiol and retinoic acid induce expression of CTSD. This complex
regulation of CTSD reflects its many normal roles in the cell including protein
degradation, antigen processing and induction of apoptosis.
We have shown that CTSD is upregulated in the growth suppressed chromosome 11
hybrid 110H2.1. Analysis of CTSD mRNA expression in a panel of ovarian, colon
and breast cancer cell-lines and HOV tumours showed clear downregulation of this
gene in all lines tested. SKOV3 cells, which we have found to have robust
expression of CTSD do not show increased mRNA expression in response to
estradiol (Hua et al., 1995). This suggests a defect in the control of CTSD that may
be due to promoter dysfunction.
Clinicopathological analysis of expression in 18 HOV samples showed that very low
expression of CTSD in patients (<6%) correlated significantly with poor survival.
Expression <20% correlated with poor differentiation status of tumours.
Furthermore, the availability of a good antibody allowed IHC analysis of 48 ovarian
tumours, which showed a trend towards association of very low protein expression
with adverse survival (p=0.0847). Loss of protein expression significantly correlated
with a serous histology. This data shows that CTSD expression is a clinical
prognostic factor for the most common histological sub-type of EOC although
further IHC is required to confirm this.
CTSD protein expression in lysates from 22 cancer cell-lines was also assayed.
Western blots were done using an antibody that detects all forms of the CTSD
protein. Three different molecular weight bands were found which are believed to
correspond to the 52kDa proenzyme, the cleaved 34kDa active form of CTSD, and a
smaller unknown protein of approx. 30kDa.
Bazzett et al analysed the presence of CTSD proteins in the sera of ovarian cancer
patients and found multiple bands ranging from 24-60kDa (Bazzett et al., 1999). In
control sera they however found a major band at 34kDa and two minor bands of 27
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and 48kDa in half of the samples. These control bands correspond with our data. Our
analysis used mini-gel westerns, which are less accurate of determining band sizes
due to decreased resolution. The largest band at 48-52kDa was seen in four ovarian
cancer cell-lines, PE023, PE04, SKOV3, and OVCAR5 and was also seen in the
estrogen treated breast cancer cell-lines MDA, MCF7, ZR75. This band may
represent the uncleaved pro-CTSD that has been shown to increase proliferation and
decrease sensitivity to chemotherapy of tumours (Bazzett et al., 1999). Interestingly,
the platinum sensitive isogenic pairs of PE023 and PE04 do not exhibit expression
of this 52kDa form confirming these findings. In the breast cancer lines we tested,
CTSD mRNA expression may have been induced by their estrogen treatment,
leading to high protein levels of all three CTSD isoforms. All of the cell-lines
expressed the activated 34kDa CTSD isoform to some extent. Leukaemia cell-lines
K562 and Jurkat however, showed very low levels of expression. No normal OSE
lysate was available, so expression in these cell-lines cannot be compared to normal
levels. The western blots did however confirm the upregulation of CTSD in 110H2.1
cells for the mature 34kDa protein and the smaller 27-30kDa protein. We also
detected a strong correlation between mRNA and 34kDa protein levels. This
suggests that the low mRNA expression seen by quantitative RT-PCR in the HOVs
may relate directly to protein expression.
The analysis of CTSD mRNA and protein expression in multiple ovarian cell-lines
and HOVs has shown that this gene is downregulated in the majority of tumours.
Clinicopathological associations suggest this gene may be important in the
progression of ovarian cancers. To prove that CTSD acts as a TSG in ovarian
tumours analysis of patient samples for evidence of mutation or methylation is
required. Full-length sense transfections of CTSD are underway and will hopefully
prove that this gene is responsible for functional suppression of the cells.
9.2.4.3 Ribosomal protein L27A: RPL27A
RPL27A lies distal to CTSD at llpl5.4. This protein forms a rRNA binding subunit
of the 60S ribosome that is essential for translation (Kusuda et al., 1999). Very few
studies have been done to determine to function of this protein out-with or even in
conjunction with its ribosomal activities. We have identified this gene as upregulated
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2.3-fold upon introduction of chromosome 11 into OVCAR3 cells. CGAP virtual
Northern data shows a significant reduction in expression of RPL27A in ovarian
tumours as compared to normal ovary. Ovarian cell-line expression of RPL27A was
lower than expression in normal OSE for all samples but one (PE04). This low
expression was also seen for the breast cancer cell-lines MDA and ZR75 although
we could not compare expression to that of normal breast tissue due to lack of
resources. HOV tumour expression of RPL27A was variable with six of the eighteen
patients having loss of expression (33%). Although expression of RPL27A did not
correlate with any clinicopathological parameters, we found a striking association
with expression of PSMD13 (p<0.0001). This correlation was seen for all samples,
including colon and breast cancer lines tested, suggesting global co-regulation of
these genes. This co-expression of two genes that are separated on the chromosome
by many other genes, including CTSD, is very interesting. Both genes code for
proteins that are involved in normal housekeeping roles as components of
multisubunit complexes. Translation is often coupled directly to protein degradation
to remove miscoded proteins from a cell.
Permanent protein complexes often have co-ordinated expression of their subunits. It
is therefore interesting that in the case of the RPL27A and PSMD13, we have not
seen a concomitant increase in expression of other ribosomal and proteasomal
proteins. This may suggest the regulatory importance of these subunits within these
multiprotein complexes. Whether the induction of expression in 110H2.1 of
RPL27A and PSMD13 is parallel or due to one regulating expression of the other
should be further studied by transfection.
SAGE data from the CGAP project showed a positive correlation between
expression of PSMD13 and two ribosomal subunits, RPL19 and RPS5 supporting
our ribosome/proteasome correlation.
9.2.4.4 Crystallin alpha-B: CRYAB
The fourth chromosome 11 positioned gene validated as upregulated in the growth
suppressed hybrid 110H2.1 is CRYAB. This gene is positioned at 11 q23.1, just
within the region transferred, and is upregulated 5.2-fold. LOH at llq22-23 is
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common in ovarian tumours (Koike et al., 1999). The gene also lies within a region
associated with paragangliomas (Baysal et al., 1999).
CRYAB codes for a small heat shock protein, which is induced by cell stress and
also functions as a chaperone in the transport of unfolded proteins to the degradation
machinery. The CRYAB protein is abundantly expressed in the lens, the tissue in
which it has been mostly studied. The mouse knockout of CRYAB displays
hyperproliferative lens epithelial cells, which also become genomically unstable
(Andley et al., 2001). This data along with the decrease in expression of CRYAB in
testicular and breast cancers as compared to their normal tissues supports a role for
the gene as a tumour suppressor (Klemenz et al., 1994; Takashi et al., 1998). CGAP
EST data showed a significant decrease in expression of CRYAB in ovarian tumours
as opposed to normal ovarian tissue.
We found that expression of CRYAB was reduced in all 15 ovarian cell-lines tested.
Furthermore there was almost no expression in the breast and colon cancer cell-lines
examined. HOV expression of CRYAB was variable but 10 of 18 (55%) had
decreased expression as compared to the normal OSE. Low tumour expression of
CRYAB was significantly associated with adverse survival and with a serous
histology. These clinicopathological associations further support the role of CRYAB
as a candidate tumour suppressor gene.
9.2.5 Validated candidate oncogenes
From the Light Cycler analysis of 78 genes we validated only four as actually down
regulated upon introduction of Chr 11 into the suppressed hybrid 11OH2.1. These
genes are hypothesised to be downregulated by functional Chr 11 TSG(s) as part of
the growth suppression pathway. Two of these genes have been previously
characterised, RALDH2 and IGFBP2. The other two represent DpnII fragments that
do not code for functional proteins as determined by in silico translation, and named
CB1 and CB2. The massive downregulation of these two non-translated sequences
by the transfer of Chr 11 is due to an unknown mechanism. Why any TSG would
downregulate genes that do not code for a functional protein is unclear. It may be
possible that these regions of DNA contain sequences similar to regulatory elements
that inadvertently affect transcription of the gene.
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RALDH2 codes for an enzyme with tissue specific activity, which is vital for the
conversion of trans-retinal to retinoic acid (Napoli, 1999). Paradoxically, all-trans-
retinoic acid is used as a treatment for solid tumours because it blocks cell cycle
progression and enhanced cisplatin induced apoptosis (Wu et al., 1997).
If RALDH2 acts as an oncogene, ovarian cancer cell-line expression would be
expected to be higher than in normal OSE. Our panel of cell-lines however generally
showed very low expression of RALDH2 except for line 59M. Five of eighteen HOV
tumours showed overexpression of the gene. There was a slight trend towards the
association of high tumour expression and poor survival. This would need to be
further analysed with a larger sample set. Knockout of expression of RALDH2 by
antisense transfection in OVCAR3 derived cells did not appear to suppress in vitro
growth. In all, our data suggests that overexpression of RALDH2 is contextual and
probably not involved as a mechanism for the progression of ovarian tumours.
Insulin-like growth factor binding protein 2, IGFBP2, is involved in the regulation of
growth factor IGF-I. It has been well researched in tumours and increased serum
levels have been detected in patients with malignancies of the colon, lung, ovary,
adrenal gland, CNS and prostate (Hoeflich et al., 2001). Serum IGFBP2 levels in
ovarian cancer patients correlates with cancer antigen 125 (CA125) (Flyvbjerg et al.,
1997). Expression of IGFBP2 increases in chemotherapy resistant ovarian cell-lines
as compared to those that are sensitive (Sakamoto et al., 2001). Interestingly, CTSD
acts as an IGFBP protease and therefore modifies the action of IGF-I in prostate
carcinoma cells (Conover et al., 1995). CTSD also degrades IGF-I and -II
suggesting it has a general role in the regulation of this proliferation enhancing and
anti-apoptotic system.
Although IGFBP2 protein is commonly reported as overexpressed in ovarian
tumours, we have not seen this at the mRNA level. All of the cancer cell-lines and
the majority of HOVs had less IGFBP2 expression than the normal OSE. Analysis of
protein expression in these cell-lines and also on tumour sections would be
interesting to see if there is an inverse correlation between CTSD and IGFBP2
protein expression.
Increased expression of IGFBP2 in ovarian tumours has been reported (Hough et al.,
2001). We have detected suppression of this transcript upon chromosome 11 transfer.
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We have not however, found global overexpression of IGFBP2 mRNA in ovarian
cell-lines and HOVs, therefore suggesting that again, suppression of this gene may
be contextual.
9.2.6 Summary of difference analysis
Using three difference analysis techniques, we have successfully identified and
validated eleven candidate TSGS. Four of these eleven reside on chromosome 11, all
within published areas of common LOH. Our approach has been successful in
minimising candidates from hundreds of genes within the regions transferred into the
growth suppressed hybrid 11OH2.1 to just four.
All eleven are good candidates as ovarian cancer associated genes. They each
perform normal role within the cell which if dysregulated may lead to a neoplastic
phenotype (Table 9.1).
The four genes we have identified on Chr 11 are all good candidates and should be



















































Table 9.1 Normal functions within a cell of our candidate TSGs. The red blocks show an
association of the gene(s) with that function.
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9.3 LOH analysis at lip15
9.3.1 LOH overview
LOH at lip 15 has been identified multiple times in ovarian cancers, suggesting the
presence of TSG(s) with in the region. The identification of three 11 p 15 situated
genes by expression difference analyses led to the construction of a dense LOH map
in this area. I aimed to minimise regions of LOH on 1 lpl5 in ovarian cancers and to
hopefully correlate these with genes identified by our functional analyses.
To do this I used 39 polymorphic microsatellite markers and 87 paired samples from
patients with EOC. By calculating the ratio of allele loss between the tumour and its
normal counterpart (ratio < 0.6), I was able to determine distinct regions of loss
within these tumours. Traditionally, LOH rates are deemed as significant if s35%
(Shelling et al., 1995). Twelve of the 39 individual markers, according to these
criteria, had significant LOH rates ranging from 35% to 44%. Marker loss on 1 lpl5
was biased towards those tumours of advanced stage suggesting a mechanism of
complete arm loss in these generally more genetically unstable tumours.
By analysing individual regions of loss in patient samples I was able to minimise the
regions harbouring candidate TSGs to 39% (7.5Mb) of the original 19.1Mb, as
characterised by nine SROs.
9.3.2 Shortest Regions of Overlap
A large number of patient samples showed LOH throughout the 1 lpl5 region (24%).
This suggests that complete loss of lip may be an important mechanism in
inactivating TSGs and suggests that there may be more than one TSG contained
within the region. This mechanism of loss makes the minimisation of regions more
complicated and also requires a large number of patient samples to be successful.
The use of 39 markers in a dense map makes the interpretation of data more
complicated than with fewer more distantly spaced markers. This is due to the large
number of samples with complex 'harlequin' patterns. To minimise regions of loss
and overcome this problem, I analysed only those samples with four or less
individual regions of loss.
I was able to identify nine individual SROs. These regions span from 77Kb to
1927Kb and contain from 3 to 20 genes. In contrast to the most comprehensive LOH
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analysis of 11pi5 in ovarian cancer, by Lu in 1997 (using 12 markers), we have been
successful in minimising the LOH regions (Lu et al., 1997). Figure 9.4 summarises
our SROs, showing the size and LOH rate of each region and highlighting any
interesting genes within that interval.
Of the nine regions, six have LOH rates >40%. These regions are lost in more
ovarian cancers and therefore most interesting to further investigate.
Clinicopathological analysis of the SROs showed no associations with histology,
grade, FIGO stage or survival (p>0.01). Some individual markers within these
regions however, e.g. D11S4188, were strongly associated with variables. This
difference leads us to ask whether we should use regions or individual markers to
interpret LOH data. Regions are important in minimising sections of chromosome to
analyse. Once minimised, I believe the markers within these regions, and their
clinicopathological associations should then be taken into account.
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Figure 9.4 Minimal regions of LOH on 1 lpl5 in ovarian cancers. Overview of the nine
regions of LOH, their size, overall LOH rate, number of genes within the region and
interesting gene candidates. Compared to Lu et al 1997, which was the most comprehensive
analysis prior to this work.
9.3.2.1 Region I; llpl5.5 - D11S4177-D11S2071
Region I spans the smallest distance of 77Kb. The overall LOH is 46% and
interestingly, PSMD13, identified as 2.3-fold upregulated in growth suppressed clone
110H2.1, is contained within this region. Marker D11S2071 is situated within an
intron of the PSMD13 gene and has an LOH rate of 39%. This marker is not
significantly associated with any clinicopathological variables but there is a trend
towards increased LOH in tumours of a serous or endometrioid histology, advanced
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FIGO stage and advanced grade. Loss surrounding D11S2071 has been implicated in
lung cancer region LOH11A (O'Briant and Bepler, 1997).
9.3.2.2 Region II; llpl5.5 -HRAS-D11S922
Region II spans 358Kb and encompasses 9 genes, including differentially expressed
CTSD. LOH for this region is 46%. Marker D11S922 lies distal to the CTSD gene.
As for D11S2071, loss at D11S922 appears to be more common in tumours of serous
or endometrioid histology and of advanced FIGO stage. LOH at D11S922 trends
towards an association with adverse survival in patients. It is also of note that low
expression of CTSD in tumours was significantly associated with adverse survival in
patients. D11S922 lies within regions of LOH identified in breast and lung cancers
(see Figure 8.13).
9.3.2.3 Region III; Ilpl5.5-pl5.4 - D11S4088-D11S4146
Region III spans 1499Kb and has the highest overall LOH of 49%. There are 15
genes within this region including the candidate TSGs KCNQ1 and CDKN1C. The
region surrounding D11S4088 has been implicated in the progression of many
cancers including breast, lung and Wilm's tumours (see Figure 8.13). This region is
contained within a fragment of 2.5Mb, which suppresses embryonal tumours,
supporting the presence of a TSG near this locus (Hoovers et al., 1995). Karnik
showed loss of a 500Kb region spanning D11S1318-D11S4088 in breast cancers and
associated this loss to early events in malignancy and invasiveness (Karnik et al.,
1998a). We have found that LOH at D11S4088 is associated with all histological
sub-types of EOC and there does not appear to be any bias towards either advanced
stage or high grade disease. This suggests that loss at this marker may be an early
step in ovarian cancer progression supporting the data found for breast cancers.
D11S4088 is situated within a region containing imprinted genes including KCNC1,
CDKN1C and SLC22A1L. These genes are imprinted by methylation in normal cells
so LOH of the non-methylated allele would result in complete knockout of the gene.
Imprinted genes are therefore more susceptible to inactivation and require only one-
hit for this. However, hypomethylation of imprinted genes around D11S4088 has
been detected in adult tumours, including breast, liver, colorectal and cervical (Scelfo
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et al., 2002). This loss of imprinting (LOI) correlates with decreased expression of
the genes suggesting that this mechanism acts by activating negative regulators of
transcription. It is therefore possible that in ovarian tumours, LOI and LOH act in
concert to knockout expression of one or more of the imprinted genes within this
region.
9.3.2.4 Region IV; llpl5.4 - D11S1338-D11S1331
Region IV encompasses 1305Kb, and contains 20 genes. This region has an LOH
rate of 43%. Marker D11S1338 (42% LOH) is lost in ovarian tumours of all
histological types and, as for D11S4088, there is no bias seen for advanced stage and
grade tumours. Loss at D1 IS 1338 is however significantly associated with tumours
that have not been debulked (p<0.01). This suggests an association with biologically
more aggressive disease. Interestingly, when the 21 tumours that show loss of the
majority of 1 lp 15 are removed from the clinicopathological analyses, LOH at
D1 IS 1338 becomes associated with early stage tumours (p=0.0185). Why there
should be a simultaneous association with irresectibility of these is unclear.
The ratio of alleles within a tumour as compared to its normal sample (R value) can
be used a guide as to how recent this genetic event is in the progression of the
tumour. If it is an early event in the tumour, the loss will often be more complete and
a larger proportion of the tumour cells will have the genetic aberration (See Figure
9.5 for an explanation).
The average ratio of allele loss within tumour-normal pairs for D1 IS 1338 is low
(r=0.28), supporting the hypothesis that loss of this marker is an early event in
progression.
LOH at D1 IS 1338 has not been identified before in ovarian tumours but is common
in esophageal cancers, leukaemia, melanoma, Wilm's tumour, and Breast cancers
(Krskova-Honzatkova et al., 2001; Lam et al., 2002) (Goldberg et al., 2000 ; Karnik









Figure 9.5 Accumulation of advantageous genetic events by a tumour. If LOH occurs early
in the progression, as represented by a green cell, then this advantageous mutation will
accumulate and account for a large proportion of the tumour mass. LOH analysis of a tumour
with an early genetic event will show a larger allelic loss (75%- R=0.25) because the
majority of cells have that lesion. Late LOH will be present in a smaller proportion of
tumour cells so the R value will be higher (40% R=0.6).
In breast cancers, TSG candidate SRBC/PRKCDBP has been identified, located just
distal to D1 IS 1338. Down regulation of the protein kinase C binding protein SRBC
is associated with hypermethylation of its promoter CpG island in 60% breast and
79% lung tumours (Xu et al., 2001). The SRBC protein has unknown function but is
known to interact with TSG BRCA1 and is postulated to play a role in cell-cycle
control making it a good candidate.
9.3.2.5 Region V; Ilpl5.4-15.3 - D11S4149-D11S1329
Region V is the largest SRO, spanning 1927Kb. It contains 15 genes and has an
overall LOH rate of 47%. The marker D11S4188, contained within this region, has
an LOH rate of 38% whereas the surrounding two markers are lost in only 28-29% of
patients. This suggests that a candidate TSG lies near to the D11S4188 marker. The
region itself shows no significant associations with any clinicopathological
parameters. D11S4188, however, is associated significantly with non-mucinous
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histology, advanced stage and poor grade (p<0.01). LOH at D11S4188 also shows a
trend towards association with adverse survival. These highly significant associations
support the hypothesis that a candidate TSG lies very near to this marker.
Interestingly, loss at D11S4188 is common in the endometrioid sub-type (47% LOH)
with a conversely low LOH rate in all other histologies (0-22%) suggesting that this
gene may be important in the specific aetiology of endometrioid tumours.
D11S4188 is situated within an intron of the gene CEGP1. This gene was recently
discovered and has yet to be characterised (Cichutek et al., 2001). By homology, the
protein has a signal peptide, a CUB domain, involved in developmental regulation,
and EGF-like domains. The EGF super family members function as ECM
components and as secreted signalling molecules and it is postulated that CEGP1
functions as the latter (Grimmond et al., 2001). The gene is highly expressed in the
mammary gland and by array profiling of breast tumours, expression was correlated
with a survival advantage in patients (Saito-Hisaminato et al., 2002; van't Veer et
al., 2002).
The association of this marker with poor prognosis endometrioid tumours suggests
this gene should be further analysed for a role in tumour development.
9.3.2.6 Region VI; llpl5.3-15.2 - D11S1334-D11S926
LOH at region VI is not as common as many of the others, at 37%. This region
contains only four genes although it spans 574Kb. Individually, all of the markers
within the region have LOH rates of only 26% except for marker D1 IS 1794, which
is lost in 37% tumours. D11S1794 lies within an intron of the ARNTL gene. The
close proximity of other markers and genes suggests that within this region,
transcription factor ARNTL is the best TSG candidate. The LOH rate of this gene is
not as impressively high as for other markers but it may still be involved in the
progression of a small number of ovarian tumours. LOH at D1 IS 1794 is seen in all
histological subtypes and, as for D11S4088 and D1 IS 1338, there is no bias towards
loss in advanced stage or poor grade tumours. Allele loss at D11S1794 may
therefore, in a few tumours, be involved at an early point.
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This region has not been previously identified as lost in cancers. This may be due to
the majority of studies focussing on the 1 lp 15.5-p 15.4 region, or due to the minimal
number of markers used within those studies.
9.3.2.7 Regions VII & VIII; llpl5.2 - D11S861-D11S4193 & D11S4121-
D11S1791
My analysis of the SROs in these regions suggested that there may be two distinct
regions of loss within this 960Kb interval. I am not however, fully confidant that
these are separate so have grouped them together for discussion.
These regions encompass six genes and have LOH rates of 35-38%. The individual
markers within this region only have LOH rates of 32-33%. Marker D11S4121 is just
short of significance for an association with adverse survival in patients (p=0.0508).
This marker lies nearest to CALCB and CALCA. Interestingly LOH at CALCA has
previously been associated with adverse survival (Eccles et al., 1992). This
association suggests that D11S4121 may be lost in a small number of tumours with a
poor prognosis.
9.3.2.8 Region IX; llpl5.1 - D11S1888-D11S4096
The final region, IX, spans three markers and 803Kb with an LOH rate of 42%. The
three individual markers within the region have LOH rates of 31-36%. This suggests
that in this area, regional loss is more important than looking at individual markers.
Loss of region IX does not correlate with any clinicopathological variables.
The area surrounding marker D1 IS 1310 was identified as a region of LOH by Lu et
al (see Figure 9.4). This marker was central to a novel 4 cM region of LOH
associated with high-grade non-mucinous tumours.
TSG101 lies within this SRO. This gene encodes for a cell cycle protein and is a
candidate TSG in breast and ovarian cancers (Zhong et al., 1998). Aberrant splicing
of TSG101 is found in breast and ovarian cancers and appears normally regulated by
p53 (Carney et al., 1998; Moyret-Lalle et al., 2001). This may therefore be the gene
that is associated with LOH of region IX.
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9.3.2.9 Summary of SROs
Of the nine SROs I have identified, there are six which are interesting and
sufficiently relevant (i.e. high rates of LOH) to warrant further investigation. These
are regions I, II, III, IV, V and IX. Interestingly, All of these regions (1 lp 15.5-15.3
and 11pi5.1) correlate to areas that have been identified as having high rates of LOH
before. This data corresponds to the llcM and 4cM regions identified by Lu et al
previously, but we have been able to minimise the regions into smaller fragments for
further analysis (Lu et al., 1997) (Figure 9.4).
Region I contains PSMD13, which we identified as differentially expressed in the
MMCT hybrid. Region II also contains a validated differentially expressed gene,
CTSD. Region III has the highest rate of LOH, contains imprinted genes and appears
to be lost at an early stage in tumour progression. Region IV includes candidate TSG
SRBC that may also be involved at an early point in tumour development. Region V
contains the marker D11S4188, which is commonly lost in endometrioid cancers
with a poor prognosis, positioned within the gene CEGP1. Finally region IX, which
includes the candidate TSG101, has an LOH rate of 42%. In all, these six regions
contain 79 genes and encompass 5.9Mb. By analysing individual markers we can
pinpoint loss even further within these regions.
There are five markers, one from each of the first five regions of LOH which appear
to represent the most important areas of LOH along 1 lpl5. The involvement of each
















Figure 9.6 Model of llpl5 allelic loss in ovarian cancer. Accumulation of 11 p 15 marker
LOH with increasing FIGO stage as associated with tumour histology.
192
9.4 Correlation of functional and positional data
MMCT of chromosome 11 into ovarian cancer cell-line OVCAR3 caused decreased
growth and suppressed tumorigenicity. Revertant analysis of clones showed loss of
one marker D11S926, which may or may not be associated with growth suppression.
Further mapping of the clone 110H2.1, which was used in the expression difference
analyses determined the extent of 1 lpl5 transfer.
Using difference analysis techniques coupled to functional suppression we have
identified four candidate TSGs within llptel-q23. Three of these were positioned
within a 9Mb region on 1 lpl5.5-15.4.
Comprehensive LOH analysis of 1 lpl5 in primary tumours identified nine regions of
LOH, six of which I believe to be important in the progression of a sub-set of ovarian
tumours. The identification of nine individual regions of loss explains why the
mechanism of complete p arm loss is common in tumours.
Further mapping of the 110H2.1 hybrid showed it had fragmented transfer of
chromosome 11 in the ptel-pl5.1 region. Using the same markers as used in the LOH
analysis I have shown that there are two fragments of 11 p 15 in the hybrid 110H2.1.
The regions of chromosome transfer and the nine regions of LOH correspond well,
except for region IX surrounding the marker D1 IS 1310 (Figure 9.7). This shows that
any of the other eight regions may harbour genes that are promoting the growth
suppressed phenotype in clone 110H2.1. This close correlation of chromosome
retention in the 110H2.1 clone and common regions of tumour LOH supports these
as candidate TSG harbouring regions and validates the approach of integrating
positional and functional analyses.
Since single genes are not commonly cloned via the MMCT approach, it may be
possible that in vivo tumour suppression may be due to the effect of a large number
of genes introduced by the chromosome transfer. The correlation of chromosome
retention in microcell hybrids with common regions of LOH in primary tumours
supports this idea.
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Figure 9.7 Comparison of 1 lpl5 transfer and regions of LOH. Red bars= regions of LOH in
relation to the markers shown from telomere down to 1 lp 15.1. Blue bars= regions of llpl5
transferred in MMCT clone 110H2.1. Not all markers were used in the mapping of
110H2.1. A blue box= transfer, a white box= no transfer and a hatched box= an
uninformative locus.
The integration of two methods of analysis have minimised the approx. 1500 genes
along chromosome 11 to seven genes which may be involved in the growth
suppression phenotype. Of these, three were identified by the functional approach
coupled to difference analysis and four others were from a comprehensive LOH
analysis of 1 lpl5. Our integrated data is shown in Figure 9.8.
Two genes were validated as both differentially expressed in the suppressed
microcell hybrid and within regions of high LOH. Another gene, RPL27A, was
identified by difference analysis and correlated with a marker, LOH of which is
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associated strongly with advanced stage (D11S932). RPL27A was not however
identified within a region of common LOH.
CTSD and PSMD13 were both identified by difference analysis as upregulated in the
growth suppressed clone 110H2.1. Furthermore, these genes correlate with regions
and markers with high rates of LOH. LOH of both are associated with tumours of a
more advanced stage and of serous or endometrioid histology.
We have shown decreased expression of PSMD13 in 22% HOV tumours and 100%
ovarian cancer cell-lines. LOH at marker D11S2071, situated within an intron of the
PSMD13 gene is found in 39% of tumours with a bias towards those with a poor
differentiation status. The correlation between PSMD13 and RPL27A expression in
tumours and cell-lines suggests co-regulation of these genes. The marker nearest to
the RPL27A gene, D11S932 does not show a high rate of LOH suggesting that it is
either inactivated by an alternative mechanism or that it does not act as a tumour
suppressor gene. It could be possible that PSMD13 directly affects transcription of
RPL27A and this correlation should be further studied.
CTSD expression is convincingly decreased in 100% of HOVs and 100% ovarian
cancer cell-lines. This clear downregulation in tumours, as well as CTSD being
situated within a region of high LOH suggests CTSD as a very strong TSG
candidate.
The association between loss of expression of CTSD in HOV samples and adverse
survival suggests this gene is very important in the progression of ovarian tumours.
We found decreased CTSD protein in some serous tumours which corresponds with
LOH being more common in this histological subtype. Further immunohistochemical
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Figure 9.8 Integrated approach for identifying candidate Tumour Suppressor Genes. By
combining a functional and positional approach we have identified genes that may be
involved in the growth suppressed phenotype. Overlap between the methods shows three
genes that should be further analysed for their roles in ovarian cancer progression.
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Of the three lip 15 genes identified by difference analysis, concurrent LOH analysis
has not excluded these from further analysis. The integrated data suggests both
PSMD13 and CTSD as good TSG candidates. RPL27A does not reside in a minimal
region of LOH but the co-expression with PSMD13 should be investigated.
CRYAB is positioned on llq23 so was not included within the region analysed for
LOH. This gene cannot therefore be excluded as a candidate functional growth-
suppressor. Expression of CRYAB is decreased in 56% HOVs and 100% ovarian
cancer cell-lines. This decrease in expression is associated with clinicopathological
parameters of serous histology and adverse patient survival. CRYAB is therefore
also a good TSG candidate.
I have identified nine regions of LOH, eight of which were transferred in the MMCT
clone 110H2.1. CTSD and PSMD13 are postulated to account for two of these
regions. Difference analysis did not identify candidates from the other six. It may be
that these regions are artefactual of the high overall rate of LOH along lip 15 and
therefore do not actually harbour TSGs. Another possibility is that the methods of
difference analysis are themselves limited. For example, arrays are limited by their
clone content and cDNA-RDA is more successful for more abundant transcripts. The
coupling of difference analysis techniques to MMCT is also limited in its ability to
identify genes that are mutated because mutations may not affect the expression of
the genes. Mutations may lead to truncated or missense transcripts, which are
expressed at a normal level but affect the protein function.
The regions identified by LOH are also worthy of further analysis. Markers
D11S4088 and D1 IS 1338 in regions III and IV respectively, are lost in multiple
tumour types, as already discussed. D11S4188 has not before been reported as lost in
tumours. Along with the strong correlation of loss with aggressive endometrioid
tumours, I think this will be an interesting region to study.
The coupling of these approaches has successfully minimised chromosome llpl5
TSG candidates to two, CTSD and PSMD13. The genes should be analysed for their
potential roles as TSGs in ovarian cancer progression.
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9.5 Summary and future directions
This study has succeeded in identifying a small number of candidate TSGs on 1 lpl5.
By combining two, normally distinct approaches we have been able to minimise the
data to just two genes. These two genes, PSMD13 and CTSD have been shown to
have decreased expression in ovarian cancer cell-lines and are both situated within
regions of high LOH.
To identify whether these genes are true TSGs, we next need to show inactivating
mutations and/or methylation. Mutation and methylation analysis of a panel of
patient samples would show the mechanisms by which these genes are switched off
in ovarian tumours.
In parallel, functional studies on these genes to prove they act upon growth
suppression, both in vitro and in vivo, should be performed. By transfecting full-
length sense transcripts into ovarian cancer cells that show very little endogenous
expression, we will determine whether these genes have a functional effect upon
growth and tumorigenicity.
We have found a clear correlation between expression of two of out four genes,
PSMD13 and RPL27A. It would be interesting to see whether multiple gene
knockout affects the phenotype of cancer cells in an additive manner.
The aim of this project was to identify candidate tumour suppressor genes from a
large potential region of chromatin (Chr 11). We have been successful in doing that.
Whether these genes will actually be confirmed as tumour suppressors awaits further
investigation. These genes may hopefully be used in the future directly in the clinic
whether in prevention, prognosis or treatment in order to improve the outcomes for
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